Feeds:
Posts
Comments

Testimonials about LPBI

2022

UPDATED on 11/15/2022

Yash Choudhary, IIT, Kanpur, Uttar Pradesh, India

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

PharmaceuticalIntelligence.com

Internship Remarks

Date: Sunday, November 13, 2022 at 4:06 PM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>
Subject: How are you ?

Hi Aviva Mam,

I hope all is well with you. 

  • How are everyone at LPBI? It’s been quite a long time. I read your emails about amazing work that’s currently going on at LPBI and how LPBI is progressing under your leadership . I was very fortunate to have a mentor like you.
  • I also wanted to give you some updates on what I’m planning to do next:- I have only one semester left before I graduate and Instead of going for a PhD directly, I’m thinking of doing a corporate job for 1-2 year. Then after that pursue PhD in Nano-sciences. The reason for this is that doing a Job for 1-2 year will give me some financial stability. 

Please let me know what are your thoughts on this.

 

Thanks 

Yash Choudhary

 

UPDATED on 7/13/2022

Madison Davis

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

PharmaceuticalIntelligence.com

Internship Remarks

13 July 2022

Throughout these past two years, my time here at Leaders in Pharmaceutical Business Intelligence has allowed me to expand my knowledge in Natural Language Processing (NLP) and general experience in the field of Artificial Intelligence.  Towards the beginning of my internship, I was offered the experience to get accustomed to storage virtualization through Amazon Web Services (AWS) and use the group’s Genomic-style text as an application on that platform.  The majority of my time was spent on topic modeling large sums of scientific papers; through the usage of Wolfram and Python, I was able to make hypergraphs, tree diagrams, and bar diagrams to visually represent summaries of text.  Beyond manipulating large amounts of  textual data, I myself also learned how to write reports as well from a scientific standpoint. 

The organization definitely strives to incorporate both undergraduate and graduate research into its permanent program.  While other companies would have side projects for interns to work on,

LPBI provided data research and projects that are directly related to their strategy and core mission. My internship involved performing Medical Text Analysis using Natural Language Processing for two of their eighteen electronically published books, these two are:

Series B: Frontiers in Genomics Research

Volume Two: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology

https://www.amazon.com/dp/B08385KF87

and

Series C: e-Books on Cancer & Oncology

Volume One: Cancer Biology & Genomics for Disease Diagnosis.

http://www.amazon.com/dp/B013RVYR2K

Being able to see other people’s coding solutions to NLP enabled me to get used to imagining new algorithms, and when other individuals did not have the coding experience necessary for certain tasks, the internship provided me with a stable platform to explain and write out the concepts in an easy-to-read format.  While mentorship is provided on identifying the problems at hand, the interns are provided a more relaxed environment to solve the problems on their own time.  This allows the intern to explore coding solutions on their own and serves to truly deepen their understanding of the topics at hand.

 

UPDATED on 5/24/2022

Equity Sharing Calculation: A Scoring System for Author’s (a) Total Articles (single author) and (b) multiple authors)(c) Total Articles Views and (d) Author’s Proportion of own articles views in the Top 14 Journal articles by Views (e) External Citations

Curators: Aviva Lev-Ari, PhD, RN and Stephen J. Williams, PhD

(e) External Citations

https://pharmaceuticalintelligence.com/2022/04/11/equity-sharing-calculation-a-scoring-system-for-authors-a-total-articles-single-author-and-multiple-authorsb-total-articles-views-and-c-authors-proportion-of-own-articles-views-in/

2021

UPDATED on 12/18/2021

From: Madison Davis <madisond2302@gmail.com>
Date: Saturday, December 18, 2021 at 5:41 PM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>
Subject: Updates

Hi Aviva,

I hope all is going well!  Exams were tough but overall went well.

I will turn it into an MS word file when we are ready.

I also wanted to thank you so much for your letter for MIT and your invaluable help with college admissions.  This Thursday, I was fortunate enough to have received an acceptance from Harvard!

– Maddie Davis

 

UPDATED on 9/29/2021

Tweet

 

MIT Technology Review @techreview

Replying to

 

and

Thanks for joining us again

 

@AVIVA1950. We loved your tweets yesterday!
 

@techreview is the handle of MIT Technology Review Twitter account

This account is followed by 1.1 Million followers. Each ReTWEET shares the retweeted Tweet with 1.1 Million followers. The following reTWEETS by @techreview is the equivalent of 3.3 Millions tweet posts

This image has an empty alt attribute; its file name is MIT-Technology-Review.png

 

 
 

MIT Technology Review

Retweeted your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT Charles Hoskinson CEO and Founder, Input Output Global; Founder, Cardano, 2015 Nation scale [Ethiopia] and Global scale – records ledger and smart contracts, credentials identity, reversible auditable that operates at scale; Cofounder, Ethereum

MIT Technology Review

liked your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT  Nick Selby Chief Security Officer, Paxos Trust Company at Timehop GDPR a bridge of security disclosure to US Citizens 5% of EU opt out 7/418 ADM password changed User database was compromised protect customers data Recovery architecture monitor

MIT Technology Review

Retweeted your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT @EmTechMIT Wendy Nather Head of Advisory CISOs @Cisco mid 90s Two-way authentications Who are the attackers, changes, abuse of the platform by users Technology to buy Proactive Refresh Tech done by vendor is best security practice

MIT Technology Review

Retweeted your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT Kevin Scott CTO @Microsoft Compute is the only constraint Open source version of OpenAI API no need to build OS. Responsible AI within Microsoft – Standard for the whole company to be rolled up soon. Regulation to consider where we are going to be

 
 
 

UPDATED on 9/22/2021

From INTERNS in 2021 LPBI’s Summer Internship

From: “Ethan Coomber [Intern 2021]” <ethancoomber6@gmail.com>
Date: Monday, September 20, 2021 at 11:54 PM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>

Hi Aviva,

This past summer, I was able to intern for LPBI. I really enjoyed being able to expand upon what I had been learning in the classroom at school, and push myself to take on new, exciting challenges. Over the summer, I was given 2 projects that were extremely interesting, but were vital in helping LPBI grow as well. With the guidance of LPBI, as well as my own outreach, I was able to expose myself to the world of text to audio conversion, as well as further my understanding of data analytics. The combination of resources at my disposal as well as Aviva’s guidance allowed me to make the most of the opportunity in front of me.

The mentorship I received from LPBI was extremely valuable. Being able to work so closely with LPBI’s founder, Aviva Lev-Ari PhD, Rn, I was able to get a detailed understanding of LPBI’s mission and how it relates to the projects I was working on. Aviva was a great resource as she allowed me to explore and be creative in discovering solutions, but was also available if I ever required guidance or leadership. I am proud of the work I was able to accomplish under Aviva’s guidance.

Looking forward to staying in touch,

Ethan

UPDATED on 8/1/2021

QUOTES

«Highest regards for the Israel Investment Summit you organized. I attended virtually from Boston. It was an amazing conference on many counts (…) Your July 27, 2021 – Israel Investment Summit, I would rank it in the top dozen. It is an outstanding achievement.»
Aviva Lev-Ari, PhD, RN, Director & Founder, Leaders in Pharmaceutical Business Intelligence (LPBI) Group
SOURCE: https://ws.eventact.com/IIS2021/Quotes

UPDATED on 6/1/2021 for May 24, 2021

From: Mass General Brigham <innovations@partners.org>

Reply-To: <innovations@partners.org>

Date: Monday, May 24, 2021 at 9:31 AM

To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>

Subject: RECAP | World Forum | Day 3 | GCT | CEOs | Harvard | Investors

Notable Tweets

 
 
 

@mandywoodland

Fascinating #WMIF2021 panel on mRNA yesterday -“mRNA is the message, and we just have to decide what message we want to deliver to the cell,” said moderator Lindsey Baden, MD. “The promise of this technology could not be more front and center for all of us.”

@LeapsByBayer

Congratulations to the 2021 Innovation Discovery Grants winners: @lynchielydia, Peter Sage, @GrishchukL, Benjamin Kleinstiver, Petr Baranov, announced at the #WMIF2021. It’s exciting to see the range of breakthrough research in #geneticdisease at @MassGenBrigham

 
 

@DrLilitGaribyan

Gene and cell therapy have scalability problems that we need to solve. This is what is echoed this week at @MGBInnovation World Medical Innovation Forum. #gct #celltherapy #healthcare #innovation

@MPDexpert

“imagine how the future could look if gene therapy cost 1/100th what it does today” @VCAmir @PolarisVC #wmif2021

@AVIVA1950 is Aviva Lev-Ari, PhD, RN

#WMIF2021 @MGBInnovation Roger Kitterman VP, Venture, Mass General Brigham Saturation reached or more investment is coming in CGT Multi OMICS and academia originated innovations are the most attractive areas @pharma_BI @AVIVA1950

@AVIVA1950_PIcs

IMG_7167

UPDATED on 2/15/2021

From: Nigel Russell <nrussell@jofpm.com>

Date: Monday, February 15, 2021 at 10:31 AM

To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>

Subject: RE: About our Venture

Dear Dr. Lev-Ari: 

Thank you for the information and outreach. You have a very interesting platform.

I am interested in chatting.

 

Kind regards,

Nigel

 

Nigel Russell

President

The Journal of Precision Medicine & the Precision Medicine Leaders Summit

Updated on 1/6/2021

From: “Jennings, Charlotte (Reuters)” <Charlotte.Jennings@thomsonreuters.com>

Date: Tuesday, January 5, 2021 at 10:47 AM

To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>

Subject: RE: REUTERS NEXT ­ Press Registration Deadline this Friday (Jan 8)

Hi Aviva,

Thanks for getting back to me. Your press pass for REUTERS NEXT is now confirmed.

It would be great if you could also please share your attendance with your network and across social media. You can find all sharing materials in the media pack here –

Attendees Pack · Reuters Next · Virtual Forum: January 11-14, 2021 (reutersevents.com)

Here’s a tracked sign-up link you can use when sharing – https://bit.ly/35ddYqO

Any other questions please don’t hesitate to reach out!

All the best,
Charlotte

2020

Updated on 8/25/2020

From: Robin Neff Clebnik <robin@internboston.com>

Date: Tuesday, August 25, 2020 at 5:23 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Thank You!

Hi Aviva,

Thank you for your contribution to a very successful summer for our InternBoston students! Your gifts of time, expertise were invaluable to our interns—and to our program as a whole. Your organization’s willingness to participate in InternBoston’s Virtual Summer60™ program allows high school and college students the opportunity to explore learning beyond the traditional limits of their classrooms. The first-hand experiences students receive in the internship will help prepare them for college and beyond.

By participating as a mentor, you have provided Noam with an exceptional opportunity to learn more about a potential career field in a structured and educational environment. Your dedication and commitment to establishing a work plan, overseeing the intern’s progress, and encouraging independence through learning have undoubtedly made a positive and lasting impact.

We look forward to continuing our partnership and will check in with you shortly to discuss more interns for Fall 2020.

 

Best,

Robin

robin neff clebnik

Chief Internship Officer

t: 617.527.0055 

m: 617.875.4614

          

Updated on 8/23/2020

 

The VOICE of Dr. Larry H. Bernstein, MD, FCAP on 8/23/2020:

I discovered a new site in 2012, and thereafter met Aviva Lev-Ari, PhD, RN, https://lnkd.in/eEyn69r

the Director & Founder of the Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston.

That led me to participate in writing for her Open Access Online Scientific Journal for five intense years, 1,400 articles in total. It is now late August 2020, and I have no longer engaged in the writing because of aging limitations.

I can indeed say, the Founder of the LPBI Group in Boston, Aviva, has really been a very fortunate leader, innovator, and collaborator in the LPBI Group’s medical and life sciences publishing endeavors. 

Aviva curated about my contributions to http://pharmaceuticalintelligence.com in the following two monumental sources: 

https://pharmaceuticalintelligence.com/2013/12/10/the-young-surgeon-and-the-retired-pathologist-on-science-medicine-and-healthcare-policy-best-writers-among-the-writers/

  • Editorial & Publication of Articles in e-Books by Leaders in Pharmaceutical Business Intelligence: Contributions of Larry H Bernstein, MD, FCAP
    Curator: Aviva Lev-Ari, PhD, RN

With heartfelt gratitude to our Dear Dr. Larry

https://pharmaceuticalintelligence.com/2014/10/16/editorial-publication-of-articles-in-e-books-by-leaders-in-pharmaceutical-business-intelligence-contributions-of-larry-h-bernstein-md-fcap/

Aviva published my authored contents in 18 volumes https://lnkd.in/ekWGNqA and in the following two memorable articles:

  • Commentaries on each Volume’s Contribution to Medical Education by L.H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN – BioMedical e-Books e-Series: Multiple Volumes in Five e-Series

Authors: L.H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/biomed-e-books/commentaries-on-each-volumes-contribution-to-medical-education-by-l-h-bernstein-md-fcap-and-aviva-lev-ari-phd-rn-biomedical-e-books-e-series-multiple-volumes-in-five-e-series/

  • My Memories Tell a Story to Share

Author: Larry Howard Bernstein, MD, FCAP

https://pharmaceuticalintelligence.com/2020/04/19/my-memories-tell-a-story-to-share-by-larry-howard-bernstein-md-fcap/

Aviva initiated, organized, edited and proposed a narrator for my interview for the following PODCAST:

  • Podcast with Dr. Larry H. Bernstein, MD, FCAP, Interview by Gail S. Thornton, PhDc, Narrator’s Voice: Stephen J. Williams, PhD

https://pharmaceuticalintelligence.com/audio-podcasts/podcast-with-dr-larry-h-bernstein-md-fcap-interview-by-gail-s-thornton-phdc-narrators-voice-stephen-j-williams-phd/

 

Updated on 8/11/2020

The VOICES of Interns of LPBI’s 2020 Summer Internship Program on Data Curation and Data Annotation

The Voice of Internship Team’s Captain, Daniel, Menzin:

LPBI has provided me with an invaluable experience this summer, which has allowed me to grow in a variety of ways. Through close mentorship, we were exposed to principles of data science (i.e. AI, ML, NLP), data curation and annotation, biochemistry, and website development. In addition to daily mentorship by Aviva, we were provided with weekly sessions where we were taught by world-renowned scientists. These sessions provided us with crucial background knowledge, as well as instructions which allowed us to execute and create deliverables while developing our professional skills. Aviva tasked me with several IT projects this summer that were challenging. It was a great opportunity for me to take advantage of the resources around me and learn on my own. Aviva mentored me throughout every step of the process, always providing feedback and showing me how I could improve my deliverables. My summer at LPBI provided me with an incredible opportunity to not only learn more, but also apply what I had learned through the creation of important deliverables. With the breadth of information I’ve been exposed to at LPBI, my professional horizons will surely now be broadened after having been taught things essential to numerous different fields.

The Voice of Noam Steiner Tomer:

Interning at LPBI has been instrumental in both my professional and personal development. Reading and curating many of the cutting edge and insightful articles that LPBI offers contributed significantly to my intellectual growth and broadened greatly my professional horizons. Through this internship I got to not only learn from many renowned researchers but gave me the unique opportunity to work with them directly. I also acquired many technical skills from the on-the-job training such as curation and improved my self-learning skills. It has absolutely been the most valuable experience of my high school career. I have learned so much from your presentations and doing the assignments, and have discovered interests I never knew I had like Hematology!

The Voice of Zach Day:

This summer I interned at Leaders in Pharmaceutical Intelligence (LPBI) in social media and market research.    In this capacity, I participated in weekly classes taught by medical experts about the latest developments in Cancer and Genetics Research. I met regularly with the company’s Director and Founder, Dr Aviva Lev-Ari and attended team meetings.  I wrote two articles about the company and its founder and uploaded them to Wikipedia. I also generated content for the company’s website including eleven WordClouds using WordItOut.com. Overall this was a great experience because I learned a lot, I contributed a lot and greatly appreciate the mentoring and support that I received working with Dr. Lev-Ari. 

 

Updated on 6/3/2020

Professor Marcus Feldman Receives Stanford Biosciences Mentoring and Service Award

Reporter: Gail S. Thornton, M.A.

Marcus Feldman, Ph.D., the Burnet C. and Mildred Finley Wohlford Professor in the School of Humanities and Sciences and Professor of Biology at Stanford University, has been selected to receive the 2019-20 Stanford
Biosciences “Excellence in Mentoring and Service Award”. This honor is given to faculty who make distinguished contributions towards enhancing the quality of training and the mentoring experiences for Stanford Biosciences graduate students.

In recognizing Professor Feldman for this honor, William S. Talbot, Ph.D., Senior Associate Dean of Graduate Education and Postdoctoral Affairs,
Professor of Developmental Biology,  at Stanford University, thanked him for his “extraordinary contributions this year.” Professor Feldman will be formally acknowledged for receiving this award and an honorarium at the School of Medicine Graduation Celebration on Saturday, June 13, 2020.

###

Updated on 5/7/2020

From: Alan Kaul <alan@mom-inc.us>

Date: Thursday, May 7, 2020 at 9:03 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Cc: Vinit Nair <vinit@pracnet.org>

Subject: Pharmaceutical Intelligence

HI Aviva,

You asked for my help in promoting your portal and I’ve done something that I haven’t done for any other organization, I put a direct link to your portal on Medical Outcomes Management’s home page.

[ see www.mom-inc.us ]

This is the only link to another business on our company’s website. We may move it’s location, but it will remain highly visible and directly linked.

I hope that this link will prove helpul to both of us

Stay safe,

Alan

Updated on 4/19/2020

ADDED to this entry by Dr. Larry H. Bernstein, MD, FCAP on 8/17/2020

“I am thankful to Aviva for the opportunity to follow my interests in retirement. I have been away from the laboratory longer than I would like, but could follow the literature.”

Sincerely,

Larry Bernstein, MD

“Prior to moving I was contacted by Aviva Lev-Ari, PhD, RN who was building an online medical forum known as Leaders in Pharmaceutical Business Intelligence (LPBI) Group, and I became the Chief Scientific Officer (CSO). Over the decade I wrote many articles (1,390) in the Open Access online Scientific Journal http://pharmaceuticalintelligence.com that were included in 18 organized e-Books in Medicine. Dr. Lev-Ari’s accomplishment is quite impressive. The e-Books are all available on Amazon.com”

https://lnkd.in/ekWGNqA

In:

My Memories Tell a Story to Share, 4/19/2020

Author: Larry Howard Bernstein, MD, FCAP

Contact: 413-727-8523

https://pharmaceuticalintelligence.com/2020/04/19/my-memories-tell-a-story-to-share-by-larry-howard-bernstein-md-fcap/

Updated on 2/9/2020

Obtained by Gail S. Thornton on 2/7/2020

Leaders in Pharmaceutical Business Intelligence (LPBI) is among the best resources of original scientific and medical content for the scientific and business community that is carefully chosen and thoughtfully organized and presented. The site offers a valuable contribution to biomedical science by advancing knowledge and research efforts through its commitment to synthesize, analyze and interpret complex, medical and scientific disease information on any subject, as well as biomedical research innovation widely available to the scientific and non-research community. There is a vast amount of quality, curated information on the site organized in three inter-related domains of an e-Journal, series of 16 e-Books and e-scientific and medical conference proceedings that is produced by an esteemed group of collaborators. 

In today’s biomedical science environment, there is a wide range of available information in journals of all subject areas and web sites, including clinical data, public health data and even genomics information, that needs to be accessed. The value and uniqueness that LPBI brings to the scientific community is its consistent and enormous success in producing non-technical reviews of technical literature in the medical field, so that the scientific findings are much more accessible in real-time. In that way, the scientific community can further delve into specific areas of interest more readily. The site is a quality, professional resource for the biomedical field, which is unique to any field. 

I’ve had the pleasure to serve as content consultant to LPBI over the years and, specifically, as an author of a newly launched e-book entitled, Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology. 

 

 —Marcus W. Feldman, Ph.D., Burnett C. and Mildred Finley Wohlford Professor of Computational Biology in the School of Humanities and Sciences, and co-director of the Center for Computational, Evolutionary and Human Genetics, Stanford University. He is the author of more than 600 scientific papers and 10 books on evolution, ecology, mathematical biology and demography. He is a member of the U.S. National Academy of Sciences, the American Academy of Arts and Sciences and the American Philosophical Society. He was the 2011 Dan David laureate in Evolution and was awarded the 2016 Kimura Prize in Evolution by the Japanese Suzuki Foundation.

Updated on 1/31/2020

Notifications from ResearchGate

Vesa Cosmin Mihai recommended your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Apr 6, 2019

Md Azree Othuman Mydin and 2 others recommended your publications: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Mar 25, 2019

Bahra Karima followed your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Mar 25, 2019

Javad Parmah followed your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Nov 27, 2018

Sebastian Nemeth recommended your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Jul 29, 2018

Daniela Gitea and Gabriela Cioca recommended your publications: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Jul 27, 2018

Vyacheslav Lyashenko followed your publication: Regenerative and Translational Medicine: The Therapeutic Promise for Cardiovascular Diseases

Oct 10, 2016

Santiago Prieto Menchero followed your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Jan 9, 2016

Musaab Salih followed your publication: Metabolic Genomics & Pharmaceutics: Volume I

Dec 12, 2015

UPDATED on 1/10/2020

The following three testimonials resulted from three interviews conducted by Prof. Sheila M. Puffer (UC, Berkeley, PhD’84) in December 2019 for Prof. Puffer’s nomination of Dr. Lev-Ari for 2020 Campanile Excellence in Achievement Award. This award recognizes an alumnus/a whose remarkable professional achievements reflect the excellence of a UC Berkeley education.

Past Recipients

https://awards.berkeley.edu/achievement-awards

The recipients will be formally presented with their awards at Berkeley Charter Gala on May 14, 2020.

Dr. Marcus Feldman

Professor of Biology, Stanford University

Dr. Feldman, who has been deeply involved in Dr. Lev-Ari’s e-publishing venture, expressed his admiration for her career and contributions in multiple and diverse scientific and medical fields. ‘She single-handedly formed the venture to curate the biological medical literature and has produced 16 online books with her collaborators. She has had enormous success in producing nontechnical reviews of technical literature in the medical field, so that the scientific findings are much more accessible to the professional side as opposed to the research side. She has worked extremely hard on developing that professional resource for the biomedical field, which is unique to any field. Her accomplishments represent the best of what Berkeley can produce.”

 

Dr. Justin Pearlman

Professor of Medicine, Practicing Cardiology, UCLA, and Practicing Cardiologist

Dr. Pearlman was one of the early members of the electronic publishing team and served as the editor of three of the volumes. He noted that it was Dr. Lev-Ari’s idea to develop an online pharmacology journal of a completely new design called curation. She also came up with the idea of multimodality, to include videos and other media. He explained that expert reviewers provide reviews and critique the strength and weaknesses of the research and provide and additional information that open eyes to new opportunities. He himself was one of those experts who willingly became deeply involved in the project, and the caliber of his credentials attests to Dr. Lev-Ari’s persuasiveness in getting such experts to devote their time and talents to the project. Dr. Pearlman already had an established reputation as the Vice Chair of Medicine at UCLA and Chief of Cardiology, was an editor and writer, and had over 4,000 citations of his publications.  He explained: “By the sheer force of her personality, Aviva put together a team of experts, and she encourages a new generation to utilize this material. This is important because the new generation is not aware that articles can have their own agenda, such as needing to please granting organizations that fund the research. Aviva has a strong entrepreneurial spirit and investigates many different avenues to make things better – business, medical, biological, and scientific.”

 

Dr. Stephen Williams

Assistant Professor of Pharmacology at the Sbarro Health Research Organization at Temple University

Dr. Williams  has known Dr. Lev-Ari since 2012 when he noticed her call for collaboration on her electronic publishing project on several LinkedIn groups. He was intrigued and contacted her, and became one of the senior editors of the publishing project. “I have never met anyone so driven as Dr. Lev-Ari. She had a great vision and knows how to put that vision into practice. She has an impressive amount and quality of people she has direct contact with.

It was a no brainer. I said, ‘I have to work with her.’ I am very, very happy with that decision. The project developed into a site that deals with all areas of medicine and related scientific disciplines. It is an open access, open science forum with the goal of breaking down silos. In addition, she developed a methodology for real-time medical conference coverage.The whole world is dying for knowledge. People are hungry for this collaboration, including in both developed and developing countries.”

He explained how she created the project: “It is amazing how she set up the venture and has grown it over such a short time and involved the top people in many fields. To me it is absolutely amazing for such a niche website. She set a goal of bringing scientists together in an online community to provide comments and insights. To the degree that happened is fantastic. She personally knows and has gained the involvement of some of the most sought-after researchers in cancer and other fields as keynote conference speakers and the like. I believe some will be future Nobel laureates. She establishes great relationships and has a great rapport with everyone.”

Regarding Dr. Lev-Ari’s accomplishments and personal character, he noted: “She has more energy than some 20 and 30-somethings. She does not stop until she sees her vision realized. She has received many accolades for her accomplishments, including her work at Mitre Corporation. Since 8/2018, Dr. Lev-Ari was contacted by the President elect of the Massachusetts Academy of Sciences (MAS), Prof. Katya Ravid of Boston University, School of Medicine, to join MAS in the role of Liaison to the Biotechnology and eScientific Publishing industries for the term of August 2018-July 2021. In the MAS, Dr. Lev-Ari serve as Board member, Fellow, and Advisor to the Governing Board. http://www.maacadsci.org

She has in-depth knowledge of many medical fields. She wrote an article that is available on the publication website about reinventing yourself. And that is something that she has done over and over again. Her career includes complex IT, nursing, and scientific publishing in biomedicine and biomedical research. In scientific careers, you’re in a constant state of reinventing yourself. For others, that may seem scary, but for her it is exciting. I tell my colleagues and students to take it the way Dr. Lev-Ari takes it – as an absolutely exciting journey. In every part of her life she looks at it as an exciting journey, even the obstacles she had to overcome.”

11/27/2019

Dear Aviva,

Thank You note from sandraleebatista@yahoo.com

Happy Thanksgiving to you and your family! I am so very grateful for your friendship and mentorship over so many years.

We will be here in Los Angeles and it will be a quiet holiday full of reflections on gratitude.

Best wishes,

Sandra

5/29/2019

From: “Klein, Susan Beth” <sbklein@indiana.edu>

Date: Wednesday, May 29, 2019 at 3:13 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Re: Permission to reprint image

Thank you very much for permission to reprint and also your useful suggestions. I shall certainly consider all of this content!

Susan

Susan B. Klein, PhD

Department of Physics

Swain West 331

Indiana University, Bloomington

812.855.9687

From: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Sent: Wednesday, May 29, 2019 12:46 PM

To: Klein, Susan Beth

Cc: Stephen Williams, PhD; Marcus W Feldman; Dr. Larry Bernstein; Aviva Lev-Ari

Subject: Re: Permission to reprint image

 

Dear Prof. Klein,

Your e-mail, below called for my re-read of Dr. Larry H. Bernstein’s article where the figure you wish to re-publish was found.

It was indeed, a special pleasure to read again his article and to realize one more time, how important the curation work is for dissemination of scientific findings. Dr. Larry is a Biochemist, retired Pathologist and one of the best writers in Medical Sciences among the livings.

See

The Young Surgeon and The Retired Pathologist: On Science, Medicine and HealthCare Policy – The Best Writers Among the WRITERS

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2013/12/10/the-young-surgeon-and-the-retired-pathologist-on-science-medicine-and-healthcare-policy-best-writers-among-the-writers/

I recommend that in your forthcoming book on Radiation Biology you will consider the following suggestions: 

A. Include Agents that Damage DNA [as in Dr. Larry’s article, not limited to it]

B. Refer the reader to Dr. Larry’s article which is a unique resource on the topic of DNA and DNA Replication 

C. Please review the Table of Contents of our Genomics, Volume One, it may assist you with A, above

https://pharmaceuticalintelligence.com/biomed-e-books/genomics-orientations-for-personalized-medicine/volume-one-genomics-orientations-for-personalized-medicine/

Regarding re-publishing the figure:

I am suggesting to add the following comment: 

Image Source

Image is the copyright of Buzzle.com, cited in A Primer on DNA and DNA Replication by Reporter and Curator: Larry H. Bernstein, MD, FCAP 

https://pharmaceuticalintelligence.com/2014/07/29/a_primer_on_dna_and_dna_replication/

I wish you best of luck with researching the scientific literature for this very important and timely forthcoming text book on Radiation Biology.

Very proud to share with you that we have on Leaders in Pharmaceutical Intelligence portal:  http://pharmaceuticalintelligence.com    

 1,627,949 e-Readers, 678 Categories of Research and +10K Tags and 5,594 scientific article CURATIONS & Scientific reporting.

 

Please keep in touch and I encourage you to continue to search our Journal archive. 

Best regards,

PS

This e-mail is your e-written permission to re-publish figure as commented, above.

Leaders in Pharmaceutical Intelligence portal:  http://pharmaceuticalintelligence.com    

LPBI Group was created in 2012 by me, Aviva Lev-Ari, Ph.D., R.N. The Group has three interrelated healthcare content products: an open-access online scientific journal (Journal archive is an article corpus); a series of 16 BioMed e-books (BioMed e-Series is an e-Book corpus); and real-time coverage of BioMed scientific and medical conferences (An archive of conference e-Proceedings corpus). Through these transformative products, the Group effectively meets and exceeds the information needs of researchers, scientists and industry pharmaceutical and biotechnology executives by offering real-time and currently available medical and scientific information on any biomedical subject (700 categories). LPBI also makes information on cutting-edge biomedical research innovation widely available to the scientific and non-research community using a process of connections to multiple social media platforms, chiefly LinkedIn, Twitter and Facebook. The method of curation includes synthesis, analysis and interpretation of complex medical and scientific areas.

Aviva Lev-Ari, PhD, RN

Director & Founder

https://lnkd.in/eEyn69r

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

Editor-in-Chief

http://pharmaceuticalintelligence.com 

e-Mail: avivalev-ari@alum.berkeley.edu

(M) 617-775-0451

https://cal.berkeley.edu/AvivaLev-Ari,PhD,RN

SkypeID: HarpPlayer83          LinkedIn Profile        Twitter Profile

From: “Klein, Susan Beth” <sbklein@indiana.edu>

Date: Wednesday, May 29, 2019 at 9:12 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Re: Permission to reprint image

Thank you so much Aviva.

The url is https://pharmaceuticalintelligence.com/2014/07/29/a_primer_on_dna_and_dna_replication/.

The name of the article is “A Primer on DNA and DNA Replication”; Reporter and Curator: Larry H. Bernstein, MD, FCAP.

Appreciatively,

Susan

Susan B. Klein, PhD

Department of Physics

Swain West 331

Indiana University, Bloomington

812.855.9687

From: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Sent: Tuesday, May 28, 2019 12:17 PM

To: Klein, Susan Beth

Cc: Stephen Williams, PhD; Marcus W Feldman

Subject: Re: Permission to reprint image

 

Dear Prof. Klein,

It is always most endearing to correspond with another fellow Alumna of Berkeley.

Congratulations on your forthcoming book, Fundamentals of Radiation Biology. The publisher of the text is World Scientific, anticipated publication in 2023.

Thank you for reaching out to me for permission to reprint a figure.

Please e-mail me the name of the article you found this figure in on our Journal http://pharmaceuticalintelligence.com 

Or in one our our 16 e-Books in Life Sciences and Medicine on Amazon.com

https://lnkd.in/ekWGNqA

I will then research and grant you re-printing permission in e-writing.

Since your forthcoming text book is on Radiation Biology, in this context, I wish to bring to your attention two points:

1.You may find of interest the following e-Books of ours

Series B: Frontiers in Genomics Research

 

  • VOLUME 1: Genomics Orientations for Personalized Medicine. On Amazon.com since 11/23/2015

http://www.amazon.com/dp/B018DHBUO6

  • VOLUME 2: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology

https://pharmaceuticalintelligence.com/biomed-e-books/genomics-orientations-for-personalized-medicine/volume-two-genomics-methodologies-ngs-bioinformatics-simulations-and-the-genome-ontology/

Work-in-Progress

 

Series C: e-Books on Cancer & Oncology

 

  • Volume 1: Cancer Biology & Genomics for Disease Diagnosis. On Amazon.com since 8/11/2015

http://www.amazon.com/dp/B013RVYR2K

  • Volume 2: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery (Series C Book 2). On Amazon.com since 5/18/2017

http://www.amazon.com/dp/B071VQ6YYK

2. My articles on medical OUTCOMES of Radiation Biology  on Cardiotoxicity

Cardio-oncology and Onco-Cardiology Programs: Treatments for Cancer Patients with a History of Cardiovascular Disease

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2014/01/08/cardio-oncology-and-onco-cardiology-programs-treatments-for-cancer-patients-with-a-history-of-cardiovascular-disease/

3rd Annual Canadian Cardiac Oncology Network Conference, June 20 – 21, 2013, Ottawa Convention Centre

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2014/01/08/3rd-annual-canadian-cardiac-oncology-network-conference-june-20-21-2013-ottawa-convention-centre/

2019

http://cardiaconcology.ca/ccon-conference-2019-modern-changing-practices-in-cardio-oncology/agenda/

My Journal on Cardiotoxicity on Scoop.it

https://www.scoop.it/topic/cardiotoxicity

Looking forward to getting name of article when the figure had appeared in our publications.

Good luck,

Aviva Lev-Ari, PhD, RN

Director & Founder

https://lnkd.in/eEyn69r

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

Editor-in-Chief

http://pharmaceuticalintelligence.com 

e-Mail: avivalev-ari@alum.berkeley.edu

(M) 617-775-0451

https://cal.berkeley.edu/AvivaLev-Ari,PhD,RN

SkypeID: HarpPlayer83          LinkedIn Profile        Twitter Profile

From: “Klein, Susan Beth” <sbklein@indiana.edu>

Date: Tuesday, May 28, 2019 at 11:11 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Permission to reprint image

Hello Aviva Lev-Ari,

I am currently writing a book: Fundamentals of Radiation Biology. I would like to know if I might have your permission to reprint this figure in a section on DNA replication. The publisher of the text is World Scientific and we anticipate publication in 2023. I would very much appreciate your permission; this is a lovely illustration!

Regards,

Susan

Susan B. Klein, PhD

Department of Physics

Swain West 331

Indiana University, Bloomington

812.855.9687

(another Berkeley alum)

April 2019

2019 Ranking of Conference Influencers: On 4/9/2019, The Partners’ 2019 World Medical Innovation Forum #WMIF19

via @symplur‘s #Healthcare Hashtags http://bit.ly/WMIF19 

  • By “Mentions” – Ranked #4: @pharma_BI and
  • By “Tweets” – Ranked #2: @AVIVA1950

via NodeXL  http://bit.ly/2KB6cPN 

  • By “Betweenness Centrality” – Ranked #3: @AVIVA1950 and @pharma_BI

https://pharmaceuticalintelligence.com/2019/04/13/the-wmif19-influencers-via-symplurs-healthcare-hashtags-http-bit-ly-wmif19-by-mentions-and-by-tweets-ranked-4-pharma_bi-and-2-aviva1950-respectively-ranked-3-via-node/

4/21/2019

From: Amnon Danzig <amnon.danzig@gmail.com>

Date: Sunday, April 21, 2019 at 4:17 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: A Letter from Amnon Danzig

Dear Aviva

Now, I read the two docs in depth.

Sure, I have a few questions for my understanding. We can devote Skype for that to make sure I understand…

It is my honor to work with you and the team.

I found Gail and Rick extremely good players, partners and colleagues at the same time. And I would like to thank you for the opportunity to work with them.

I would like to thank you for your very fine and warm words about my contribution. GREAT!

I must confess that in the last three months I couldn’t do any real intellectual work. I need to finalize my speech at the conference and couldn’t touch it.

Why?

My thinking was always going to the ways to present LPBI Group the best it can.

I found myself very busy intellectually and emotionally how we can improve the way the IB will see us.

Example: the last two weeks I invested happily dozens and dozens for this assignment. On Thursday afternoon my son arrives and we spent a few hours together. Then, on 9 PM I set down to make the corrections you asked me. Took me another 3 hours, sent it and waited another two hours to see whether I need some more. Because I knew that on Friday you MUST send. It was kind of relief after two hours. When you sent us the update I saw it and felt “everything is okay” and I can put my mobile away for 24 hours: all the family, friends were around I thought it better to be disconnected.

I am very glad you found my contribution significant. Also, the way you express it is outstanding. Thank you!

Now, I will spend a few days about the conference and also looking for ways to find significant people to meet and discuss my new book. The idea to find more audience and hopefully potential clients.

If you happen to have ideas for me, great.

This is the reason I extend my time in NYC. 

BR 

Amnon

@@@@@

4/19/2019

LPBI Group: The Business Opportunity

Voice of Prof. Marcus W. Feldman

The intellectual property of LPBI is of three types: a corpus of curated articles in an open access online scientific Journal, a corpus of e-books in Medicine and Life Sciences, and a corpus of Biotech e-proceedings. This IP is highly relevant to five industrial and services sectors across twelve economic segments. LPBI has pioneered production of scientific content with unique curation methodology by a highly knowledgeable group of experts. The content and the potential consumers & acquirers and valuers of this content are represented graphically below. The three types of corpus, together with the very large audience that follows the content on various media, represent intangible assets of LPBI Group and can be represented as such to potential investors. Together with the tangible assets described in Document #2, the combination represents a unique opportunity for acquisition.

@@@@@

4/19/2019

LPBI Group: The Business Plan

Voice of Aviva Lev-Ari, Founder

The Business Plan representing work-in-progress generated by our business professionals, Amnon Danzig (AD), Gail Thornton (GST) and Rick Mandahl (RM).

  • The content is extracted from Document #2, the concept of the “Client End-User Perspective” and the “Acquirer Perspective” are contributions by Amnon Danzig (AD). 
  • The positioning of 12 economic segments in a 3D structure for each of these two perspectives represent contributions of AD, GST and RM, under the leadership of AD. They took the microeconomics Theory of the Firm to most interesting interpretation given for several Demand aspects related to the performance of Knowledge Workers in the digital workplace as potential users of LPBI Group’s products.
  • They followed the 3D illustration developed by Aviva Lev-Ari, PhD, RN (ALA) using three different axes for representation of same 12 economic segments. The view taken by ALA is of Industrial Organization Economics theoretical framework of comparisons among industrial and services sectors and within each sector competition among player drawing strategies for augmenting the competitive advantage by horizontal and vertical mergers. Opportunities for economies or scale, externalities, diversification and product differentiation. In ALA’s perspective, LPBI Group’s IP represents Supply side, a series of technologies poised to augment the core competencies of players in 12 economic segments as in Appendix C, below [which is identical to Table developed by ALA for Sections #4 & #5 in Document #2.
  • Further development of this Business Plan document will follow in the near future.

This Business Plan is based on and is complementary to Document #2 that provides a distinctive view on Intangible Assets, Sections #1 to #12 vs Tangible Assets and royalty payments which are present in Section #13 & #14 of Document #2.

This Business Plan consists of a conceptual framework developed by the business side of our Final Improvement Team (FIT members N=12). This conceptual framework is indeed unique in depth and breadth placing the unmet needs of potential acquirers by name, each in an economic segment, each economic segment within an Industrial and Services Sector. It demonstrates deep understanding of Demand side economics of the End-User in each of the 12 economic segments. This strategic thought process represents well AD’s business acumen for placing in the center the ultimate demand of end-users and the unmet needs of potential Acquirers that will be fulfilled on their behalf by LPBI Group’s IP – the features and functionality of the technologies we have developed since 2012.

 

@@@@@

4/14/2019

The #WMIF19 Influencers via ‘s  Hashtags http://bit.ly/WMIF19 – By Mentions and By Tweets Ranked #4: @pharma_BI and #2: @AVIVA1950, respectively. Ranked #3 via NodeXL Betweenness Centrality http://bit.ly/2KB6cPN

https://pharmaceuticalintelligence.com/2019/04/13/the-wmif19-influencers-via-symplurs-healthcare-hashtags-http-bit-ly-wmif19-by-mentions-and-by-tweets-ranked-4-pharma_bi-and-2-aviva1950-respectively-ranked-3-via-node/

4/13/2019

Twitter Data for LPBI Group’s Founder’s Twitter handle @AVIVA1950 was updated 

On 2/24/2019 — Tweets 8,060 Following 1,412 Followers 359 Likes 2,752

On 4/13/2019 — Tweets 9,018 Following 1,461 Followers 390 Likes 3,654

 

4/11/2019

Top 3 Ranked by Betweenness Centrality in Top 10 Influencers #WMIF19 @phsinnovation @evankirstel @aviva1950 –Tweeter Analytics by NodeXL http://bit.ly/2KB6cPNfor #WMIF19 by @PHSInnovation  at World Medical Innovation Forum ARTIFICIAL INTELLIGENCE, Boston, MA USA, Monday, April 8-10, 2019

https://pharmaceuticalintelligence.com/2019/04/11/top-3-ranked-by-betweenness-centrality-in-top-10-influencers-wmif19-phsinnovation-evankirstel-aviva1950-tweeter-analytics-by-nodexl-http-bit-ly-2kb6cpn-for-wmif19-by-phs/

@@@@

‘s  Hashtags  – Twitter Analytics published for http://bit.ly/WMIF19 

  • [Top 10 by Mentions – @pharma_BI = 4 with 181 mentions]  
  • [Top 10 by Tweets @AVIVA1950 = 2 with 229 Tweets (N = 152 Direct messages)]
 Pinned Tweet

⚡️As World   Forum comes to a close, here are TOP   via ‘s  Hashtags 🙏 to organizers for a stellar event & to all on  for a robust conversation!   👏 

@@@@

Top influencer 3rd place @AVIVA1950

This is a great analysis and I love that you found these two programs, NodeXL and Betweeness Centrality. These offer the best Twitter analytics and node analysis I have ever seen. Thanks for sharing and a great conference and great conference coverage in real time. Show the power of REALTIME CONFERENCE COVERAGE methodology @pharma_BI and @AVIVA1950 as well as power of LBPI Group.

https://nodexlgraphgallery.org/Pages/InteractiveGraph.aspx?graphID=193125

 

@@@@

From: “Gregory Piatetsky, KDnuggets” <editor1@kdnuggets.com>

Date: Wednesday, April 10, 2019 at 10:16 PM

To: Aviva Lev-Ari <aviva.lev-ari@comcast.net>, Gil Press <gpress900@gmail.com>

Subject: Re: Fwd: NodeXL Graph Gallery: Interactive Graph

Well done!  3rd place for #WMIF19 is good

See

Comparative Analysis of the Level of Engagement for Four Twitter Accounts: @KDNuggets (Big Data) @GilPress @Forbes @pharma_BI @AVIVA1950

 

@@@@

From: Leny <gochevav@mit.edu>

Date: Wednesday, November 28, 2018 at 11:30 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Re: MIT Center for Precision Cancer Medicine Inaugural Symposium – Question from Aviva Lev-Ari, PhD, RN

Dear Dr. Lev-Ari,

I actually have been meaning to reach out to you with an invitation to our symposium. We were both at the Personalized Medicine Coalition’s conference two week ago at Harvard Medical School, but I didn’t get a chance to speak to you in person.

To get a complimentary press pass, please visit cpcm.eventbrite.com -> select Tickets ->  select “Enter Promotional Code”-> enter CPCM2018 and that will allow you to select “Press” tickets.

Please do not hesitate to reach out if you have any additional questions.

Best,

Leny

Vasilena Gocheva, PhD | Assistant Director  | MIT Center for Precision Cancer Medicine  | 77 Massachusetts Avenue, 76-353  | Cambridge, MA 02139  | cpcm.mit.edu

From: Shankar Khatkale <shankar.k@gminsights.com>

Date: Tuesday, November 27, 2018 at 6:48 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Article Submission Request

Dear Editor,

An industry news titled ‘Precision Medicine Market Size worth $96.6bn by 2024’ by Global Market Insights is relevant to your esteemed website https://pharmaceuticalintelligence.com. This email is a suggestion to publish this news (content attached in word format or can be picked from link mentioned below) on your website with an objective to share the information with your audiences.

News Link: https://www.gminsights.com/pressrelease/precision-medicine-market

 Looking forward to hear from you.

 On behalf of and as instructed by Global Market Insights, Inc.

 Best Regards,

Shankar Khatkale |SEO Executive

 

From: Daphne Kwee <daphnekwee@farrerpark.com> on behalf of Daphne Kwee <daphnekwee@farrerpark.com>

Date: Monday, October 29, 2018 at 9:33 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Post retirement doctors establishing new career heights – Story Consideration

Dear Aviva,

Would you be interested in interviewing personalities in the medical Fraternity?

Particularly, Dr Leslie Lam. One of the renowned personality who was sued by the SMC and won after a 7 year battle. He is a medical veteran in his 70s but shows no signs of slowing down. He has re-established himself in Farrer Park Hospital and is blazing a trail with his new clinic. Having recently been conferred the Distinguished Graduate Award by the University College Dublin School of Medicine for his contribution toward medical education, research and support toward the community. Previous recipients of this award includes Professor Connor Ward who pioneered work on Cardiac abnormalities such as the co-described Ward-Romanov Syndrome.   

Dr Lam’s story strikes a chord with the government’s stand of lifelong learning and contribution. In addition to his clinical work, Dr Lam is an advisor to the Seychelles ministry of health, contributes regularly to teaching doctors and donating medical equipment to Myanmar. He also established a leading wine collection in order to fund his philanthropic works with charities in Singapore and Ireland, where he received his medical education. 

I have attached the award letter to this email for your information. 

Should you be interested in such a story angle, I do have other personalities here at Farrer Park Hospital for your consideration. Professor Tan Yew Oo, Singapore first medical oncologist, as well as Professor Soo Khee Chee, the founding director of Singapore’s National Cancer Centre. All these renowned medical personalities, who in their post retirement years, are still actively contributing toward Singapore’s future.

Do let me know if you would like to find out more to explore story possibilities. I would be happy to catch up over lunch or tea for a discussion.

 

Best regards,

Daphne

Executive

Corporate Communications

DID (65) 6705 2769  

www.farrerpark.com/hospital

From: “Prof. Nathan F. SAYRE (Chairman, Geography)” <nsayre@berkeley.edu>

Date: Friday, June 1, 2018 at 3:26 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Cc: Christian Gordon <cmgordon@berkeley.edu>, Robert Rhew <rrhew@berkeley.edu>

Subject: Re: I will be on BERKELEY Campus for the Homecoming Week, few days before and After, October 11, 2018 to October 16, 2018 — Hope to meet again

Dear Dr. Lev-Ari,

Thank you for your kind note, and wonderful to hear that you will be visiting campus in October. I’m happy to hear that you will see Professor Birgeneau and other Cal alumni in New England. I know the university will be ramping up its efforts in Boston and surrounding areas, to create more opportunities for alumni to connect with each other, and with Berkeley.

I would like to introduce you to Christian Gordon, our partner in development and alumni relations for geography and the division of social sciences. Christian can assist with setting up your visit and relevant meetings while you are on campus. He’s also happy to follow up with additional information, as well as additional opportunities in Boston to connect with Berkeley between now and October.

Very much looking forward to seeing you at Homecoming. Thanks again for sending your recollections of Allan and Berkeley!

Best,

Nathan

PS I’m cc’ing Professor Rob Rhew, who will succeed me as department chair on July 1st.

From: “Prof. Michael Watts” <mwatts@berkeley.edu>

Date: Sunday, May 13, 2018 at 1:29 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Re: Sharing with you — This May 2018, Official Newsletter has a Global distribution of half a million Inboxes: See article on Aviva Lev-Ari in ALUMNI SPOTLIGHT of American Friends of Hebrew University

Dear Aviva: a very long time!  Nice to hear from you and your later extraordinary career!  And it seems like you are now on Phase IV.  Very exciting.

I am retiring in June but will of course keep writing and conducting research.

You may have heard that Allan’s wife Hjordis passed away relatively recently.   It was nice to see their children again at the memorial.

Warmly, Michael

On Fri, May 11, 2018 at 12:01 PM, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu> wrote:

Sharing with you — This May 2018, Official Newsletter has a Global distribution of half a million Inboxes:  

See article on Aviva Lev-Ari in ALUMNI SPOTLIGHT of American Friends of Hebrew University – Please scroll down

If interested to read more, click on:

Aviva’s books on AMAZON.COM

https://www.amazon.com/s/ref=nb_sb_noss?url=search-alias%3Ddigital-text&field-keywords=Aviva+Lev-Ari&rh=n%3A133140011%2Ck%3AAviva+Lev-Ari

On Fri, May 25, 2018 at 12:44 PM, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu> wrote:

Dear Professors, Watts, Walker, Sayre, Laguerr and Segev, 

I hope you are well and will enjoy the months of Summer coming up.

We will have dinner with Berkeley’s ex-Chancellor, Prof. Robert Birgeneau in Boston on 6/16/2018, meeting with Alumni in New England. I am much looking forward to his talk and meeting alumni.

I will be on BERKELEY Campus on October 11, 2018 to October 16, 2018, planning to attend the Homecoming Week, October 12-14, 2018.

It will be my great pleasure to meet again, I hope you will be on Campus at least one day of the week in October 2018 when I will be on Campus and could meet you. Allan Pred will be missing on this visit, so sad.

I recently wrote my Recollections of my five years at Berkeley in two Parts, which you may find of interest to read, in particular, Part 2, which I authored as a curation, after my e-mail exchange with Prof. Michael Watts in May, 2018.

  • Recollections: Part 1 – My days at Berkeley, 9/1978 – 12/1983 – About my doctoral advisor, Allan Pred, other Professors and other Peers

https://pharmaceuticalintelligence.com/2018/03/15/recollections-my-days-at-berkeley-9-1978-12-1983-about-my-doctoral-advisor-allan-pred-other-professors-and-other-peer/

  • Recollections: Part 2 – “While Rolling” is preceded by “While Enrolling” Autobiographical Alumna Recollections of Berkeley – Aviva Lev-Ari, PhD’83

https://pharmaceuticalintelligence.com/2018/05/24/recollections-part-2-while-rolling-is-preceded-by-while-enrolling-autobiographical-alumna-recollections-of-berkeley-aviva-lev-ari-phd83/

Please Read these two:

I attended the 1998 – 100 years Geography Department celebration.

Please review the following, it can be included in the future Itinerant Geographer.

Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018

https://pharmaceuticalintelligence.com/2018/03/06/reflections-on-a-four-phase-career-aviva-lev-ari-phd-rn-march-2018/

Thank you – Good Luck to you

From: “Prof. Nathan F. SAYRE (Chairman, Geography)” <nsayre@berkeley.edu>

Date: Thursday, March 8, 2018 at 6:07 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Re: I MADE A CONTRIBUTION IN MEMORY OF PROF. ALLAN PRED few weeks ago

Dear Aviva,

Thank you for writing. Yes, we did receive your donation in Allan’s honor–thank you!–and we put a letter of thanks and acknowledgement in the mail last week. Please look out for it.

You are not alone in missing Allan–many many people do. Sadly, his widow, Hjordis, also passed away not long ago.

Michael Watts is not yet technically retired, but he thought he would two years ago, and since we made a big public announcement then we’ve kept the technical truth quiet. He will in fact retire this summer. As you assumed, Walker, Reed, and Nat have all retired, as have Beatriz Manz, Gillian Hart, Paul Groth, Michael Johns, and Roger Byrne. We are anxiously awaiting authorization to recruit new human geography faculty.

It’s kind of hard to think of any of us as adequate to fill Allan’s shoes, but we all try to preserve his flexibility of mind and lucidity of thought. Our graduate students perhaps carry on his intellectual legacy best. If you haven’t heard of Trevor Paglen, he was one of Allan’s last PhDs:

http://www.paglen.com/

Thank you also for the links to your eulogies for Allan and David, and to your reflections. I am touched by your words and your enduring support for the department.

Best,

Nathan

On Monday, July 24, 2017 at 9:27 PM

From: marzan Khan <marzan.khan@mail.mcgill.ca>

Date: Monday, July 24, 2017 at 9:27 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Re: SERIES E VOLUME 2 –>>> FORMAT CONVERSION — I MUST find out what has been done to FINISH up this format conversion – Series E Volume 2

Hello Aviva,

Thank you very much for your kindness and support. It was great working for you. I apologize for not being able to finish my task to completion. You have been an excellent mentor and I will be grateful to you always.

Best of luck on the e-book and all your endeavors.

Sincerely,

Marzan Khan

On June 18, 2017, 9;39AM

Dear Aviva Lev-Ari,

Thank you very much for your email.

First of all I would like to congratulate you to your outstanding work, if I may. You are one of the very few people with really meaningful and scientific articles/updates on LinkedIn.

I recently liked one of your articles/updates “Molecular Pathogenesis of Progressive Lung Diseases” on LinkedIn, because it was an interesting article. We have a project here in China “Natural Breathing”, where we look at solutions for COPD. With all the air pollution in China, this is already a majour burden, and it is one that will become a larger burden in the coming years. As for your email, I am not quite sure what to make out of it honestly. Is it an offer to write or publish an article? In regards to China: Please do not hesitate to contact me, if you have questions or if I may help with contacts in the healthcare industry. We have a quite good network here.

Sincerely from Beijing

Dennis Wilkens, Managing Director, Medical Devices, Health 4.0, Toronto, Hamburg, Beijing, Distribution Network, Investments & Ventures, Jadevita International Inc., University of Hamburg

On 6/15/17, 5:43 AM, “Anamika Sarkar” <sarkaranamika@yahoo.com> wrote:

Hi Aviva,

Thanks! I am also excited to join Regeneron.

Congratulations to your success of publishing in Amazon. Your focus and perseverance to science is admirable.

Best

Anamika Sarkar, PhD

@@@@@@

From: “Mark Cobbold, MD, PhD, MGH” <mcobbold@mgh.harvard.edu>

Date: Wednesday, April 27, 2016 at 11:32 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: RE: LIVE ­ 8:00 am ­ 12:00 pm 4/25/2016 ­ First Look: The Next Wave of Cancer Breakthroughs @2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Westin Hotel, Boston | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Thanks Aviva.

You obviously work hard on this!

Keep up the hard work.

Mark

MARK COBBOLD, MD, PHD

Headshot

Associate Professor of Medicine, MGH Cancer Center

http://worldmedicalinnovation.org/speakers/mark-cobbold-md-phd/

 

From: Aviva Lev-Ari [mailto:AvivaLev-Ari@alum.berkeley.edu]
Sent: Tuesday, April 26, 2016 7:53 PM
To: Cobbold, Mark
Subject: LIVE ­ 8:00 am ­ 12:00 pm 4/25/2016 ­ First Look: The Next Wave of Cancer Breakthroughs @2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Westin Hotel, Boston | Leaders in Pharmaceutical Business Intelligence (LPBI) Group
 

https://pharmaceuticalintelligence.com/2016/04/25/live-800-am-1200-pm-4252016-first-look-the-next-wave-of-cancer-breakthroughs-2016-world-medical-innovation-forum-cancer-april-25-27-2016-westin-hotel-boston/

Aviva Lev-Ari, PhD, RN

Director & Founder

Leaders in Pharmaceutical Business Intelligence Group, Boston

Editor-in-Chief

http://pharmaceuticalintelligence.com

e-Mail: avivalev-ari@alum.berkeley.edu

SkypeID: HarpPlayer83 

LinkedIn Profile        Twitter Profile

@@@@@

From: Arquisch Tony <Tony.Arquisch@cpagroup.ch>

Date: Friday, March 18, 2016 at 11:46 AM

To: Aviva Lev-Ari <aviva.lev-ari@comcast.net>

Cc: Arie Berger <arisimonberger@gmail.com>, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>, ‘Maggie You’ <maggie.you@oriental-ventures.com>

Subject: RE: REVOTEK follow up for 3D printing – AVIVA

Hello Aviva: 

To answer your questions:

The ownership at regenHU is as is.

The CEO of regenHU is Mr. Marc Thurner

The other CPA Group companies are unchanged i.e. no updates

With that said, of course until there are any official announcements, we continue to sell products and services accordingly. If there is interest in a particular product and/or service I will be more than happy to assist. If there is an investment interest then please send me an official inquiry (in writing) with as many details as possible upon which I will present it to management. Once there is an interest we will send Non-disclosure agreements and start the negation phase accordingly.

I truly hope we can work together since I’m impressed with your activities. Have a great weekend.

Regards,

Tony

Tony Arquisch

Business Development Manager
Direct +41 26 653 71 84
Mobile +41 79 349 20 44
tony.arquisch@cpagroup.ch

CPA Group SA
Z.I. du Vivier 22
CH-1690 Villaz-St-Pierre

Switzerland
Tel. +41 26 653 71 71
www.cpagroup.ch

LinkedIn Profile  /  XING Profile  / Twitter Profile

@@@@@@@

From: Christopher Wells <cwells@personalizedmedicinecoalition.org>

Date: February 19, 2016 at 3:40:19 PM EST

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Cc: David Davenport <ddavenport@personalizedmedicinecoalition.org>

Subject: Re: I wish to nominate Larry H. Bernstein, MD, FCAP for 12th Annual Award for Leadership in Personalized Medicine

Dr. Lev-Ari:

Thank you so much for what is clearly a strong nomination. David Davenport, copied here, will make sure that our Board of Directors gives careful consideration to Dr. Bernstein’s qualifications for this award, and I will follow up with you personally once we have made a final decision. 

By the way, I am a fan of your work on Leaders in Pharmaceutical Business Intelligence. I am sure it is helpful for many personalized medicine stakeholders. 

Have a good weekend. 

Very sincerely,

Chris

Christopher J. Wells, M.P.A.

Communications Director

Cwells@personalizedmedicinecoalition.org

Direct: 202-589-1755 I Mobile: 202-580-9780

Personalized Medicine Coalition

Blog: Education & Advocacy

Twitter: @PerMedCoalition

1710 Rhode Island Ave. NW I Suite 700 I Washington, DC 20036

www.PersonalizedMedicineCoalition.org  

@@@@@@@

2/12/2016

2016 Communication Awards for Excellence in Reporting and Communicating Science, Medicine and Engineering Nomination

Book Title: * Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation
Publisher(s): * Amazon Kindle Direct
Publication Date: (Please select one): * November 2015
Book Entry Summary (Please limit to 100 words): * The explosion of scientific information has created difficulties tying together disparate discoveries, ideas, and potential applications. Pharmaceutical Business Intelligence is developing an innovative methodology for Global access to Biomedical knowledge rather than traditional search. To attain this complex goal they disseminate ORIGINAL Research via Content Curation by experts using critical thinking process & interpretation over open access networks, offering better organization and visibility of critical information useful for innovations in academic, clinical, and industrial research. Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation at http://www.amazon.com/dp/B018Q5MCN8 is nominated as an example of this methodology.
   

@@@@@@@

2/2/2016

Nominations for 2016 National Academies Communication Awards For Excellence in Reporting and Communicating Sciences, Engineering, and Medicine, Keck Futures Initiative

Editor-in-Chief: Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2016/02/02/nominations-for-2016-national-academies-communication-awards-for-excellence-in-reporting-and-communicating-sciences-engineering-and-medicine/

@@@@@@@@@

From: “Tilda Barliya, PhD” <tildabarliya@gmail.com>

Date: Tuesday, January 19, 2016 at 1:09 PM

To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>

Press Releases from Leaders in Pharmaceutical Business Intelligence (LPBI): FIVE new e-Book in our BioMed e-Series are NOW available for Kindle on Amazon.com | Leaders in Pharmaceutical Business Intelligence

Wow!!!!! That’s very impressive. So proud of being part of this group and project.  Good job everyone.

Thank you Aviva for being the leader of this group and pushing us forward. Thank you for being you.

Good job everyone!!!

Best

Tilda

@@@@@@@@@

From: Gregory Piatetsky-Shapiro <gregory@kdnuggets.com>

Date: Sunday, January 10, 2016 at 6:13 AM

To: Aviva Lev-Ari <aviva.lev-ari@comcast.net>

Subject: Re: big data start up for you to talk to…

Dear Aviva,

Happy New Year and congratulations on your amazing success in your latest venture – Pharmaceutical Intelligence!

Gregory

On 1/9/2016,  I wrote to Gregory:

My eight years in HealthCare, 2005-2012, could have been an entry into HealthCareIT, as we discussed in 2012. However, I decided to tackle Pharmaceutical Intelligence , instead. The learning curve was very steep and it was conquered in record time, as evidenced by building an amazing impactful infrastructure in Scientific Media in Pharmaceutical Intelligence:

Journal, ~4000 articles archived, 900,000 e-Readers

e-Books, 15 Title BioMed e-Series, eight are on Amazon.com in 2015, seven forthcoming, in 2016

Conference Press Coverage in Real Time, sixteen of the Leading in BioTech. In 4/2016, Partners HealthCare, Global Cancer Conference in Boston.

In 3D BioPrinting, we lunched a Subsidiary, TEAM is involved in Product Concepts Development using

  • BioMEMS for Gene Editing
  • BioMEMS for Tissue Engineering
  • BioMEMS and Stem Cells for Gene Therapy and Regenerative Medicine.

We are also involved involved in (a) Drug Discovery by structuring Joint Ventures and in (b) Funding Early Stage Biologics Drug Development and Medical Device Development.

@@@@@@@@

Please see #3

Mayo Clinic Center for Innovation is citing LPBI’s Article by Dr. Larry H Bernstein, MD, FCAP

16 NOV 5 FOR TODAY

Posted at 06:30h in Morning Update by Center for Innovation 0 Comments Share

  1. Responsible innovation in health care and dual use research. [ Health Kid ]
  2. A patient’s point of view. [ HRBR ]
  3. Drivers of Patient Experience. [ LPBI ]
  4. 5 ways providers can improve the patient experience. [ FierceHealthIT ]
  5. Telehealth is essential to lowering readmission rates. [ mHealthNews ]

@@@@@@@@

From: “Dr. MD. K. Singler” <Dr.MD.K.Singler@sciarticles.net>

Reply-To: “Dr. MD. K. Singler” <Dr.MD.K.Singler@sciarticles.net>

Date: Friday, November 13, 2015 at 10:14 AM

To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>

Subject: Invitation

Science and Education

November, 2015

Submit a manuscript

Journals

Articles

Subscribe

Search

Unsubscribe

Dear Colleague,

I am writing to let you know about recent highly accessed articles published in our open access journals and invite you to submit your next manuscript to the journal.

Read our top articles

Dr. MD. K. Singler

Editorial Assistant, Science and Education Publishing

@@@@@@@@@

From: Anne Sim <georgeclinicalau@gmail.com>

Date: Monday, August 3, 2015 at 3:39 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: contributing

Hello,

I am contacting you on behalf of George Clinical, a leading non-profit CRO in the Asia Pacific region. Our parent organization, The George Institute is a renowned medical research institute which has impacted medical practice and policy globally.

We are currently working to build upon our brand awareness by sharing our extensive knowledge and experience within the scientific and medical community. We would love to learn more about any opportunities (publishing, marketing, sponsorship, co-authorship) that you might have available.

We appreciate your time, and If you would be kind enough to provide us information on possible opportunities that you offer, we can review them and see which are a good fit between our organization and yours.

Thanks,

Anne Sim

@@@@@@@@@@@@@@@@@

From: Christopher Wells <cwells@personalizedmedicinecoalition.org>

Date: Wednesday, September 2, 2015 at 11:36 AM

To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>

Subject: Thank you for re-blogging our post

Hi Dr. Lev-Ari:

I noticed that you re-blogged our recent post on Education & Advocacy, titled “Turning a Corner: How This Month’s Decisions at FDA Inform the Debate on Drug Costs.” I just wanted to thank you for that. We are working to build a following for the blog, and a re-posting from an established and reputable source like your blog is helpful. 

I will keep an eye on content from your blog moving forward. Feel free to let me know if you ever post anything on personalized medicine. 

Thank you again.

Sincerely,

Chris

Christopher J. Wells, M.P.A.

Communications Director

Cwells@personalizedmedicinecoalition.org

Direct: 202-589-1755 I Mobile: 202-580-9780

Personalized Medicine Coalition

Blog:Education & Advocacy

Twitter: @PerMedCoalition

1710 Rhode Island Ave. NW I Suite 700 I Washington, DC 20036

www.PersonalizedMedicineCoalition.org  

Unknown@@@@@@@@@@@@@@@@@

 
10/19/2015

Dear Aviva:

I want to applaud you for building your own publishing and scientific communications empire. You have really grown since 5/2013 when you and Larry and I first met. Anyway, down to business. I need help in “telling my story” of why the current 5 Nucleotide Watson Crick Genetic Code (ATGCU) need to expand with two additional and natural purine nucleotides to cover the epigenetic level of gene regulation so that Novagon’s 7 nucleotide ATUICGX genetic + epigenetic = genomic code is more valid than the current 5 code which has never built a man made prescription drug or any therapy which does not have multiple side effects including thousands of deaths. This project has got to big for me and I would like to join with your group to be discuss, strategically, how we can logically and empirically prove natures natural 7 code is the right number of codes and not 5. I don’t know how to proceed, but if you are interested we could meet i.e. whoever you want to bring into the project is fine by me; there are people in your group who can edit and write or rewrite what I have done much better than me. Remember, I grew up in Helena, Arkansas, in the Delta region, on the Mississippi river. Lots of cotton, but not many brains, especially in the teaching ranks. Any way I have come along way from there but I still am deficit or maybe lazy in writing and editing. Although my ADHD might be a strong contributing factor. Any, way I have tried and finally willing to concede, One person cannot do it alone. I have reached out to you because you were the first to ask me to join your team as Expert, author writer. Kind of ironic now that I am coming to you with great content but unorganized with no media plan or strategy. If Larry is interested I should would like him part of the project, if you decide to accept my scientific content and as publisher you we jointly publish what value proposition we determine as a team. Thanks for your notice. I took it as a cosmic sign, and it would be your 7th venture, quite ironic under the circumstances. Thank you for your time and I hope you decide to let me into your publishing umbrella and get some help in creating content for your growing empire. Thanks, John Berger Novagon DNA

John Berger

Founder at Novagon DNA

   
 
@@@@@@@@@@@@@@@@@@

 

   

 

Dear Dr. Aviva Lev-Ari,

Greetings from SciRes Literature!

It is a great pleasure to invite you for the Editorial Board membership in SciRes Literature member Journals. SciRes Literature is an Open Access Publisher of twenty-eight internationally refereed, online, peer-reviewed scholarly Journals designed for scientists, physicians, doctors and researchers across the globe. Our mission is to support the rising horizons of the scientific innovations and promote the advancement in research community by increasing the online accessibility of quality research articles.

The Editorial Office is actively seeking qualified researchers and experts to be a part of our journal Editorial Board. In recognition to your distinguished accomplishments in the area of Immunology (related areas), we are pleased to invite you to be a part of our SRL Immunology & Immunotherapy journal.

You can find more information by visiting us at:
http://scireslit.com/Immunology

You can support, strengthen and contribute to our vision through your expertise in area by joining our Editorial Board.

If you are interested in serving as an editor, kindly send us your short biography, Research interests, CV and Photo to immunology@scireslit.com for review.

Please feel free to contact for any further queries

Anticipating a positive response.

Sincerely,

SASHA Sims
Editorial Office, SciRes Literature
SRL Immunology & Immunotherapy
1692 Coastal Highway
Delaware 19958, USA
Email: immunology@scireslit.com

 

 

Testimonials about LPBI

2021

UPDATED on 9/29/2021

Tweet

 
MIT Technology Review
 
@techreview
Replying to

and

Thanks for joining us again
@AVIVA1950. We loved your tweets yesterday!
 
@techreview is the handle of MIT Technology Review Twitter account followed by 1.1 Million followers

MIT Technology Review

 

Retweeted your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT Charles Hoskinson CEO and Founder, Input Output Global; Founder, Cardano, 2015 Nation scale [Ethiopia] and Global scale – records ledger and smart contracts, credentials identity, reversible auditable that operates at scale; Cofounder, Ethereum

This image has an empty alt attribute; its file name is MIT-Technology-Review.png
 
 

MIT Technology Review

Retweeted your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT Charles Hoskinson CEO and Founder, Input Output Global; Founder, Cardano, 2015 Nation scale [Ethiopia] and Global scale – records ledger and smart contracts, credentials identity, reversible auditable that operates at scale; Cofounder, Ethereum

MIT Technology Review

liked your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT  Nick Selby Chief Security Officer, Paxos Trust Company at Timehop GDPR a bridge of security disclosure to US Citizens 5% of EU opt out 7/418 ADM password changed User database was compromised protect customers data Recovery architecture monitor

MIT Technology Review

Retweeted your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT @EmTechMIT Wendy Nather Head of Advisory CISOs @Cisco mid 90s Two-way authentications Who are the attackers, changes, abuse of the platform by users Technology to buy Proactive Refresh Tech done by vendor is best security practice

MIT Technology Review

Retweeted your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT Kevin Scott CTO @Microsoft Compute is the only constraint Open source version of OpenAI API no need to build OS. Responsible AI within Microsoft – Standard for the whole company to be rolled up soon. Regulation to consider where we are going to be

 
 
 

 

UPDATED on 9/22/2021

From INTERNS in 2021 LPBI’s Summer Internship

From: “Ethan Coomber [Intern 2021]” <ethancoomber6@gmail.com>
Date: Monday, September 20, 2021 at 11:54 PM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>

Hi Aviva,

This past summer, I was able to intern for LPBI. I really enjoyed being able to expand upon what I had been learning in the classroom at school, and push myself to take on new, exciting challenges. Over the summer, I was given 2 projects that were extremely interesting, but were vital in helping LPBI grow as well. With the guidance of LPBI, as well as my own outreach, I was able to expose myself to the world of text to audio conversion, as well as further my understanding of data analytics. The combination of resources at my disposal as well as Aviva’s guidance allowed me to make the most of the opportunity in front of me.

The mentorship I received from LPBI was extremely valuable. Being able to work so closely with LPBI’s founder, Aviva Lev-Ari PhD, Rn, I was able to get a detailed understanding of LPBI’s mission and how it relates to the projects I was working on. Aviva was a great resource as she allowed me to explore and be creative in discovering solutions, but was also available if I ever required guidance or leadership. I am proud of the work I was able to accomplish under Aviva’s guidance.

Looking forward to staying in touch,

Ethan

UPDATED on 6/1/2021 for May 24, 2021

From: Mass General Brigham <innovations@partners.org>

Reply-To: <innovations@partners.org>

Date: Monday, May 24, 2021 at 9:31 AM

To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>

Subject: RECAP | World Forum | Day 3 | GCT | CEOs | Harvard | Investors

Notable Tweets

 
 
 

@mandywoodland

Fascinating #WMIF2021 panel on mRNA yesterday -“mRNA is the message, and we just have to decide what message we want to deliver to the cell,” said moderator Lindsey Baden, MD. “The promise of this technology could not be more front and center for all of us.”

@LeapsByBayer

Congratulations to the 2021 Innovation Discovery Grants winners: @lynchielydia, Peter Sage, @GrishchukL, Benjamin Kleinstiver, Petr Baranov, announced at the #WMIF2021. It’s exciting to see the range of breakthrough research in #geneticdisease at @MassGenBrigham

 
 

@DrLilitGaribyan

Gene and cell therapy have scalability problems that we need to solve. This is what is echoed this week at @MGBInnovation World Medical Innovation Forum. #gct #celltherapy #healthcare #innovation

@MPDexpert

“imagine how the future could look if gene therapy cost 1/100th what it does today” @VCAmir @PolarisVC #wmif2021

@AVIVA1950 is Aviva Lev-Ari, PhD, RN

#WMIF2021 @MGBInnovation Roger Kitterman VP, Venture, Mass General Brigham Saturation reached or more investment is coming in CGT Multi OMICS and academia originated innovations are the most attractive areas @pharma_BI @AVIVA1950

@AVIVA1950_PIcs

IMG_7167

UPDATED on 2/15/2021

From: Nigel Russell <nrussell@jofpm.com>

Date: Monday, February 15, 2021 at 10:31 AM

To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>

Subject: RE: About our Venture

Dear Dr. Lev-Ari: 

Thank you for the information and outreach. You have a very interesting platform.

I am interested in chatting.

 

Kind regards,

Nigel

 

Nigel Russell

President

The Journal of Precision Medicine & the Precision Medicine Leaders Summit

Updated on 1/6/2021

From: “Jennings, Charlotte (Reuters)” <Charlotte.Jennings@thomsonreuters.com>

Date: Tuesday, January 5, 2021 at 10:47 AM

To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>

Subject: RE: REUTERS NEXT ­ Press Registration Deadline this Friday (Jan 8)

Hi Aviva,

Thanks for getting back to me. Your press pass for REUTERS NEXT is now confirmed.

It would be great if you could also please share your attendance with your network and across social media. You can find all sharing materials in the media pack here –

Attendees Pack · Reuters Next · Virtual Forum: January 11-14, 2021 (reutersevents.com)

Here’s a tracked sign-up link you can use when sharing – https://bit.ly/35ddYqO

Any other questions please don’t hesitate to reach out!

All the best,
Charlotte

2020

Updated on 8/25/2020

From: Robin Neff Clebnik <robin@internboston.com>

Date: Tuesday, August 25, 2020 at 5:23 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Thank You!

Hi Aviva,

Thank you for your contribution to a very successful summer for our InternBoston students! Your gifts of time, expertise were invaluable to our interns—and to our program as a whole. Your organization’s willingness to participate in InternBoston’s Virtual Summer60™ program allows high school and college students the opportunity to explore learning beyond the traditional limits of their classrooms. The first-hand experiences students receive in the internship will help prepare them for college and beyond.

By participating as a mentor, you have provided Noam with an exceptional opportunity to learn more about a potential career field in a structured and educational environment. Your dedication and commitment to establishing a work plan, overseeing the intern’s progress, and encouraging independence through learning have undoubtedly made a positive and lasting impact.

We look forward to continuing our partnership and will check in with you shortly to discuss more interns for Fall 2020.

 

Best,

Robin

robin neff clebnik

Chief Internship Officer

t: 617.527.0055 

m: 617.875.4614

          

Updated on 8/23/2020

 

The VOICE of Dr. Larry H. Bernstein, MD, FCAP on 8/23/2020:

I discovered a new site in 2012, and thereafter met Aviva Lev-Ari, PhD, RN, https://lnkd.in/eEyn69r

the Director & Founder of the Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston.

That led me to participate in writing for her Open Access Online Scientific Journal for five intense years, 1,400 articles in total. It is now late August 2020, and I have no longer engaged in the writing because of aging limitations.

I can indeed say, the Founder of the LPBI Group in Boston, Aviva, has really been a very fortunate leader, innovator, and collaborator in the LPBI Group’s medical and life sciences publishing endeavors. 

Aviva curated about my contributions to http://pharmaceuticalintelligence.com in the following two monumental sources: 

https://pharmaceuticalintelligence.com/2013/12/10/the-young-surgeon-and-the-retired-pathologist-on-science-medicine-and-healthcare-policy-best-writers-among-the-writers/

  • Editorial & Publication of Articles in e-Books by Leaders in Pharmaceutical Business Intelligence: Contributions of Larry H Bernstein, MD, FCAP
    Curator: Aviva Lev-Ari, PhD, RN

With heartfelt gratitude to our Dear Dr. Larry

https://pharmaceuticalintelligence.com/2014/10/16/editorial-publication-of-articles-in-e-books-by-leaders-in-pharmaceutical-business-intelligence-contributions-of-larry-h-bernstein-md-fcap/

Aviva published my authored contents in 18 volumes https://lnkd.in/ekWGNqA and in the following two memorable articles:

  • Commentaries on each Volume’s Contribution to Medical Education by L.H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN – BioMedical e-Books e-Series: Multiple Volumes in Five e-Series

Authors: L.H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/biomed-e-books/commentaries-on-each-volumes-contribution-to-medical-education-by-l-h-bernstein-md-fcap-and-aviva-lev-ari-phd-rn-biomedical-e-books-e-series-multiple-volumes-in-five-e-series/

  • My Memories Tell a Story to Share

Author: Larry Howard Bernstein, MD, FCAP

https://pharmaceuticalintelligence.com/2020/04/19/my-memories-tell-a-story-to-share-by-larry-howard-bernstein-md-fcap/

Aviva initiated, organized, edited and proposed a narrator for my interview for the following PODCAST:

  • Podcast with Dr. Larry H. Bernstein, MD, FCAP, Interview by Gail S. Thornton, PhDc, Narrator’s Voice: Stephen J. Williams, PhD

https://pharmaceuticalintelligence.com/audio-podcasts/podcast-with-dr-larry-h-bernstein-md-fcap-interview-by-gail-s-thornton-phdc-narrators-voice-stephen-j-williams-phd/

 

Updated on 8/11/2020

The VOICES of Interns of LPBI’s 2020 Summer Internship Program on Data Curation and Data Annotation

The Voice of Internship Team’s Captain, Daniel, Menzin:

LPBI has provided me with an invaluable experience this summer, which has allowed me to grow in a variety of ways. Through close mentorship, we were exposed to principles of data science (i.e. AI, ML, NLP), data curation and annotation, biochemistry, and website development. In addition to daily mentorship by Aviva, we were provided with weekly sessions where we were taught by world-renowned scientists. These sessions provided us with crucial background knowledge, as well as instructions which allowed us to execute and create deliverables while developing our professional skills. Aviva tasked me with several IT projects this summer that were challenging. It was a great opportunity for me to take advantage of the resources around me and learn on my own. Aviva mentored me throughout every step of the process, always providing feedback and showing me how I could improve my deliverables. My summer at LPBI provided me with an incredible opportunity to not only learn more, but also apply what I had learned through the creation of important deliverables. With the breadth of information I’ve been exposed to at LPBI, my professional horizons will surely now be broadened after having been taught things essential to numerous different fields.

The Voice of Noam Steiner Tomer:

Interning at LPBI has been instrumental in both my professional and personal development. Reading and curating many of the cutting edge and insightful articles that LPBI offers contributed significantly to my intellectual growth and broadened greatly my professional horizons. Through this internship I got to not only learn from many renowned researchers but gave me the unique opportunity to work with them directly. I also acquired many technical skills from the on-the-job training such as curation and improved my self-learning skills. It has absolutely been the most valuable experience of my high school career. I have learned so much from your presentations and doing the assignments, and have discovered interests I never knew I had like Hematology!

The Voice of Zach Day:

This summer I interned at Leaders in Pharmaceutical Intelligence (LPBI) in social media and market research.    In this capacity, I participated in weekly classes taught by medical experts about the latest developments in Cancer and Genetics Research. I met regularly with the company’s Director and Founder, Dr Aviva Lev-Ari and attended team meetings.  I wrote two articles about the company and its founder and uploaded them to Wikipedia. I also generated content for the company’s website including eleven WordClouds using WordItOut.com. Overall this was a great experience because I learned a lot, I contributed a lot and greatly appreciate the mentoring and support that I received working with Dr. Lev-Ari. 

 

Updated on 6/3/2020

Professor Marcus Feldman Receives Stanford Biosciences Mentoring and Service Award

Reporter: Gail S. Thornton, M.A.

Marcus Feldman, Ph.D., the Burnet C. and Mildred Finley Wohlford Professor in the School of Humanities and Sciences and Professor of Biology at Stanford University, has been selected to receive the 2019-20 Stanford
Biosciences “Excellence in Mentoring and Service Award”. This honor is given to faculty who make distinguished contributions towards enhancing the quality of training and the mentoring experiences for Stanford Biosciences graduate students.

In recognizing Professor Feldman for this honor, William S. Talbot, Ph.D., Senior Associate Dean of Graduate Education and Postdoctoral Affairs,
Professor of Developmental Biology,  at Stanford University, thanked him for his “extraordinary contributions this year.” Professor Feldman will be formally acknowledged for receiving this award and an honorarium at the School of Medicine Graduation Celebration on Saturday, June 13, 2020.

###

Updated on 5/7/2020

From: Alan Kaul <alan@mom-inc.us>

Date: Thursday, May 7, 2020 at 9:03 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Cc: Vinit Nair <vinit@pracnet.org>

Subject: Pharmaceutical Intelligence

HI Aviva,

You asked for my help in promoting your portal and I’ve done something that I haven’t done for any other organization, I put a direct link to your portal on Medical Outcomes Management’s home page.

[ see www.mom-inc.us ]

This is the only link to another business on our company’s website. We may move it’s location, but it will remain highly visible and directly linked.

I hope that this link will prove helpul to both of us

Stay safe,

Alan

Updated on 4/19/2020

ADDED to this entry by Dr. Larry H. Bernstein, MD, FCAP on 8/17/2020

“I am thankful to Aviva for the opportunity to follow my interests in retirement. I have been away from the laboratory longer than I would like, but could follow the literature.”

Sincerely,

Larry Bernstein, MD

“Prior to moving I was contacted by Aviva Lev-Ari, PhD, RN who was building an online medical forum known as Leaders in Pharmaceutical Business Intelligence (LPBI) Group, and I became the Chief Scientific Officer (CSO). Over the decade I wrote many articles (1,390) in the Open Access online Scientific Journal http://pharmaceuticalintelligence.com that were included in 18 organized e-Books in Medicine. Dr. Lev-Ari’s accomplishment is quite impressive. The e-Books are all available on Amazon.com”

https://lnkd.in/ekWGNqA

In:

My Memories Tell a Story to Share, 4/19/2020

Author: Larry Howard Bernstein, MD, FCAP

Contact: 413-727-8523

https://pharmaceuticalintelligence.com/2020/04/19/my-memories-tell-a-story-to-share-by-larry-howard-bernstein-md-fcap/

Updated on 2/9/2020

Obtained by Gail S. Thornton on 2/7/2020

Leaders in Pharmaceutical Business Intelligence (LPBI) is among the best resources of original scientific and medical content for the scientific and business community that is carefully chosen and thoughtfully organized and presented. The site offers a valuable contribution to biomedical science by advancing knowledge and research efforts through its commitment to synthesize, analyze and interpret complex, medical and scientific disease information on any subject, as well as biomedical research innovation widely available to the scientific and non-research community. There is a vast amount of quality, curated information on the site organized in three inter-related domains of an e-Journal, series of 16 e-Books and e-scientific and medical conference proceedings that is produced by an esteemed group of collaborators. 

In today’s biomedical science environment, there is a wide range of available information in journals of all subject areas and web sites, including clinical data, public health data and even genomics information, that needs to be accessed. The value and uniqueness that LPBI brings to the scientific community is its consistent and enormous success in producing non-technical reviews of technical literature in the medical field, so that the scientific findings are much more accessible in real-time. In that way, the scientific community can further delve into specific areas of interest more readily. The site is a quality, professional resource for the biomedical field, which is unique to any field. 

I’ve had the pleasure to serve as content consultant to LPBI over the years and, specifically, as an author of a newly launched e-book entitled, Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology. 

 

 —Marcus W. Feldman, Ph.D., Burnett C. and Mildred Finley Wohlford Professor of Computational Biology in the School of Humanities and Sciences, and co-director of the Center for Computational, Evolutionary and Human Genetics, Stanford University. He is the author of more than 600 scientific papers and 10 books on evolution, ecology, mathematical biology and demography. He is a member of the U.S. National Academy of Sciences, the American Academy of Arts and Sciences and the American Philosophical Society. He was the 2011 Dan David laureate in Evolution and was awarded the 2016 Kimura Prize in Evolution by the Japanese Suzuki Foundation.

Updated on 1/31/2020

Notifications from ResearchGate

Vesa Cosmin Mihai recommended your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Apr 6, 2019

Md Azree Othuman Mydin and 2 others recommended your publications: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Mar 25, 2019

Bahra Karima followed your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Mar 25, 2019

Javad Parmah followed your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Nov 27, 2018

Sebastian Nemeth recommended your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Jul 29, 2018

Daniela Gitea and Gabriela Cioca recommended your publications: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Jul 27, 2018

Vyacheslav Lyashenko followed your publication: Regenerative and Translational Medicine: The Therapeutic Promise for Cardiovascular Diseases

Oct 10, 2016

Santiago Prieto Menchero followed your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Jan 9, 2016

Musaab Salih followed your publication: Metabolic Genomics & Pharmaceutics: Volume I

Dec 12, 2015

UPDATED on 1/10/2020

The following three testimonials resulted from three interviews conducted by Prof. Sheila M. Puffer (UC, Berkeley, PhD’84) in December 2019 for Prof. Puffer’s nomination of Dr. Lev-Ari for 2020 Campanile Excellence in Achievement Award. This award recognizes an alumnus/a whose remarkable professional achievements reflect the excellence of a UC Berkeley education.

Past Recipients

https://awards.berkeley.edu/achievement-awards

The recipients will be formally presented with their awards at Berkeley Charter Gala on May 14, 2020.

Dr. Marcus Feldman

Professor of Biology, Stanford University

Dr. Feldman, who has been deeply involved in Dr. Lev-Ari’s e-publishing venture, expressed his admiration for her career and contributions in multiple and diverse scientific and medical fields. ‘She single-handedly formed the venture to curate the biological medical literature and has produced 16 online books with her collaborators. She has had enormous success in producing nontechnical reviews of technical literature in the medical field, so that the scientific findings are much more accessible to the professional side as opposed to the research side. She has worked extremely hard on developing that professional resource for the biomedical field, which is unique to any field. Her accomplishments represent the best of what Berkeley can produce.”

 

Dr. Justin Pearlman

Professor of Medicine, Practicing Cardiology, UCLA, and Practicing Cardiologist

Dr. Pearlman was one of the early members of the electronic publishing team and served as the editor of three of the volumes. He noted that it was Dr. Lev-Ari’s idea to develop an online pharmacology journal of a completely new design called curation. She also came up with the idea of multimodality, to include videos and other media. He explained that expert reviewers provide reviews and critique the strength and weaknesses of the research and provide and additional information that open eyes to new opportunities. He himself was one of those experts who willingly became deeply involved in the project, and the caliber of his credentials attests to Dr. Lev-Ari’s persuasiveness in getting such experts to devote their time and talents to the project. Dr. Pearlman already had an established reputation as the Vice Chair of Medicine at UCLA and Chief of Cardiology, was an editor and writer, and had over 4,000 citations of his publications.  He explained: “By the sheer force of her personality, Aviva put together a team of experts, and she encourages a new generation to utilize this material. This is important because the new generation is not aware that articles can have their own agenda, such as needing to please granting organizations that fund the research. Aviva has a strong entrepreneurial spirit and investigates many different avenues to make things better – business, medical, biological, and scientific.”

 

Dr. Stephen Williams

Assistant Professor of Pharmacology at the Sbarro Health Research Organization at Temple University

Dr. Williams  has known Dr. Lev-Ari since 2012 when he noticed her call for collaboration on her electronic publishing project on several LinkedIn groups. He was intrigued and contacted her, and became one of the senior editors of the publishing project. “I have never met anyone so driven as Dr. Lev-Ari. She had a great vision and knows how to put that vision into practice. She has an impressive amount and quality of people she has direct contact with.

It was a no brainer. I said, ‘I have to work with her.’ I am very, very happy with that decision. The project developed into a site that deals with all areas of medicine and related scientific disciplines. It is an open access, open science forum with the goal of breaking down silos. In addition, she developed a methodology for real-time medical conference coverage.The whole world is dying for knowledge. People are hungry for this collaboration, including in both developed and developing countries.”

He explained how she created the project: “It is amazing how she set up the venture and has grown it over such a short time and involved the top people in many fields. To me it is absolutely amazing for such a niche website. She set a goal of bringing scientists together in an online community to provide comments and insights. To the degree that happened is fantastic. She personally knows and has gained the involvement of some of the most sought-after researchers in cancer and other fields as keynote conference speakers and the like. I believe some will be future Nobel laureates. She establishes great relationships and has a great rapport with everyone.”

Regarding Dr. Lev-Ari’s accomplishments and personal character, he noted: “She has more energy than some 20 and 30-somethings. She does not stop until she sees her vision realized. She has received many accolades for her accomplishments, including her work at Mitre Corporation. Since 8/2018, Dr. Lev-Ari was contacted by the President elect of the Massachusetts Academy of Sciences (MAS), Prof. Katya Ravid of Boston University, School of Medicine, to join MAS in the role of Liaison to the Biotechnology and eScientific Publishing industries for the term of August 2018-July 2021. In the MAS, Dr. Lev-Ari serve as Board member, Fellow, and Advisor to the Governing Board. http://www.maacadsci.org

She has in-depth knowledge of many medical fields. She wrote an article that is available on the publication website about reinventing yourself. And that is something that she has done over and over again. Her career includes complex IT, nursing, and scientific publishing in biomedicine and biomedical research. In scientific careers, you’re in a constant state of reinventing yourself. For others, that may seem scary, but for her it is exciting. I tell my colleagues and students to take it the way Dr. Lev-Ari takes it – as an absolutely exciting journey. In every part of her life she looks at it as an exciting journey, even the obstacles she had to overcome.”

11/27/2019

Dear Aviva,

Thank You note from sandraleebatista@yahoo.com

Happy Thanksgiving to you and your family! I am so very grateful for your friendship and mentorship over so many years.

We will be here in Los Angeles and it will be a quiet holiday full of reflections on gratitude.

Best wishes,

Sandra

5/29/2019

From: “Klein, Susan Beth” <sbklein@indiana.edu>

Date: Wednesday, May 29, 2019 at 3:13 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Re: Permission to reprint image

Thank you very much for permission to reprint and also your useful suggestions. I shall certainly consider all of this content!

Susan

Susan B. Klein, PhD

Department of Physics

Swain West 331

Indiana University, Bloomington

812.855.9687

From: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Sent: Wednesday, May 29, 2019 12:46 PM

To: Klein, Susan Beth

Cc: Stephen Williams, PhD; Marcus W Feldman; Dr. Larry Bernstein; Aviva Lev-Ari

Subject: Re: Permission to reprint image

 

Dear Prof. Klein,

Your e-mail, below called for my re-read of Dr. Larry H. Bernstein’s article where the figure you wish to re-publish was found.

It was indeed, a special pleasure to read again his article and to realize one more time, how important the curation work is for dissemination of scientific findings. Dr. Larry is a Biochemist, retired Pathologist and one of the best writers in Medical Sciences among the livings.

See

The Young Surgeon and The Retired Pathologist: On Science, Medicine and HealthCare Policy – The Best Writers Among the WRITERS

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2013/12/10/the-young-surgeon-and-the-retired-pathologist-on-science-medicine-and-healthcare-policy-best-writers-among-the-writers/

I recommend that in your forthcoming book on Radiation Biology you will consider the following suggestions: 

A. Include Agents that Damage DNA [as in Dr. Larry’s article, not limited to it]

B. Refer the reader to Dr. Larry’s article which is a unique resource on the topic of DNA and DNA Replication 

C. Please review the Table of Contents of our Genomics, Volume One, it may assist you with A, above

https://pharmaceuticalintelligence.com/biomed-e-books/genomics-orientations-for-personalized-medicine/volume-one-genomics-orientations-for-personalized-medicine/

Regarding re-publishing the figure:

I am suggesting to add the following comment: 

Image Source

Image is the copyright of Buzzle.com, cited in A Primer on DNA and DNA Replication by Reporter and Curator: Larry H. Bernstein, MD, FCAP 

https://pharmaceuticalintelligence.com/2014/07/29/a_primer_on_dna_and_dna_replication/

I wish you best of luck with researching the scientific literature for this very important and timely forthcoming text book on Radiation Biology.

Very proud to share with you that we have on Leaders in Pharmaceutical Intelligence portal:  http://pharmaceuticalintelligence.com    

 1,627,949 e-Readers, 678 Categories of Research and +10K Tags and 5,594 scientific article CURATIONS & Scientific reporting.

 

Please keep in touch and I encourage you to continue to search our Journal archive. 

Best regards,

PS

This e-mail is your e-written permission to re-publish figure as commented, above.

Leaders in Pharmaceutical Intelligence portal:  http://pharmaceuticalintelligence.com    

LPBI Group was created in 2012 by me, Aviva Lev-Ari, Ph.D., R.N. The Group has three interrelated healthcare content products: an open-access online scientific journal (Journal archive is an article corpus); a series of 16 BioMed e-books (BioMed e-Series is an e-Book corpus); and real-time coverage of BioMed scientific and medical conferences (An archive of conference e-Proceedings corpus). Through these transformative products, the Group effectively meets and exceeds the information needs of researchers, scientists and industry pharmaceutical and biotechnology executives by offering real-time and currently available medical and scientific information on any biomedical subject (700 categories). LPBI also makes information on cutting-edge biomedical research innovation widely available to the scientific and non-research community using a process of connections to multiple social media platforms, chiefly LinkedIn, Twitter and Facebook. The method of curation includes synthesis, analysis and interpretation of complex medical and scientific areas.

Aviva Lev-Ari, PhD, RN

Director & Founder

https://lnkd.in/eEyn69r

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

Editor-in-Chief

http://pharmaceuticalintelligence.com 

e-Mail: avivalev-ari@alum.berkeley.edu

(M) 617-775-0451

https://cal.berkeley.edu/AvivaLev-Ari,PhD,RN

SkypeID: HarpPlayer83          LinkedIn Profile        Twitter Profile

From: “Klein, Susan Beth” <sbklein@indiana.edu>

Date: Wednesday, May 29, 2019 at 9:12 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Re: Permission to reprint image

Thank you so much Aviva.

The url is https://pharmaceuticalintelligence.com/2014/07/29/a_primer_on_dna_and_dna_replication/.

The name of the article is “A Primer on DNA and DNA Replication”; Reporter and Curator: Larry H. Bernstein, MD, FCAP.

Appreciatively,

Susan

Susan B. Klein, PhD

Department of Physics

Swain West 331

Indiana University, Bloomington

812.855.9687

From: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Sent: Tuesday, May 28, 2019 12:17 PM

To: Klein, Susan Beth

Cc: Stephen Williams, PhD; Marcus W Feldman

Subject: Re: Permission to reprint image

 

Dear Prof. Klein,

It is always most endearing to correspond with another fellow Alumna of Berkeley.

Congratulations on your forthcoming book, Fundamentals of Radiation Biology. The publisher of the text is World Scientific, anticipated publication in 2023.

Thank you for reaching out to me for permission to reprint a figure.

Please e-mail me the name of the article you found this figure in on our Journal http://pharmaceuticalintelligence.com 

Or in one our our 16 e-Books in Life Sciences and Medicine on Amazon.com

https://lnkd.in/ekWGNqA

I will then research and grant you re-printing permission in e-writing.

Since your forthcoming text book is on Radiation Biology, in this context, I wish to bring to your attention two points:

1.You may find of interest the following e-Books of ours

Series B: Frontiers in Genomics Research

 

  • VOLUME 1: Genomics Orientations for Personalized Medicine. On Amazon.com since 11/23/2015

http://www.amazon.com/dp/B018DHBUO6

  • VOLUME 2: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology

https://pharmaceuticalintelligence.com/biomed-e-books/genomics-orientations-for-personalized-medicine/volume-two-genomics-methodologies-ngs-bioinformatics-simulations-and-the-genome-ontology/

Work-in-Progress

 

Series C: e-Books on Cancer & Oncology

 

  • Volume 1: Cancer Biology & Genomics for Disease Diagnosis. On Amazon.com since 8/11/2015

http://www.amazon.com/dp/B013RVYR2K

  • Volume 2: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery (Series C Book 2). On Amazon.com since 5/18/2017

http://www.amazon.com/dp/B071VQ6YYK

2. My articles on medical OUTCOMES of Radiation Biology  on Cardiotoxicity

Cardio-oncology and Onco-Cardiology Programs: Treatments for Cancer Patients with a History of Cardiovascular Disease

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2014/01/08/cardio-oncology-and-onco-cardiology-programs-treatments-for-cancer-patients-with-a-history-of-cardiovascular-disease/

3rd Annual Canadian Cardiac Oncology Network Conference, June 20 – 21, 2013, Ottawa Convention Centre

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2014/01/08/3rd-annual-canadian-cardiac-oncology-network-conference-june-20-21-2013-ottawa-convention-centre/

2019

http://cardiaconcology.ca/ccon-conference-2019-modern-changing-practices-in-cardio-oncology/agenda/

My Journal on Cardiotoxicity on Scoop.it

https://www.scoop.it/topic/cardiotoxicity

Looking forward to getting name of article when the figure had appeared in our publications.

Good luck,

Aviva Lev-Ari, PhD, RN

Director & Founder

https://lnkd.in/eEyn69r

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

Editor-in-Chief

http://pharmaceuticalintelligence.com 

e-Mail: avivalev-ari@alum.berkeley.edu

(M) 617-775-0451

https://cal.berkeley.edu/AvivaLev-Ari,PhD,RN

SkypeID: HarpPlayer83          LinkedIn Profile        Twitter Profile

From: “Klein, Susan Beth” <sbklein@indiana.edu>

Date: Tuesday, May 28, 2019 at 11:11 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Permission to reprint image

Hello Aviva Lev-Ari,

I am currently writing a book: Fundamentals of Radiation Biology. I would like to know if I might have your permission to reprint this figure in a section on DNA replication. The publisher of the text is World Scientific and we anticipate publication in 2023. I would very much appreciate your permission; this is a lovely illustration!

Regards,

Susan

Susan B. Klein, PhD

Department of Physics

Swain West 331

Indiana University, Bloomington

812.855.9687

(another Berkeley alum)

April 2019

2019 Ranking of Conference Influencers: On 4/9/2019, The Partners’ 2019 World Medical Innovation Forum #WMIF19

via @symplur‘s #Healthcare Hashtags http://bit.ly/WMIF19 

  • By “Mentions” – Ranked #4: @pharma_BI and
  • By “Tweets” – Ranked #2: @AVIVA1950

via NodeXL  http://bit.ly/2KB6cPN 

  • By “Betweenness Centrality” – Ranked #3: @AVIVA1950 and @pharma_BI

https://pharmaceuticalintelligence.com/2019/04/13/the-wmif19-influencers-via-symplurs-healthcare-hashtags-http-bit-ly-wmif19-by-mentions-and-by-tweets-ranked-4-pharma_bi-and-2-aviva1950-respectively-ranked-3-via-node/

4/21/2019

From: Amnon Danzig <amnon.danzig@gmail.com>

Date: Sunday, April 21, 2019 at 4:17 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: A Letter from Amnon Danzig

Dear Aviva

Now, I read the two docs in depth.

Sure, I have a few questions for my understanding. We can devote Skype for that to make sure I understand…

It is my honor to work with you and the team.

I found Gail and Rick extremely good players, partners and colleagues at the same time. And I would like to thank you for the opportunity to work with them.

I would like to thank you for your very fine and warm words about my contribution. GREAT!

I must confess that in the last three months I couldn’t do any real intellectual work. I need to finalize my speech at the conference and couldn’t touch it.

Why?

My thinking was always going to the ways to present LPBI Group the best it can.

I found myself very busy intellectually and emotionally how we can improve the way the IB will see us.

Example: the last two weeks I invested happily dozens and dozens for this assignment. On Thursday afternoon my son arrives and we spent a few hours together. Then, on 9 PM I set down to make the corrections you asked me. Took me another 3 hours, sent it and waited another two hours to see whether I need some more. Because I knew that on Friday you MUST send. It was kind of relief after two hours. When you sent us the update I saw it and felt “everything is okay” and I can put my mobile away for 24 hours: all the family, friends were around I thought it better to be disconnected.

I am very glad you found my contribution significant. Also, the way you express it is outstanding. Thank you!

Now, I will spend a few days about the conference and also looking for ways to find significant people to meet and discuss my new book. The idea to find more audience and hopefully potential clients.

If you happen to have ideas for me, great.

This is the reason I extend my time in NYC. 

BR 

Amnon

@@@@@

4/19/2019

LPBI Group: The Business Opportunity

Voice of Prof. Marcus W. Feldman

The intellectual property of LPBI is of three types: a corpus of curated articles in an open access online scientific Journal, a corpus of e-books in Medicine and Life Sciences, and a corpus of Biotech e-proceedings. This IP is highly relevant to five industrial and services sectors across twelve economic segments. LPBI has pioneered production of scientific content with unique curation methodology by a highly knowledgeable group of experts. The content and the potential consumers & acquirers and valuers of this content are represented graphically below. The three types of corpus, together with the very large audience that follows the content on various media, represent intangible assets of LPBI Group and can be represented as such to potential investors. Together with the tangible assets described in Document #2, the combination represents a unique opportunity for acquisition.

@@@@@

4/19/2019

LPBI Group: The Business Plan

Voice of Aviva Lev-Ari, Founder

The Business Plan representing work-in-progress generated by our business professionals, Amnon Danzig (AD), Gail Thornton (GST) and Rick Mandahl (RM).

  • The content is extracted from Document #2, the concept of the “Client End-User Perspective” and the “Acquirer Perspective” are contributions by Amnon Danzig (AD). 
  • The positioning of 12 economic segments in a 3D structure for each of these two perspectives represent contributions of AD, GST and RM, under the leadership of AD. They took the microeconomics Theory of the Firm to most interesting interpretation given for several Demand aspects related to the performance of Knowledge Workers in the digital workplace as potential users of LPBI Group’s products.
  • They followed the 3D illustration developed by Aviva Lev-Ari, PhD, RN (ALA) using three different axes for representation of same 12 economic segments. The view taken by ALA is of Industrial Organization Economics theoretical framework of comparisons among industrial and services sectors and within each sector competition among player drawing strategies for augmenting the competitive advantage by horizontal and vertical mergers. Opportunities for economies or scale, externalities, diversification and product differentiation. In ALA’s perspective, LPBI Group’s IP represents Supply side, a series of technologies poised to augment the core competencies of players in 12 economic segments as in Appendix C, below [which is identical to Table developed by ALA for Sections #4 & #5 in Document #2.
  • Further development of this Business Plan document will follow in the near future.

This Business Plan is based on and is complementary to Document #2 that provides a distinctive view on Intangible Assets, Sections #1 to #12 vs Tangible Assets and royalty payments which are present in Section #13 & #14 of Document #2.

This Business Plan consists of a conceptual framework developed by the business side of our Final Improvement Team (FIT members N=12). This conceptual framework is indeed unique in depth and breadth placing the unmet needs of potential acquirers by name, each in an economic segment, each economic segment within an Industrial and Services Sector. It demonstrates deep understanding of Demand side economics of the End-User in each of the 12 economic segments. This strategic thought process represents well AD’s business acumen for placing in the center the ultimate demand of end-users and the unmet needs of potential Acquirers that will be fulfilled on their behalf by LPBI Group’s IP – the features and functionality of the technologies we have developed since 2012.

 

@@@@@

4/14/2019

The #WMIF19 Influencers via ‘s  Hashtags http://bit.ly/WMIF19 – By Mentions and By Tweets Ranked #4: @pharma_BI and #2: @AVIVA1950, respectively. Ranked #3 via NodeXL Betweenness Centrality http://bit.ly/2KB6cPN

https://pharmaceuticalintelligence.com/2019/04/13/the-wmif19-influencers-via-symplurs-healthcare-hashtags-http-bit-ly-wmif19-by-mentions-and-by-tweets-ranked-4-pharma_bi-and-2-aviva1950-respectively-ranked-3-via-node/

4/13/2019

Twitter Data for LPBI Group’s Founder’s Twitter handle @AVIVA1950 was updated 

On 2/24/2019 — Tweets 8,060 Following 1,412 Followers 359 Likes 2,752

On 4/13/2019 — Tweets 9,018 Following 1,461 Followers 390 Likes 3,654

 

4/11/2019

Top 3 Ranked by Betweenness Centrality in Top 10 Influencers #WMIF19 @phsinnovation @evankirstel @aviva1950 –Tweeter Analytics by NodeXL http://bit.ly/2KB6cPNfor #WMIF19 by @PHSInnovation  at World Medical Innovation Forum ARTIFICIAL INTELLIGENCE, Boston, MA USA, Monday, April 8-10, 2019

https://pharmaceuticalintelligence.com/2019/04/11/top-3-ranked-by-betweenness-centrality-in-top-10-influencers-wmif19-phsinnovation-evankirstel-aviva1950-tweeter-analytics-by-nodexl-http-bit-ly-2kb6cpn-for-wmif19-by-phs/

@@@@

‘s  Hashtags  – Twitter Analytics published for http://bit.ly/WMIF19 

  • [Top 10 by Mentions – @pharma_BI = 4 with 181 mentions]  
  • [Top 10 by Tweets @AVIVA1950 = 2 with 229 Tweets (N = 152 Direct messages)]
 Pinned Tweet

⚡️As World   Forum comes to a close, here are TOP   via ‘s  Hashtags 🙏 to organizers for a stellar event & to all on  for a robust conversation!   👏 

@@@@

Top influencer 3rd place @AVIVA1950

This is a great analysis and I love that you found these two programs, NodeXL and Betweeness Centrality. These offer the best Twitter analytics and node analysis I have ever seen. Thanks for sharing and a great conference and great conference coverage in real time. Show the power of REALTIME CONFERENCE COVERAGE methodology @pharma_BI and @AVIVA1950 as well as power of LBPI Group.

https://nodexlgraphgallery.org/Pages/InteractiveGraph.aspx?graphID=193125

 

@@@@

From: “Gregory Piatetsky, KDnuggets” <editor1@kdnuggets.com>

Date: Wednesday, April 10, 2019 at 10:16 PM

To: Aviva Lev-Ari <aviva.lev-ari@comcast.net>, Gil Press <gpress900@gmail.com>

Subject: Re: Fwd: NodeXL Graph Gallery: Interactive Graph

Well done!  3rd place for #WMIF19 is good

See

Comparative Analysis of the Level of Engagement for Four Twitter Accounts: @KDNuggets (Big Data) @GilPress @Forbes @pharma_BI @AVIVA1950

 

@@@@

From: Leny <gochevav@mit.edu>

Date: Wednesday, November 28, 2018 at 11:30 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Re: MIT Center for Precision Cancer Medicine Inaugural Symposium – Question from Aviva Lev-Ari, PhD, RN

Dear Dr. Lev-Ari,

I actually have been meaning to reach out to you with an invitation to our symposium. We were both at the Personalized Medicine Coalition’s conference two week ago at Harvard Medical School, but I didn’t get a chance to speak to you in person.

To get a complimentary press pass, please visit cpcm.eventbrite.com -> select Tickets ->  select “Enter Promotional Code”-> enter CPCM2018 and that will allow you to select “Press” tickets.

Please do not hesitate to reach out if you have any additional questions.

Best,

Leny

Vasilena Gocheva, PhD | Assistant Director  | MIT Center for Precision Cancer Medicine  | 77 Massachusetts Avenue, 76-353  | Cambridge, MA 02139  | cpcm.mit.edu

From: Shankar Khatkale <shankar.k@gminsights.com>

Date: Tuesday, November 27, 2018 at 6:48 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Article Submission Request

Dear Editor,

An industry news titled ‘Precision Medicine Market Size worth $96.6bn by 2024’ by Global Market Insights is relevant to your esteemed website https://pharmaceuticalintelligence.com. This email is a suggestion to publish this news (content attached in word format or can be picked from link mentioned below) on your website with an objective to share the information with your audiences.

News Link: https://www.gminsights.com/pressrelease/precision-medicine-market

 Looking forward to hear from you.

 On behalf of and as instructed by Global Market Insights, Inc.

 Best Regards,

Shankar Khatkale |SEO Executive

 

From: Daphne Kwee <daphnekwee@farrerpark.com> on behalf of Daphne Kwee <daphnekwee@farrerpark.com>

Date: Monday, October 29, 2018 at 9:33 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Post retirement doctors establishing new career heights – Story Consideration

Dear Aviva,

Would you be interested in interviewing personalities in the medical Fraternity?

Particularly, Dr Leslie Lam. One of the renowned personality who was sued by the SMC and won after a 7 year battle. He is a medical veteran in his 70s but shows no signs of slowing down. He has re-established himself in Farrer Park Hospital and is blazing a trail with his new clinic. Having recently been conferred the Distinguished Graduate Award by the University College Dublin School of Medicine for his contribution toward medical education, research and support toward the community. Previous recipients of this award includes Professor Connor Ward who pioneered work on Cardiac abnormalities such as the co-described Ward-Romanov Syndrome.   

Dr Lam’s story strikes a chord with the government’s stand of lifelong learning and contribution. In addition to his clinical work, Dr Lam is an advisor to the Seychelles ministry of health, contributes regularly to teaching doctors and donating medical equipment to Myanmar. He also established a leading wine collection in order to fund his philanthropic works with charities in Singapore and Ireland, where he received his medical education. 

I have attached the award letter to this email for your information. 

Should you be interested in such a story angle, I do have other personalities here at Farrer Park Hospital for your consideration. Professor Tan Yew Oo, Singapore first medical oncologist, as well as Professor Soo Khee Chee, the founding director of Singapore’s National Cancer Centre. All these renowned medical personalities, who in their post retirement years, are still actively contributing toward Singapore’s future.

Do let me know if you would like to find out more to explore story possibilities. I would be happy to catch up over lunch or tea for a discussion.

 

Best regards,

Daphne

Executive

Corporate Communications

DID (65) 6705 2769  

www.farrerpark.com/hospital

From: “Prof. Nathan F. SAYRE (Chairman, Geography)” <nsayre@berkeley.edu>

Date: Friday, June 1, 2018 at 3:26 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Cc: Christian Gordon <cmgordon@berkeley.edu>, Robert Rhew <rrhew@berkeley.edu>

Subject: Re: I will be on BERKELEY Campus for the Homecoming Week, few days before and After, October 11, 2018 to October 16, 2018 — Hope to meet again

Dear Dr. Lev-Ari,

Thank you for your kind note, and wonderful to hear that you will be visiting campus in October. I’m happy to hear that you will see Professor Birgeneau and other Cal alumni in New England. I know the university will be ramping up its efforts in Boston and surrounding areas, to create more opportunities for alumni to connect with each other, and with Berkeley.

I would like to introduce you to Christian Gordon, our partner in development and alumni relations for geography and the division of social sciences. Christian can assist with setting up your visit and relevant meetings while you are on campus. He’s also happy to follow up with additional information, as well as additional opportunities in Boston to connect with Berkeley between now and October.

Very much looking forward to seeing you at Homecoming. Thanks again for sending your recollections of Allan and Berkeley!

Best,

Nathan

PS I’m cc’ing Professor Rob Rhew, who will succeed me as department chair on July 1st.

From: “Prof. Michael Watts” <mwatts@berkeley.edu>

Date: Sunday, May 13, 2018 at 1:29 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Re: Sharing with you — This May 2018, Official Newsletter has a Global distribution of half a million Inboxes: See article on Aviva Lev-Ari in ALUMNI SPOTLIGHT of American Friends of Hebrew University

Dear Aviva: a very long time!  Nice to hear from you and your later extraordinary career!  And it seems like you are now on Phase IV.  Very exciting.

I am retiring in June but will of course keep writing and conducting research.

You may have heard that Allan’s wife Hjordis passed away relatively recently.   It was nice to see their children again at the memorial.

Warmly, Michael

On Fri, May 11, 2018 at 12:01 PM, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu> wrote:

Sharing with you — This May 2018, Official Newsletter has a Global distribution of half a million Inboxes:  

See article on Aviva Lev-Ari in ALUMNI SPOTLIGHT of American Friends of Hebrew University – Please scroll down

If interested to read more, click on:

Aviva’s books on AMAZON.COM

https://www.amazon.com/s/ref=nb_sb_noss?url=search-alias%3Ddigital-text&field-keywords=Aviva+Lev-Ari&rh=n%3A133140011%2Ck%3AAviva+Lev-Ari

On Fri, May 25, 2018 at 12:44 PM, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu> wrote:

Dear Professors, Watts, Walker, Sayre, Laguerr and Segev, 

I hope you are well and will enjoy the months of Summer coming up.

We will have dinner with Berkeley’s ex-Chancellor, Prof. Robert Birgeneau in Boston on 6/16/2018, meeting with Alumni in New England. I am much looking forward to his talk and meeting alumni.

I will be on BERKELEY Campus on October 11, 2018 to October 16, 2018, planning to attend the Homecoming Week, October 12-14, 2018.

It will be my great pleasure to meet again, I hope you will be on Campus at least one day of the week in October 2018 when I will be on Campus and could meet you. Allan Pred will be missing on this visit, so sad.

I recently wrote my Recollections of my five years at Berkeley in two Parts, which you may find of interest to read, in particular, Part 2, which I authored as a curation, after my e-mail exchange with Prof. Michael Watts in May, 2018.

  • Recollections: Part 1 – My days at Berkeley, 9/1978 – 12/1983 – About my doctoral advisor, Allan Pred, other Professors and other Peers

https://pharmaceuticalintelligence.com/2018/03/15/recollections-my-days-at-berkeley-9-1978-12-1983-about-my-doctoral-advisor-allan-pred-other-professors-and-other-peer/

  • Recollections: Part 2 – “While Rolling” is preceded by “While Enrolling” Autobiographical Alumna Recollections of Berkeley – Aviva Lev-Ari, PhD’83

https://pharmaceuticalintelligence.com/2018/05/24/recollections-part-2-while-rolling-is-preceded-by-while-enrolling-autobiographical-alumna-recollections-of-berkeley-aviva-lev-ari-phd83/

Please Read these two:

I attended the 1998 – 100 years Geography Department celebration.

Please review the following, it can be included in the future Itinerant Geographer.

Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018

https://pharmaceuticalintelligence.com/2018/03/06/reflections-on-a-four-phase-career-aviva-lev-ari-phd-rn-march-2018/

Thank you – Good Luck to you

From: “Prof. Nathan F. SAYRE (Chairman, Geography)” <nsayre@berkeley.edu>

Date: Thursday, March 8, 2018 at 6:07 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Re: I MADE A CONTRIBUTION IN MEMORY OF PROF. ALLAN PRED few weeks ago

Dear Aviva,

Thank you for writing. Yes, we did receive your donation in Allan’s honor–thank you!–and we put a letter of thanks and acknowledgement in the mail last week. Please look out for it.

You are not alone in missing Allan–many many people do. Sadly, his widow, Hjordis, also passed away not long ago.

Michael Watts is not yet technically retired, but he thought he would two years ago, and since we made a big public announcement then we’ve kept the technical truth quiet. He will in fact retire this summer. As you assumed, Walker, Reed, and Nat have all retired, as have Beatriz Manz, Gillian Hart, Paul Groth, Michael Johns, and Roger Byrne. We are anxiously awaiting authorization to recruit new human geography faculty.

It’s kind of hard to think of any of us as adequate to fill Allan’s shoes, but we all try to preserve his flexibility of mind and lucidity of thought. Our graduate students perhaps carry on his intellectual legacy best. If you haven’t heard of Trevor Paglen, he was one of Allan’s last PhDs:

http://www.paglen.com/

Thank you also for the links to your eulogies for Allan and David, and to your reflections. I am touched by your words and your enduring support for the department.

Best,

Nathan

On Monday, July 24, 2017 at 9:27 PM

From: marzan Khan <marzan.khan@mail.mcgill.ca>

Date: Monday, July 24, 2017 at 9:27 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Re: SERIES E VOLUME 2 –>>> FORMAT CONVERSION — I MUST find out what has been done to FINISH up this format conversion – Series E Volume 2

Hello Aviva,

Thank you very much for your kindness and support. It was great working for you. I apologize for not being able to finish my task to completion. You have been an excellent mentor and I will be grateful to you always.

Best of luck on the e-book and all your endeavors.

Sincerely,

Marzan Khan

On June 18, 2017, 9;39AM

Dear Aviva Lev-Ari,

Thank you very much for your email.

First of all I would like to congratulate you to your outstanding work, if I may. You are one of the very few people with really meaningful and scientific articles/updates on LinkedIn.

I recently liked one of your articles/updates “Molecular Pathogenesis of Progressive Lung Diseases” on LinkedIn, because it was an interesting article. We have a project here in China “Natural Breathing”, where we look at solutions for COPD. With all the air pollution in China, this is already a majour burden, and it is one that will become a larger burden in the coming years. As for your email, I am not quite sure what to make out of it honestly. Is it an offer to write or publish an article? In regards to China: Please do not hesitate to contact me, if you have questions or if I may help with contacts in the healthcare industry. We have a quite good network here.

Sincerely from Beijing

Dennis Wilkens, Managing Director, Medical Devices, Health 4.0, Toronto, Hamburg, Beijing, Distribution Network, Investments & Ventures, Jadevita International Inc., University of Hamburg

On 6/15/17, 5:43 AM, “Anamika Sarkar” <sarkaranamika@yahoo.com> wrote:

Hi Aviva,

Thanks! I am also excited to join Regeneron.

Congratulations to your success of publishing in Amazon. Your focus and perseverance to science is admirable.

Best

Anamika Sarkar, PhD

@@@@@@

From: “Mark Cobbold, MD, PhD, MGH” <mcobbold@mgh.harvard.edu>

Date: Wednesday, April 27, 2016 at 11:32 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: RE: LIVE ­ 8:00 am ­ 12:00 pm 4/25/2016 ­ First Look: The Next Wave of Cancer Breakthroughs @2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Westin Hotel, Boston | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Thanks Aviva.

You obviously work hard on this!

Keep up the hard work.

Mark

MARK COBBOLD, MD, PHD

Headshot

Associate Professor of Medicine, MGH Cancer Center

http://worldmedicalinnovation.org/speakers/mark-cobbold-md-phd/

 

From: Aviva Lev-Ari [mailto:AvivaLev-Ari@alum.berkeley.edu]
Sent: Tuesday, April 26, 2016 7:53 PM
To: Cobbold, Mark
Subject: LIVE ­ 8:00 am ­ 12:00 pm 4/25/2016 ­ First Look: The Next Wave of Cancer Breakthroughs @2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Westin Hotel, Boston | Leaders in Pharmaceutical Business Intelligence (LPBI) Group
 

https://pharmaceuticalintelligence.com/2016/04/25/live-800-am-1200-pm-4252016-first-look-the-next-wave-of-cancer-breakthroughs-2016-world-medical-innovation-forum-cancer-april-25-27-2016-westin-hotel-boston/

Aviva Lev-Ari, PhD, RN

Director & Founder

Leaders in Pharmaceutical Business Intelligence Group, Boston

Editor-in-Chief

http://pharmaceuticalintelligence.com

e-Mail: avivalev-ari@alum.berkeley.edu

SkypeID: HarpPlayer83 

LinkedIn Profile        Twitter Profile

@@@@@

From: Arquisch Tony <Tony.Arquisch@cpagroup.ch>

Date: Friday, March 18, 2016 at 11:46 AM

To: Aviva Lev-Ari <aviva.lev-ari@comcast.net>

Cc: Arie Berger <arisimonberger@gmail.com>, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>, ‘Maggie You’ <maggie.you@oriental-ventures.com>

Subject: RE: REVOTEK follow up for 3D printing – AVIVA

Hello Aviva: 

To answer your questions:

The ownership at regenHU is as is.

The CEO of regenHU is Mr. Marc Thurner

The other CPA Group companies are unchanged i.e. no updates

With that said, of course until there are any official announcements, we continue to sell products and services accordingly. If there is interest in a particular product and/or service I will be more than happy to assist. If there is an investment interest then please send me an official inquiry (in writing) with as many details as possible upon which I will present it to management. Once there is an interest we will send Non-disclosure agreements and start the negation phase accordingly.

I truly hope we can work together since I’m impressed with your activities. Have a great weekend.

Regards,

Tony

Tony Arquisch

Business Development Manager
Direct +41 26 653 71 84
Mobile +41 79 349 20 44
tony.arquisch@cpagroup.ch

CPA Group SA
Z.I. du Vivier 22
CH-1690 Villaz-St-Pierre

Switzerland
Tel. +41 26 653 71 71
www.cpagroup.ch

LinkedIn Profile  /  XING Profile  / Twitter Profile

@@@@@@@

From: Christopher Wells <cwells@personalizedmedicinecoalition.org>

Date: February 19, 2016 at 3:40:19 PM EST

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Cc: David Davenport <ddavenport@personalizedmedicinecoalition.org>

Subject: Re: I wish to nominate Larry H. Bernstein, MD, FCAP for 12th Annual Award for Leadership in Personalized Medicine

Dr. Lev-Ari:

Thank you so much for what is clearly a strong nomination. David Davenport, copied here, will make sure that our Board of Directors gives careful consideration to Dr. Bernstein’s qualifications for this award, and I will follow up with you personally once we have made a final decision. 

By the way, I am a fan of your work on Leaders in Pharmaceutical Business Intelligence. I am sure it is helpful for many personalized medicine stakeholders. 

Have a good weekend. 

Very sincerely,

Chris

Christopher J. Wells, M.P.A.

Communications Director

Cwells@personalizedmedicinecoalition.org

Direct: 202-589-1755 I Mobile: 202-580-9780

Personalized Medicine Coalition

Blog: Education & Advocacy

Twitter: @PerMedCoalition

1710 Rhode Island Ave. NW I Suite 700 I Washington, DC 20036

www.PersonalizedMedicineCoalition.org  

@@@@@@@

2/12/2016

2016 Communication Awards for Excellence in Reporting and Communicating Science, Medicine and Engineering Nomination

Book Title: * Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation
Publisher(s): * Amazon Kindle Direct
Publication Date: (Please select one): * November 2015
Book Entry Summary (Please limit to 100 words): * The explosion of scientific information has created difficulties tying together disparate discoveries, ideas, and potential applications. Pharmaceutical Business Intelligence is developing an innovative methodology for Global access to Biomedical knowledge rather than traditional search. To attain this complex goal they disseminate ORIGINAL Research via Content Curation by experts using critical thinking process & interpretation over open access networks, offering better organization and visibility of critical information useful for innovations in academic, clinical, and industrial research. Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation at http://www.amazon.com/dp/B018Q5MCN8 is nominated as an example of this methodology.
   

@@@@@@@

2/2/2016

Nominations for 2016 National Academies Communication Awards For Excellence in Reporting and Communicating Sciences, Engineering, and Medicine, Keck Futures Initiative

Editor-in-Chief: Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2016/02/02/nominations-for-2016-national-academies-communication-awards-for-excellence-in-reporting-and-communicating-sciences-engineering-and-medicine/

@@@@@@@@@

From: “Tilda Barliya, PhD” <tildabarliya@gmail.com>

Date: Tuesday, January 19, 2016 at 1:09 PM

To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>

Press Releases from Leaders in Pharmaceutical Business Intelligence (LPBI): FIVE new e-Book in our BioMed e-Series are NOW available for Kindle on Amazon.com | Leaders in Pharmaceutical Business Intelligence

Wow!!!!! That’s very impressive. So proud of being part of this group and project.  Good job everyone.

Thank you Aviva for being the leader of this group and pushing us forward. Thank you for being you.

Good job everyone!!!

Best

Tilda

@@@@@@@@@

From: Gregory Piatetsky-Shapiro <gregory@kdnuggets.com>

Date: Sunday, January 10, 2016 at 6:13 AM

To: Aviva Lev-Ari <aviva.lev-ari@comcast.net>

Subject: Re: big data start up for you to talk to…

Dear Aviva,

Happy New Year and congratulations on your amazing success in your latest venture – Pharmaceutical Intelligence!

Gregory

On 1/9/2016,  I wrote to Gregory:

My eight years in HealthCare, 2005-2012, could have been an entry into HealthCareIT, as we discussed in 2012. However, I decided to tackle Pharmaceutical Intelligence , instead. The learning curve was very steep and it was conquered in record time, as evidenced by building an amazing impactful infrastructure in Scientific Media in Pharmaceutical Intelligence:

Journal, ~4000 articles archived, 900,000 e-Readers

e-Books, 15 Title BioMed e-Series, eight are on Amazon.com in 2015, seven forthcoming, in 2016

Conference Press Coverage in Real Time, sixteen of the Leading in BioTech. In 4/2016, Partners HealthCare, Global Cancer Conference in Boston.

In 3D BioPrinting, we lunched a Subsidiary, TEAM is involved in Product Concepts Development using

  • BioMEMS for Gene Editing
  • BioMEMS for Tissue Engineering
  • BioMEMS and Stem Cells for Gene Therapy and Regenerative Medicine.

We are also involved involved in (a) Drug Discovery by structuring Joint Ventures and in (b) Funding Early Stage Biologics Drug Development and Medical Device Development.

@@@@@@@@

Please see #3

Mayo Clinic Center for Innovation is citing LPBI’s Article by Dr. Larry H Bernstein, MD, FCAP

16 NOV 5 FOR TODAY

Posted at 06:30h in Morning Update by Center for Innovation 0 Comments Share

  1. Responsible innovation in health care and dual use research. [ Health Kid ]
  2. A patient’s point of view. [ HRBR ]
  3. Drivers of Patient Experience. [ LPBI ]
  4. 5 ways providers can improve the patient experience. [ FierceHealthIT ]
  5. Telehealth is essential to lowering readmission rates. [ mHealthNews ]

@@@@@@@@

From: “Dr. MD. K. Singler” <Dr.MD.K.Singler@sciarticles.net>

Reply-To: “Dr. MD. K. Singler” <Dr.MD.K.Singler@sciarticles.net>

Date: Friday, November 13, 2015 at 10:14 AM

To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>

Subject: Invitation

Science and Education

November, 2015

Submit a manuscript

Journals

Articles

Subscribe

Search

Unsubscribe

Dear Colleague,

I am writing to let you know about recent highly accessed articles published in our open access journals and invite you to submit your next manuscript to the journal.

Read our top articles

Dr. MD. K. Singler

Editorial Assistant, Science and Education Publishing

@@@@@@@@@

From: Anne Sim <georgeclinicalau@gmail.com>

Date: Monday, August 3, 2015 at 3:39 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: contributing

Hello,

I am contacting you on behalf of George Clinical, a leading non-profit CRO in the Asia Pacific region. Our parent organization, The George Institute is a renowned medical research institute which has impacted medical practice and policy globally.

We are currently working to build upon our brand awareness by sharing our extensive knowledge and experience within the scientific and medical community. We would love to learn more about any opportunities (publishing, marketing, sponsorship, co-authorship) that you might have available.

We appreciate your time, and If you would be kind enough to provide us information on possible opportunities that you offer, we can review them and see which are a good fit between our organization and yours.

Thanks,

Anne Sim

@@@@@@@@@@@@@@@@@

From: Christopher Wells <cwells@personalizedmedicinecoalition.org>

Date: Wednesday, September 2, 2015 at 11:36 AM

To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>

Subject: Thank you for re-blogging our post

Hi Dr. Lev-Ari:

I noticed that you re-blogged our recent post on Education & Advocacy, titled “Turning a Corner: How This Month’s Decisions at FDA Inform the Debate on Drug Costs.” I just wanted to thank you for that. We are working to build a following for the blog, and a re-posting from an established and reputable source like your blog is helpful. 

I will keep an eye on content from your blog moving forward. Feel free to let me know if you ever post anything on personalized medicine. 

Thank you again.

Sincerely,

Chris

Christopher J. Wells, M.P.A.

Communications Director

Cwells@personalizedmedicinecoalition.org

Direct: 202-589-1755 I Mobile: 202-580-9780

Personalized Medicine Coalition

Blog:Education & Advocacy

Twitter: @PerMedCoalition

1710 Rhode Island Ave. NW I Suite 700 I Washington, DC 20036

www.PersonalizedMedicineCoalition.org  

Unknown@@@@@@@@@@@@@@@@@

 
10/19/2015

Dear Aviva:

I want to applaud you for building your own publishing and scientific communications empire. You have really grown since 5/2013 when you and Larry and I first met. Anyway, down to business. I need help in “telling my story” of why the current 5 Nucleotide Watson Crick Genetic Code (ATGCU) need to expand with two additional and natural purine nucleotides to cover the epigenetic level of gene regulation so that Novagon’s 7 nucleotide ATUICGX genetic + epigenetic = genomic code is more valid than the current 5 code which has never built a man made prescription drug or any therapy which does not have multiple side effects including thousands of deaths. This project has got to big for me and I would like to join with your group to be discuss, strategically, how we can logically and empirically prove natures natural 7 code is the right number of codes and not 5. I don’t know how to proceed, but if you are interested we could meet i.e. whoever you want to bring into the project is fine by me; there are people in your group who can edit and write or rewrite what I have done much better than me. Remember, I grew up in Helena, Arkansas, in the Delta region, on the Mississippi river. Lots of cotton, but not many brains, especially in the teaching ranks. Any way I have come along way from there but I still am deficit or maybe lazy in writing and editing. Although my ADHD might be a strong contributing factor. Any, way I have tried and finally willing to concede, One person cannot do it alone. I have reached out to you because you were the first to ask me to join your team as Expert, author writer. Kind of ironic now that I am coming to you with great content but unorganized with no media plan or strategy. If Larry is interested I should would like him part of the project, if you decide to accept my scientific content and as publisher you we jointly publish what value proposition we determine as a team. Thanks for your notice. I took it as a cosmic sign, and it would be your 7th venture, quite ironic under the circumstances. Thank you for your time and I hope you decide to let me into your publishing umbrella and get some help in creating content for your growing empire. Thanks, John Berger Novagon DNA

John Berger

Founder at Novagon DNA

   
 
@@@@@@@@@@@@@@@@@@

 

   

 

Dear Dr. Aviva Lev-Ari,

Greetings from SciRes Literature!

It is a great pleasure to invite you for the Editorial Board membership in SciRes Literature member Journals. SciRes Literature is an Open Access Publisher of twenty-eight internationally refereed, online, peer-reviewed scholarly Journals designed for scientists, physicians, doctors and researchers across the globe. Our mission is to support the rising horizons of the scientific innovations and promote the advancement in research community by increasing the online accessibility of quality research articles.

The Editorial Office is actively seeking qualified researchers and experts to be a part of our journal Editorial Board. In recognition to your distinguished accomplishments in the area of Immunology (related areas), we are pleased to invite you to be a part of our SRL Immunology & Immunotherapy journal.

You can find more information by visiting us at:
http://scireslit.com/Immunology

You can support, strengthen and contribute to our vision through your expertise in area by joining our Editorial Board.

If you are interested in serving as an editor, kindly send us your short biography, Research interests, CV and Photo to immunology@scireslit.com for review.

Please feel free to contact for any further queries

Anticipating a positive response.

Sincerely,

SASHA Sims
Editorial Office, SciRes Literature
SRL Immunology & Immunotherapy
1692 Coastal Highway
Delaware 19958, USA
Email: immunology@scireslit.com

 

 

Testimonials about LPBI

2021

UPDATED on 9/29/2021

Tweet

 
MIT Technology Review
 
@techreview
Replying to

and

Thanks for joining us again
@AVIVA1950. We loved your tweets yesterday!
 
@techreview is the handle of MIT Technology Review Twitter account followed by 1.1 Million followers

MIT Technology Review

 

Retweeted your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT Charles Hoskinson CEO and Founder, Input Output Global; Founder, Cardano, 2015 Nation scale [Ethiopia] and Global scale – records ledger and smart contracts, credentials identity, reversible auditable that operates at scale; Cofounder, Ethereum

This image has an empty alt attribute; its file name is MIT-Technology-Review.png
 
 

MIT Technology Review

Retweeted your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT Charles Hoskinson CEO and Founder, Input Output Global; Founder, Cardano, 2015 Nation scale [Ethiopia] and Global scale – records ledger and smart contracts, credentials identity, reversible auditable that operates at scale; Cofounder, Ethereum

MIT Technology Review

liked your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT  Nick Selby Chief Security Officer, Paxos Trust Company at Timehop GDPR a bridge of security disclosure to US Citizens 5% of EU opt out 7/418 ADM password changed User database was compromised protect customers data Recovery architecture monitor

MIT Technology Review

Retweeted your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT @EmTechMIT Wendy Nather Head of Advisory CISOs @Cisco mid 90s Two-way authentications Who are the attackers, changes, abuse of the platform by users Technology to buy Proactive Refresh Tech done by vendor is best security practice

MIT Technology Review

Retweeted your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT Kevin Scott CTO @Microsoft Compute is the only constraint Open source version of OpenAI API no need to build OS. Responsible AI within Microsoft – Standard for the whole company to be rolled up soon. Regulation to consider where we are going to be

 
 
 

 

UPDATED on 9/22/2021

From INTERNS in 2021 LPBI’s Summer Internship

From: “Ethan Coomber [Intern 2021]” <ethancoomber6@gmail.com>
Date: Monday, September 20, 2021 at 11:54 PM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>

Hi Aviva,

This past summer, I was able to intern for LPBI. I really enjoyed being able to expand upon what I had been learning in the classroom at school, and push myself to take on new, exciting challenges. Over the summer, I was given 2 projects that were extremely interesting, but were vital in helping LPBI grow as well. With the guidance of LPBI, as well as my own outreach, I was able to expose myself to the world of text to audio conversion, as well as further my understanding of data analytics. The combination of resources at my disposal as well as Aviva’s guidance allowed me to make the most of the opportunity in front of me.

The mentorship I received from LPBI was extremely valuable. Being able to work so closely with LPBI’s founder, Aviva Lev-Ari PhD, Rn, I was able to get a detailed understanding of LPBI’s mission and how it relates to the projects I was working on. Aviva was a great resource as she allowed me to explore and be creative in discovering solutions, but was also available if I ever required guidance or leadership. I am proud of the work I was able to accomplish under Aviva’s guidance.

Looking forward to staying in touch,

Ethan

UPDATED on 6/1/2021 for May 24, 2021

From: Mass General Brigham <innovations@partners.org>

Reply-To: <innovations@partners.org>

Date: Monday, May 24, 2021 at 9:31 AM

To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>

Subject: RECAP | World Forum | Day 3 | GCT | CEOs | Harvard | Investors

Notable Tweets

 
 
 

@mandywoodland

Fascinating #WMIF2021 panel on mRNA yesterday -“mRNA is the message, and we just have to decide what message we want to deliver to the cell,” said moderator Lindsey Baden, MD. “The promise of this technology could not be more front and center for all of us.”

@LeapsByBayer

Congratulations to the 2021 Innovation Discovery Grants winners: @lynchielydia, Peter Sage, @GrishchukL, Benjamin Kleinstiver, Petr Baranov, announced at the #WMIF2021. It’s exciting to see the range of breakthrough research in #geneticdisease at @MassGenBrigham

 
 

@DrLilitGaribyan

Gene and cell therapy have scalability problems that we need to solve. This is what is echoed this week at @MGBInnovation World Medical Innovation Forum. #gct #celltherapy #healthcare #innovation

@MPDexpert

“imagine how the future could look if gene therapy cost 1/100th what it does today” @VCAmir @PolarisVC #wmif2021

@AVIVA1950 is Aviva Lev-Ari, PhD, RN

#WMIF2021 @MGBInnovation Roger Kitterman VP, Venture, Mass General Brigham Saturation reached or more investment is coming in CGT Multi OMICS and academia originated innovations are the most attractive areas @pharma_BI @AVIVA1950

@AVIVA1950_PIcs

IMG_7167

UPDATED on 2/15/2021

From: Nigel Russell <nrussell@jofpm.com>

Date: Monday, February 15, 2021 at 10:31 AM

To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>

Subject: RE: About our Venture

Dear Dr. Lev-Ari: 

Thank you for the information and outreach. You have a very interesting platform.

I am interested in chatting.

 

Kind regards,

Nigel

 

Nigel Russell

President

The Journal of Precision Medicine & the Precision Medicine Leaders Summit

Updated on 1/6/2021

From: “Jennings, Charlotte (Reuters)” <Charlotte.Jennings@thomsonreuters.com>

Date: Tuesday, January 5, 2021 at 10:47 AM

To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>

Subject: RE: REUTERS NEXT ­ Press Registration Deadline this Friday (Jan 8)

Hi Aviva,

Thanks for getting back to me. Your press pass for REUTERS NEXT is now confirmed.

It would be great if you could also please share your attendance with your network and across social media. You can find all sharing materials in the media pack here –

Attendees Pack · Reuters Next · Virtual Forum: January 11-14, 2021 (reutersevents.com)

Here’s a tracked sign-up link you can use when sharing – https://bit.ly/35ddYqO

Any other questions please don’t hesitate to reach out!

All the best,
Charlotte

2020

Updated on 8/25/2020

From: Robin Neff Clebnik <robin@internboston.com>

Date: Tuesday, August 25, 2020 at 5:23 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Thank You!

Hi Aviva,

Thank you for your contribution to a very successful summer for our InternBoston students! Your gifts of time, expertise were invaluable to our interns—and to our program as a whole. Your organization’s willingness to participate in InternBoston’s Virtual Summer60™ program allows high school and college students the opportunity to explore learning beyond the traditional limits of their classrooms. The first-hand experiences students receive in the internship will help prepare them for college and beyond.

By participating as a mentor, you have provided Noam with an exceptional opportunity to learn more about a potential career field in a structured and educational environment. Your dedication and commitment to establishing a work plan, overseeing the intern’s progress, and encouraging independence through learning have undoubtedly made a positive and lasting impact.

We look forward to continuing our partnership and will check in with you shortly to discuss more interns for Fall 2020.

 

Best,

Robin

robin neff clebnik

Chief Internship Officer

t: 617.527.0055 

m: 617.875.4614

          

Updated on 8/23/2020

 

The VOICE of Dr. Larry H. Bernstein, MD, FCAP on 8/23/2020:

I discovered a new site in 2012, and thereafter met Aviva Lev-Ari, PhD, RN, https://lnkd.in/eEyn69r

the Director & Founder of the Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston.

That led me to participate in writing for her Open Access Online Scientific Journal for five intense years, 1,400 articles in total. It is now late August 2020, and I have no longer engaged in the writing because of aging limitations.

I can indeed say, the Founder of the LPBI Group in Boston, Aviva, has really been a very fortunate leader, innovator, and collaborator in the LPBI Group’s medical and life sciences publishing endeavors. 

Aviva curated about my contributions to http://pharmaceuticalintelligence.com in the following two monumental sources: 

https://pharmaceuticalintelligence.com/2013/12/10/the-young-surgeon-and-the-retired-pathologist-on-science-medicine-and-healthcare-policy-best-writers-among-the-writers/

  • Editorial & Publication of Articles in e-Books by Leaders in Pharmaceutical Business Intelligence: Contributions of Larry H Bernstein, MD, FCAP
    Curator: Aviva Lev-Ari, PhD, RN

With heartfelt gratitude to our Dear Dr. Larry

https://pharmaceuticalintelligence.com/2014/10/16/editorial-publication-of-articles-in-e-books-by-leaders-in-pharmaceutical-business-intelligence-contributions-of-larry-h-bernstein-md-fcap/

Aviva published my authored contents in 18 volumes https://lnkd.in/ekWGNqA and in the following two memorable articles:

  • Commentaries on each Volume’s Contribution to Medical Education by L.H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN – BioMedical e-Books e-Series: Multiple Volumes in Five e-Series

Authors: L.H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/biomed-e-books/commentaries-on-each-volumes-contribution-to-medical-education-by-l-h-bernstein-md-fcap-and-aviva-lev-ari-phd-rn-biomedical-e-books-e-series-multiple-volumes-in-five-e-series/

  • My Memories Tell a Story to Share

Author: Larry Howard Bernstein, MD, FCAP

https://pharmaceuticalintelligence.com/2020/04/19/my-memories-tell-a-story-to-share-by-larry-howard-bernstein-md-fcap/

Aviva initiated, organized, edited and proposed a narrator for my interview for the following PODCAST:

  • Podcast with Dr. Larry H. Bernstein, MD, FCAP, Interview by Gail S. Thornton, PhDc, Narrator’s Voice: Stephen J. Williams, PhD

https://pharmaceuticalintelligence.com/audio-podcasts/podcast-with-dr-larry-h-bernstein-md-fcap-interview-by-gail-s-thornton-phdc-narrators-voice-stephen-j-williams-phd/

 

Updated on 8/11/2020

The VOICES of Interns of LPBI’s 2020 Summer Internship Program on Data Curation and Data Annotation

The Voice of Internship Team’s Captain, Daniel, Menzin:

LPBI has provided me with an invaluable experience this summer, which has allowed me to grow in a variety of ways. Through close mentorship, we were exposed to principles of data science (i.e. AI, ML, NLP), data curation and annotation, biochemistry, and website development. In addition to daily mentorship by Aviva, we were provided with weekly sessions where we were taught by world-renowned scientists. These sessions provided us with crucial background knowledge, as well as instructions which allowed us to execute and create deliverables while developing our professional skills. Aviva tasked me with several IT projects this summer that were challenging. It was a great opportunity for me to take advantage of the resources around me and learn on my own. Aviva mentored me throughout every step of the process, always providing feedback and showing me how I could improve my deliverables. My summer at LPBI provided me with an incredible opportunity to not only learn more, but also apply what I had learned through the creation of important deliverables. With the breadth of information I’ve been exposed to at LPBI, my professional horizons will surely now be broadened after having been taught things essential to numerous different fields.

The Voice of Noam Steiner Tomer:

Interning at LPBI has been instrumental in both my professional and personal development. Reading and curating many of the cutting edge and insightful articles that LPBI offers contributed significantly to my intellectual growth and broadened greatly my professional horizons. Through this internship I got to not only learn from many renowned researchers but gave me the unique opportunity to work with them directly. I also acquired many technical skills from the on-the-job training such as curation and improved my self-learning skills. It has absolutely been the most valuable experience of my high school career. I have learned so much from your presentations and doing the assignments, and have discovered interests I never knew I had like Hematology!

The Voice of Zach Day:

This summer I interned at Leaders in Pharmaceutical Intelligence (LPBI) in social media and market research.    In this capacity, I participated in weekly classes taught by medical experts about the latest developments in Cancer and Genetics Research. I met regularly with the company’s Director and Founder, Dr Aviva Lev-Ari and attended team meetings.  I wrote two articles about the company and its founder and uploaded them to Wikipedia. I also generated content for the company’s website including eleven WordClouds using WordItOut.com. Overall this was a great experience because I learned a lot, I contributed a lot and greatly appreciate the mentoring and support that I received working with Dr. Lev-Ari. 

 

Updated on 6/3/2020

Professor Marcus Feldman Receives Stanford Biosciences Mentoring and Service Award

Reporter: Gail S. Thornton, M.A.

Marcus Feldman, Ph.D., the Burnet C. and Mildred Finley Wohlford Professor in the School of Humanities and Sciences and Professor of Biology at Stanford University, has been selected to receive the 2019-20 Stanford
Biosciences “Excellence in Mentoring and Service Award”. This honor is given to faculty who make distinguished contributions towards enhancing the quality of training and the mentoring experiences for Stanford Biosciences graduate students.

In recognizing Professor Feldman for this honor, William S. Talbot, Ph.D., Senior Associate Dean of Graduate Education and Postdoctoral Affairs,
Professor of Developmental Biology,  at Stanford University, thanked him for his “extraordinary contributions this year.” Professor Feldman will be formally acknowledged for receiving this award and an honorarium at the School of Medicine Graduation Celebration on Saturday, June 13, 2020.

###

Updated on 5/7/2020

From: Alan Kaul <alan@mom-inc.us>

Date: Thursday, May 7, 2020 at 9:03 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Cc: Vinit Nair <vinit@pracnet.org>

Subject: Pharmaceutical Intelligence

HI Aviva,

You asked for my help in promoting your portal and I’ve done something that I haven’t done for any other organization, I put a direct link to your portal on Medical Outcomes Management’s home page.

[ see www.mom-inc.us ]

This is the only link to another business on our company’s website. We may move it’s location, but it will remain highly visible and directly linked.

I hope that this link will prove helpul to both of us

Stay safe,

Alan

Updated on 4/19/2020

ADDED to this entry by Dr. Larry H. Bernstein, MD, FCAP on 8/17/2020

“I am thankful to Aviva for the opportunity to follow my interests in retirement. I have been away from the laboratory longer than I would like, but could follow the literature.”

Sincerely,

Larry Bernstein, MD

“Prior to moving I was contacted by Aviva Lev-Ari, PhD, RN who was building an online medical forum known as Leaders in Pharmaceutical Business Intelligence (LPBI) Group, and I became the Chief Scientific Officer (CSO). Over the decade I wrote many articles (1,390) in the Open Access online Scientific Journal http://pharmaceuticalintelligence.com that were included in 18 organized e-Books in Medicine. Dr. Lev-Ari’s accomplishment is quite impressive. The e-Books are all available on Amazon.com”

https://lnkd.in/ekWGNqA

In:

My Memories Tell a Story to Share, 4/19/2020

Author: Larry Howard Bernstein, MD, FCAP

Contact: 413-727-8523

https://pharmaceuticalintelligence.com/2020/04/19/my-memories-tell-a-story-to-share-by-larry-howard-bernstein-md-fcap/

Updated on 2/9/2020

Obtained by Gail S. Thornton on 2/7/2020

Leaders in Pharmaceutical Business Intelligence (LPBI) is among the best resources of original scientific and medical content for the scientific and business community that is carefully chosen and thoughtfully organized and presented. The site offers a valuable contribution to biomedical science by advancing knowledge and research efforts through its commitment to synthesize, analyze and interpret complex, medical and scientific disease information on any subject, as well as biomedical research innovation widely available to the scientific and non-research community. There is a vast amount of quality, curated information on the site organized in three inter-related domains of an e-Journal, series of 16 e-Books and e-scientific and medical conference proceedings that is produced by an esteemed group of collaborators. 

In today’s biomedical science environment, there is a wide range of available information in journals of all subject areas and web sites, including clinical data, public health data and even genomics information, that needs to be accessed. The value and uniqueness that LPBI brings to the scientific community is its consistent and enormous success in producing non-technical reviews of technical literature in the medical field, so that the scientific findings are much more accessible in real-time. In that way, the scientific community can further delve into specific areas of interest more readily. The site is a quality, professional resource for the biomedical field, which is unique to any field. 

I’ve had the pleasure to serve as content consultant to LPBI over the years and, specifically, as an author of a newly launched e-book entitled, Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology. 

 

 —Marcus W. Feldman, Ph.D., Burnett C. and Mildred Finley Wohlford Professor of Computational Biology in the School of Humanities and Sciences, and co-director of the Center for Computational, Evolutionary and Human Genetics, Stanford University. He is the author of more than 600 scientific papers and 10 books on evolution, ecology, mathematical biology and demography. He is a member of the U.S. National Academy of Sciences, the American Academy of Arts and Sciences and the American Philosophical Society. He was the 2011 Dan David laureate in Evolution and was awarded the 2016 Kimura Prize in Evolution by the Japanese Suzuki Foundation.

Updated on 1/31/2020

Notifications from ResearchGate

Vesa Cosmin Mihai recommended your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Apr 6, 2019

Md Azree Othuman Mydin and 2 others recommended your publications: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Mar 25, 2019

Bahra Karima followed your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Mar 25, 2019

Javad Parmah followed your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Nov 27, 2018

Sebastian Nemeth recommended your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Jul 29, 2018

Daniela Gitea and Gabriela Cioca recommended your publications: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Jul 27, 2018

Vyacheslav Lyashenko followed your publication: Regenerative and Translational Medicine: The Therapeutic Promise for Cardiovascular Diseases

Oct 10, 2016

Santiago Prieto Menchero followed your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Jan 9, 2016

Musaab Salih followed your publication: Metabolic Genomics & Pharmaceutics: Volume I

Dec 12, 2015

UPDATED on 1/10/2020

The following three testimonials resulted from three interviews conducted by Prof. Sheila M. Puffer (UC, Berkeley, PhD’84) in December 2019 for Prof. Puffer’s nomination of Dr. Lev-Ari for 2020 Campanile Excellence in Achievement Award. This award recognizes an alumnus/a whose remarkable professional achievements reflect the excellence of a UC Berkeley education.

Past Recipients

https://awards.berkeley.edu/achievement-awards

The recipients will be formally presented with their awards at Berkeley Charter Gala on May 14, 2020.

Dr. Marcus Feldman

Professor of Biology, Stanford University

Dr. Feldman, who has been deeply involved in Dr. Lev-Ari’s e-publishing venture, expressed his admiration for her career and contributions in multiple and diverse scientific and medical fields. ‘She single-handedly formed the venture to curate the biological medical literature and has produced 16 online books with her collaborators. She has had enormous success in producing nontechnical reviews of technical literature in the medical field, so that the scientific findings are much more accessible to the professional side as opposed to the research side. She has worked extremely hard on developing that professional resource for the biomedical field, which is unique to any field. Her accomplishments represent the best of what Berkeley can produce.”

 

Dr. Justin Pearlman

Professor of Medicine, Practicing Cardiology, UCLA, and Practicing Cardiologist

Dr. Pearlman was one of the early members of the electronic publishing team and served as the editor of three of the volumes. He noted that it was Dr. Lev-Ari’s idea to develop an online pharmacology journal of a completely new design called curation. She also came up with the idea of multimodality, to include videos and other media. He explained that expert reviewers provide reviews and critique the strength and weaknesses of the research and provide and additional information that open eyes to new opportunities. He himself was one of those experts who willingly became deeply involved in the project, and the caliber of his credentials attests to Dr. Lev-Ari’s persuasiveness in getting such experts to devote their time and talents to the project. Dr. Pearlman already had an established reputation as the Vice Chair of Medicine at UCLA and Chief of Cardiology, was an editor and writer, and had over 4,000 citations of his publications.  He explained: “By the sheer force of her personality, Aviva put together a team of experts, and she encourages a new generation to utilize this material. This is important because the new generation is not aware that articles can have their own agenda, such as needing to please granting organizations that fund the research. Aviva has a strong entrepreneurial spirit and investigates many different avenues to make things better – business, medical, biological, and scientific.”

 

Dr. Stephen Williams

Assistant Professor of Pharmacology at the Sbarro Health Research Organization at Temple University

Dr. Williams  has known Dr. Lev-Ari since 2012 when he noticed her call for collaboration on her electronic publishing project on several LinkedIn groups. He was intrigued and contacted her, and became one of the senior editors of the publishing project. “I have never met anyone so driven as Dr. Lev-Ari. She had a great vision and knows how to put that vision into practice. She has an impressive amount and quality of people she has direct contact with.

It was a no brainer. I said, ‘I have to work with her.’ I am very, very happy with that decision. The project developed into a site that deals with all areas of medicine and related scientific disciplines. It is an open access, open science forum with the goal of breaking down silos. In addition, she developed a methodology for real-time medical conference coverage.The whole world is dying for knowledge. People are hungry for this collaboration, including in both developed and developing countries.”

He explained how she created the project: “It is amazing how she set up the venture and has grown it over such a short time and involved the top people in many fields. To me it is absolutely amazing for such a niche website. She set a goal of bringing scientists together in an online community to provide comments and insights. To the degree that happened is fantastic. She personally knows and has gained the involvement of some of the most sought-after researchers in cancer and other fields as keynote conference speakers and the like. I believe some will be future Nobel laureates. She establishes great relationships and has a great rapport with everyone.”

Regarding Dr. Lev-Ari’s accomplishments and personal character, he noted: “She has more energy than some 20 and 30-somethings. She does not stop until she sees her vision realized. She has received many accolades for her accomplishments, including her work at Mitre Corporation. Since 8/2018, Dr. Lev-Ari was contacted by the President elect of the Massachusetts Academy of Sciences (MAS), Prof. Katya Ravid of Boston University, School of Medicine, to join MAS in the role of Liaison to the Biotechnology and eScientific Publishing industries for the term of August 2018-July 2021. In the MAS, Dr. Lev-Ari serve as Board member, Fellow, and Advisor to the Governing Board. http://www.maacadsci.org

She has in-depth knowledge of many medical fields. She wrote an article that is available on the publication website about reinventing yourself. And that is something that she has done over and over again. Her career includes complex IT, nursing, and scientific publishing in biomedicine and biomedical research. In scientific careers, you’re in a constant state of reinventing yourself. For others, that may seem scary, but for her it is exciting. I tell my colleagues and students to take it the way Dr. Lev-Ari takes it – as an absolutely exciting journey. In every part of her life she looks at it as an exciting journey, even the obstacles she had to overcome.”

11/27/2019

Dear Aviva,

Thank You note from sandraleebatista@yahoo.com

Happy Thanksgiving to you and your family! I am so very grateful for your friendship and mentorship over so many years.

We will be here in Los Angeles and it will be a quiet holiday full of reflections on gratitude.

Best wishes,

Sandra

5/29/2019

From: “Klein, Susan Beth” <sbklein@indiana.edu>

Date: Wednesday, May 29, 2019 at 3:13 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Re: Permission to reprint image

Thank you very much for permission to reprint and also your useful suggestions. I shall certainly consider all of this content!

Susan

Susan B. Klein, PhD

Department of Physics

Swain West 331

Indiana University, Bloomington

812.855.9687

From: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Sent: Wednesday, May 29, 2019 12:46 PM

To: Klein, Susan Beth

Cc: Stephen Williams, PhD; Marcus W Feldman; Dr. Larry Bernstein; Aviva Lev-Ari

Subject: Re: Permission to reprint image

 

Dear Prof. Klein,

Your e-mail, below called for my re-read of Dr. Larry H. Bernstein’s article where the figure you wish to re-publish was found.

It was indeed, a special pleasure to read again his article and to realize one more time, how important the curation work is for dissemination of scientific findings. Dr. Larry is a Biochemist, retired Pathologist and one of the best writers in Medical Sciences among the livings.

See

The Young Surgeon and The Retired Pathologist: On Science, Medicine and HealthCare Policy – The Best Writers Among the WRITERS

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2013/12/10/the-young-surgeon-and-the-retired-pathologist-on-science-medicine-and-healthcare-policy-best-writers-among-the-writers/

I recommend that in your forthcoming book on Radiation Biology you will consider the following suggestions: 

A. Include Agents that Damage DNA [as in Dr. Larry’s article, not limited to it]

B. Refer the reader to Dr. Larry’s article which is a unique resource on the topic of DNA and DNA Replication 

C. Please review the Table of Contents of our Genomics, Volume One, it may assist you with A, above

https://pharmaceuticalintelligence.com/biomed-e-books/genomics-orientations-for-personalized-medicine/volume-one-genomics-orientations-for-personalized-medicine/

Regarding re-publishing the figure:

I am suggesting to add the following comment: 

Image Source

Image is the copyright of Buzzle.com, cited in A Primer on DNA and DNA Replication by Reporter and Curator: Larry H. Bernstein, MD, FCAP 

https://pharmaceuticalintelligence.com/2014/07/29/a_primer_on_dna_and_dna_replication/

I wish you best of luck with researching the scientific literature for this very important and timely forthcoming text book on Radiation Biology.

Very proud to share with you that we have on Leaders in Pharmaceutical Intelligence portal:  http://pharmaceuticalintelligence.com    

 1,627,949 e-Readers, 678 Categories of Research and +10K Tags and 5,594 scientific article CURATIONS & Scientific reporting.

 

Please keep in touch and I encourage you to continue to search our Journal archive. 

Best regards,

PS

This e-mail is your e-written permission to re-publish figure as commented, above.

Leaders in Pharmaceutical Intelligence portal:  http://pharmaceuticalintelligence.com    

LPBI Group was created in 2012 by me, Aviva Lev-Ari, Ph.D., R.N. The Group has three interrelated healthcare content products: an open-access online scientific journal (Journal archive is an article corpus); a series of 16 BioMed e-books (BioMed e-Series is an e-Book corpus); and real-time coverage of BioMed scientific and medical conferences (An archive of conference e-Proceedings corpus). Through these transformative products, the Group effectively meets and exceeds the information needs of researchers, scientists and industry pharmaceutical and biotechnology executives by offering real-time and currently available medical and scientific information on any biomedical subject (700 categories). LPBI also makes information on cutting-edge biomedical research innovation widely available to the scientific and non-research community using a process of connections to multiple social media platforms, chiefly LinkedIn, Twitter and Facebook. The method of curation includes synthesis, analysis and interpretation of complex medical and scientific areas.

Aviva Lev-Ari, PhD, RN

Director & Founder

https://lnkd.in/eEyn69r

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

Editor-in-Chief

http://pharmaceuticalintelligence.com 

e-Mail: avivalev-ari@alum.berkeley.edu

(M) 617-775-0451

https://cal.berkeley.edu/AvivaLev-Ari,PhD,RN

SkypeID: HarpPlayer83          LinkedIn Profile        Twitter Profile

From: “Klein, Susan Beth” <sbklein@indiana.edu>

Date: Wednesday, May 29, 2019 at 9:12 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Re: Permission to reprint image

Thank you so much Aviva.

The url is https://pharmaceuticalintelligence.com/2014/07/29/a_primer_on_dna_and_dna_replication/.

The name of the article is “A Primer on DNA and DNA Replication”; Reporter and Curator: Larry H. Bernstein, MD, FCAP.

Appreciatively,

Susan

Susan B. Klein, PhD

Department of Physics

Swain West 331

Indiana University, Bloomington

812.855.9687

From: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Sent: Tuesday, May 28, 2019 12:17 PM

To: Klein, Susan Beth

Cc: Stephen Williams, PhD; Marcus W Feldman

Subject: Re: Permission to reprint image

 

Dear Prof. Klein,

It is always most endearing to correspond with another fellow Alumna of Berkeley.

Congratulations on your forthcoming book, Fundamentals of Radiation Biology. The publisher of the text is World Scientific, anticipated publication in 2023.

Thank you for reaching out to me for permission to reprint a figure.

Please e-mail me the name of the article you found this figure in on our Journal http://pharmaceuticalintelligence.com 

Or in one our our 16 e-Books in Life Sciences and Medicine on Amazon.com

https://lnkd.in/ekWGNqA

I will then research and grant you re-printing permission in e-writing.

Since your forthcoming text book is on Radiation Biology, in this context, I wish to bring to your attention two points:

1.You may find of interest the following e-Books of ours

Series B: Frontiers in Genomics Research

 

  • VOLUME 1: Genomics Orientations for Personalized Medicine. On Amazon.com since 11/23/2015

http://www.amazon.com/dp/B018DHBUO6

  • VOLUME 2: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology

https://pharmaceuticalintelligence.com/biomed-e-books/genomics-orientations-for-personalized-medicine/volume-two-genomics-methodologies-ngs-bioinformatics-simulations-and-the-genome-ontology/

Work-in-Progress

 

Series C: e-Books on Cancer & Oncology

 

  • Volume 1: Cancer Biology & Genomics for Disease Diagnosis. On Amazon.com since 8/11/2015

http://www.amazon.com/dp/B013RVYR2K

  • Volume 2: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery (Series C Book 2). On Amazon.com since 5/18/2017

http://www.amazon.com/dp/B071VQ6YYK

2. My articles on medical OUTCOMES of Radiation Biology  on Cardiotoxicity

Cardio-oncology and Onco-Cardiology Programs: Treatments for Cancer Patients with a History of Cardiovascular Disease

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2014/01/08/cardio-oncology-and-onco-cardiology-programs-treatments-for-cancer-patients-with-a-history-of-cardiovascular-disease/

3rd Annual Canadian Cardiac Oncology Network Conference, June 20 – 21, 2013, Ottawa Convention Centre

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2014/01/08/3rd-annual-canadian-cardiac-oncology-network-conference-june-20-21-2013-ottawa-convention-centre/

2019

http://cardiaconcology.ca/ccon-conference-2019-modern-changing-practices-in-cardio-oncology/agenda/

My Journal on Cardiotoxicity on Scoop.it

https://www.scoop.it/topic/cardiotoxicity

Looking forward to getting name of article when the figure had appeared in our publications.

Good luck,

Aviva Lev-Ari, PhD, RN

Director & Founder

https://lnkd.in/eEyn69r

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

Editor-in-Chief

http://pharmaceuticalintelligence.com 

e-Mail: avivalev-ari@alum.berkeley.edu

(M) 617-775-0451

https://cal.berkeley.edu/AvivaLev-Ari,PhD,RN

SkypeID: HarpPlayer83          LinkedIn Profile        Twitter Profile

From: “Klein, Susan Beth” <sbklein@indiana.edu>

Date: Tuesday, May 28, 2019 at 11:11 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Permission to reprint image

Hello Aviva Lev-Ari,

I am currently writing a book: Fundamentals of Radiation Biology. I would like to know if I might have your permission to reprint this figure in a section on DNA replication. The publisher of the text is World Scientific and we anticipate publication in 2023. I would very much appreciate your permission; this is a lovely illustration!

Regards,

Susan

Susan B. Klein, PhD

Department of Physics

Swain West 331

Indiana University, Bloomington

812.855.9687

(another Berkeley alum)

April 2019

2019 Ranking of Conference Influencers: On 4/9/2019, The Partners’ 2019 World Medical Innovation Forum #WMIF19

via @symplur‘s #Healthcare Hashtags http://bit.ly/WMIF19 

  • By “Mentions” – Ranked #4: @pharma_BI and
  • By “Tweets” – Ranked #2: @AVIVA1950

via NodeXL  http://bit.ly/2KB6cPN 

  • By “Betweenness Centrality” – Ranked #3: @AVIVA1950 and @pharma_BI

https://pharmaceuticalintelligence.com/2019/04/13/the-wmif19-influencers-via-symplurs-healthcare-hashtags-http-bit-ly-wmif19-by-mentions-and-by-tweets-ranked-4-pharma_bi-and-2-aviva1950-respectively-ranked-3-via-node/

4/21/2019

From: Amnon Danzig <amnon.danzig@gmail.com>

Date: Sunday, April 21, 2019 at 4:17 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: A Letter from Amnon Danzig

Dear Aviva

Now, I read the two docs in depth.

Sure, I have a few questions for my understanding. We can devote Skype for that to make sure I understand…

It is my honor to work with you and the team.

I found Gail and Rick extremely good players, partners and colleagues at the same time. And I would like to thank you for the opportunity to work with them.

I would like to thank you for your very fine and warm words about my contribution. GREAT!

I must confess that in the last three months I couldn’t do any real intellectual work. I need to finalize my speech at the conference and couldn’t touch it.

Why?

My thinking was always going to the ways to present LPBI Group the best it can.

I found myself very busy intellectually and emotionally how we can improve the way the IB will see us.

Example: the last two weeks I invested happily dozens and dozens for this assignment. On Thursday afternoon my son arrives and we spent a few hours together. Then, on 9 PM I set down to make the corrections you asked me. Took me another 3 hours, sent it and waited another two hours to see whether I need some more. Because I knew that on Friday you MUST send. It was kind of relief after two hours. When you sent us the update I saw it and felt “everything is okay” and I can put my mobile away for 24 hours: all the family, friends were around I thought it better to be disconnected.

I am very glad you found my contribution significant. Also, the way you express it is outstanding. Thank you!

Now, I will spend a few days about the conference and also looking for ways to find significant people to meet and discuss my new book. The idea to find more audience and hopefully potential clients.

If you happen to have ideas for me, great.

This is the reason I extend my time in NYC. 

BR 

Amnon

@@@@@

4/19/2019

LPBI Group: The Business Opportunity

Voice of Prof. Marcus W. Feldman

The intellectual property of LPBI is of three types: a corpus of curated articles in an open access online scientific Journal, a corpus of e-books in Medicine and Life Sciences, and a corpus of Biotech e-proceedings. This IP is highly relevant to five industrial and services sectors across twelve economic segments. LPBI has pioneered production of scientific content with unique curation methodology by a highly knowledgeable group of experts. The content and the potential consumers & acquirers and valuers of this content are represented graphically below. The three types of corpus, together with the very large audience that follows the content on various media, represent intangible assets of LPBI Group and can be represented as such to potential investors. Together with the tangible assets described in Document #2, the combination represents a unique opportunity for acquisition.

@@@@@

4/19/2019

LPBI Group: The Business Plan

Voice of Aviva Lev-Ari, Founder

The Business Plan representing work-in-progress generated by our business professionals, Amnon Danzig (AD), Gail Thornton (GST) and Rick Mandahl (RM).

  • The content is extracted from Document #2, the concept of the “Client End-User Perspective” and the “Acquirer Perspective” are contributions by Amnon Danzig (AD). 
  • The positioning of 12 economic segments in a 3D structure for each of these two perspectives represent contributions of AD, GST and RM, under the leadership of AD. They took the microeconomics Theory of the Firm to most interesting interpretation given for several Demand aspects related to the performance of Knowledge Workers in the digital workplace as potential users of LPBI Group’s products.
  • They followed the 3D illustration developed by Aviva Lev-Ari, PhD, RN (ALA) using three different axes for representation of same 12 economic segments. The view taken by ALA is of Industrial Organization Economics theoretical framework of comparisons among industrial and services sectors and within each sector competition among player drawing strategies for augmenting the competitive advantage by horizontal and vertical mergers. Opportunities for economies or scale, externalities, diversification and product differentiation. In ALA’s perspective, LPBI Group’s IP represents Supply side, a series of technologies poised to augment the core competencies of players in 12 economic segments as in Appendix C, below [which is identical to Table developed by ALA for Sections #4 & #5 in Document #2.
  • Further development of this Business Plan document will follow in the near future.

This Business Plan is based on and is complementary to Document #2 that provides a distinctive view on Intangible Assets, Sections #1 to #12 vs Tangible Assets and royalty payments which are present in Section #13 & #14 of Document #2.

This Business Plan consists of a conceptual framework developed by the business side of our Final Improvement Team (FIT members N=12). This conceptual framework is indeed unique in depth and breadth placing the unmet needs of potential acquirers by name, each in an economic segment, each economic segment within an Industrial and Services Sector. It demonstrates deep understanding of Demand side economics of the End-User in each of the 12 economic segments. This strategic thought process represents well AD’s business acumen for placing in the center the ultimate demand of end-users and the unmet needs of potential Acquirers that will be fulfilled on their behalf by LPBI Group’s IP – the features and functionality of the technologies we have developed since 2012.

 

@@@@@

4/14/2019

The #WMIF19 Influencers via ‘s  Hashtags http://bit.ly/WMIF19 – By Mentions and By Tweets Ranked #4: @pharma_BI and #2: @AVIVA1950, respectively. Ranked #3 via NodeXL Betweenness Centrality http://bit.ly/2KB6cPN

https://pharmaceuticalintelligence.com/2019/04/13/the-wmif19-influencers-via-symplurs-healthcare-hashtags-http-bit-ly-wmif19-by-mentions-and-by-tweets-ranked-4-pharma_bi-and-2-aviva1950-respectively-ranked-3-via-node/

4/13/2019

Twitter Data for LPBI Group’s Founder’s Twitter handle @AVIVA1950 was updated 

On 2/24/2019 — Tweets 8,060 Following 1,412 Followers 359 Likes 2,752

On 4/13/2019 — Tweets 9,018 Following 1,461 Followers 390 Likes 3,654

 

4/11/2019

Top 3 Ranked by Betweenness Centrality in Top 10 Influencers #WMIF19 @phsinnovation @evankirstel @aviva1950 –Tweeter Analytics by NodeXL http://bit.ly/2KB6cPNfor #WMIF19 by @PHSInnovation  at World Medical Innovation Forum ARTIFICIAL INTELLIGENCE, Boston, MA USA, Monday, April 8-10, 2019

https://pharmaceuticalintelligence.com/2019/04/11/top-3-ranked-by-betweenness-centrality-in-top-10-influencers-wmif19-phsinnovation-evankirstel-aviva1950-tweeter-analytics-by-nodexl-http-bit-ly-2kb6cpn-for-wmif19-by-phs/

@@@@

‘s  Hashtags  – Twitter Analytics published for http://bit.ly/WMIF19 

  • [Top 10 by Mentions – @pharma_BI = 4 with 181 mentions]  
  • [Top 10 by Tweets @AVIVA1950 = 2 with 229 Tweets (N = 152 Direct messages)]
 Pinned Tweet

⚡️As World   Forum comes to a close, here are TOP   via ‘s  Hashtags 🙏 to organizers for a stellar event & to all on  for a robust conversation!   👏 

@@@@

Top influencer 3rd place @AVIVA1950

This is a great analysis and I love that you found these two programs, NodeXL and Betweeness Centrality. These offer the best Twitter analytics and node analysis I have ever seen. Thanks for sharing and a great conference and great conference coverage in real time. Show the power of REALTIME CONFERENCE COVERAGE methodology @pharma_BI and @AVIVA1950 as well as power of LBPI Group.

https://nodexlgraphgallery.org/Pages/InteractiveGraph.aspx?graphID=193125

 

@@@@

From: “Gregory Piatetsky, KDnuggets” <editor1@kdnuggets.com>

Date: Wednesday, April 10, 2019 at 10:16 PM

To: Aviva Lev-Ari <aviva.lev-ari@comcast.net>, Gil Press <gpress900@gmail.com>

Subject: Re: Fwd: NodeXL Graph Gallery: Interactive Graph

Well done!  3rd place for #WMIF19 is good

See

Comparative Analysis of the Level of Engagement for Four Twitter Accounts: @KDNuggets (Big Data) @GilPress @Forbes @pharma_BI @AVIVA1950

 

@@@@

From: Leny <gochevav@mit.edu>

Date: Wednesday, November 28, 2018 at 11:30 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Re: MIT Center for Precision Cancer Medicine Inaugural Symposium – Question from Aviva Lev-Ari, PhD, RN

Dear Dr. Lev-Ari,

I actually have been meaning to reach out to you with an invitation to our symposium. We were both at the Personalized Medicine Coalition’s conference two week ago at Harvard Medical School, but I didn’t get a chance to speak to you in person.

To get a complimentary press pass, please visit cpcm.eventbrite.com -> select Tickets ->  select “Enter Promotional Code”-> enter CPCM2018 and that will allow you to select “Press” tickets.

Please do not hesitate to reach out if you have any additional questions.

Best,

Leny

Vasilena Gocheva, PhD | Assistant Director  | MIT Center for Precision Cancer Medicine  | 77 Massachusetts Avenue, 76-353  | Cambridge, MA 02139  | cpcm.mit.edu

From: Shankar Khatkale <shankar.k@gminsights.com>

Date: Tuesday, November 27, 2018 at 6:48 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Article Submission Request

Dear Editor,

An industry news titled ‘Precision Medicine Market Size worth $96.6bn by 2024’ by Global Market Insights is relevant to your esteemed website https://pharmaceuticalintelligence.com. This email is a suggestion to publish this news (content attached in word format or can be picked from link mentioned below) on your website with an objective to share the information with your audiences.

News Link: https://www.gminsights.com/pressrelease/precision-medicine-market

 Looking forward to hear from you.

 On behalf of and as instructed by Global Market Insights, Inc.

 Best Regards,

Shankar Khatkale |SEO Executive

 

From: Daphne Kwee <daphnekwee@farrerpark.com> on behalf of Daphne Kwee <daphnekwee@farrerpark.com>

Date: Monday, October 29, 2018 at 9:33 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Post retirement doctors establishing new career heights – Story Consideration

Dear Aviva,

Would you be interested in interviewing personalities in the medical Fraternity?

Particularly, Dr Leslie Lam. One of the renowned personality who was sued by the SMC and won after a 7 year battle. He is a medical veteran in his 70s but shows no signs of slowing down. He has re-established himself in Farrer Park Hospital and is blazing a trail with his new clinic. Having recently been conferred the Distinguished Graduate Award by the University College Dublin School of Medicine for his contribution toward medical education, research and support toward the community. Previous recipients of this award includes Professor Connor Ward who pioneered work on Cardiac abnormalities such as the co-described Ward-Romanov Syndrome.   

Dr Lam’s story strikes a chord with the government’s stand of lifelong learning and contribution. In addition to his clinical work, Dr Lam is an advisor to the Seychelles ministry of health, contributes regularly to teaching doctors and donating medical equipment to Myanmar. He also established a leading wine collection in order to fund his philanthropic works with charities in Singapore and Ireland, where he received his medical education. 

I have attached the award letter to this email for your information. 

Should you be interested in such a story angle, I do have other personalities here at Farrer Park Hospital for your consideration. Professor Tan Yew Oo, Singapore first medical oncologist, as well as Professor Soo Khee Chee, the founding director of Singapore’s National Cancer Centre. All these renowned medical personalities, who in their post retirement years, are still actively contributing toward Singapore’s future.

Do let me know if you would like to find out more to explore story possibilities. I would be happy to catch up over lunch or tea for a discussion.

 

Best regards,

Daphne

Executive

Corporate Communications

DID (65) 6705 2769  

www.farrerpark.com/hospital

From: “Prof. Nathan F. SAYRE (Chairman, Geography)” <nsayre@berkeley.edu>

Date: Friday, June 1, 2018 at 3:26 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Cc: Christian Gordon <cmgordon@berkeley.edu>, Robert Rhew <rrhew@berkeley.edu>

Subject: Re: I will be on BERKELEY Campus for the Homecoming Week, few days before and After, October 11, 2018 to October 16, 2018 — Hope to meet again

Dear Dr. Lev-Ari,

Thank you for your kind note, and wonderful to hear that you will be visiting campus in October. I’m happy to hear that you will see Professor Birgeneau and other Cal alumni in New England. I know the university will be ramping up its efforts in Boston and surrounding areas, to create more opportunities for alumni to connect with each other, and with Berkeley.

I would like to introduce you to Christian Gordon, our partner in development and alumni relations for geography and the division of social sciences. Christian can assist with setting up your visit and relevant meetings while you are on campus. He’s also happy to follow up with additional information, as well as additional opportunities in Boston to connect with Berkeley between now and October.

Very much looking forward to seeing you at Homecoming. Thanks again for sending your recollections of Allan and Berkeley!

Best,

Nathan

PS I’m cc’ing Professor Rob Rhew, who will succeed me as department chair on July 1st.

From: “Prof. Michael Watts” <mwatts@berkeley.edu>

Date: Sunday, May 13, 2018 at 1:29 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Re: Sharing with you — This May 2018, Official Newsletter has a Global distribution of half a million Inboxes: See article on Aviva Lev-Ari in ALUMNI SPOTLIGHT of American Friends of Hebrew University

Dear Aviva: a very long time!  Nice to hear from you and your later extraordinary career!  And it seems like you are now on Phase IV.  Very exciting.

I am retiring in June but will of course keep writing and conducting research.

You may have heard that Allan’s wife Hjordis passed away relatively recently.   It was nice to see their children again at the memorial.

Warmly, Michael

On Fri, May 11, 2018 at 12:01 PM, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu> wrote:

Sharing with you — This May 2018, Official Newsletter has a Global distribution of half a million Inboxes:  

See article on Aviva Lev-Ari in ALUMNI SPOTLIGHT of American Friends of Hebrew University – Please scroll down

If interested to read more, click on:

Aviva’s books on AMAZON.COM

https://www.amazon.com/s/ref=nb_sb_noss?url=search-alias%3Ddigital-text&field-keywords=Aviva+Lev-Ari&rh=n%3A133140011%2Ck%3AAviva+Lev-Ari

On Fri, May 25, 2018 at 12:44 PM, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu> wrote:

Dear Professors, Watts, Walker, Sayre, Laguerr and Segev, 

I hope you are well and will enjoy the months of Summer coming up.

We will have dinner with Berkeley’s ex-Chancellor, Prof. Robert Birgeneau in Boston on 6/16/2018, meeting with Alumni in New England. I am much looking forward to his talk and meeting alumni.

I will be on BERKELEY Campus on October 11, 2018 to October 16, 2018, planning to attend the Homecoming Week, October 12-14, 2018.

It will be my great pleasure to meet again, I hope you will be on Campus at least one day of the week in October 2018 when I will be on Campus and could meet you. Allan Pred will be missing on this visit, so sad.

I recently wrote my Recollections of my five years at Berkeley in two Parts, which you may find of interest to read, in particular, Part 2, which I authored as a curation, after my e-mail exchange with Prof. Michael Watts in May, 2018.

  • Recollections: Part 1 – My days at Berkeley, 9/1978 – 12/1983 – About my doctoral advisor, Allan Pred, other Professors and other Peers

https://pharmaceuticalintelligence.com/2018/03/15/recollections-my-days-at-berkeley-9-1978-12-1983-about-my-doctoral-advisor-allan-pred-other-professors-and-other-peer/

  • Recollections: Part 2 – “While Rolling” is preceded by “While Enrolling” Autobiographical Alumna Recollections of Berkeley – Aviva Lev-Ari, PhD’83

https://pharmaceuticalintelligence.com/2018/05/24/recollections-part-2-while-rolling-is-preceded-by-while-enrolling-autobiographical-alumna-recollections-of-berkeley-aviva-lev-ari-phd83/

Please Read these two:

I attended the 1998 – 100 years Geography Department celebration.

Please review the following, it can be included in the future Itinerant Geographer.

Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018

https://pharmaceuticalintelligence.com/2018/03/06/reflections-on-a-four-phase-career-aviva-lev-ari-phd-rn-march-2018/

Thank you – Good Luck to you

From: “Prof. Nathan F. SAYRE (Chairman, Geography)” <nsayre@berkeley.edu>

Date: Thursday, March 8, 2018 at 6:07 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Re: I MADE A CONTRIBUTION IN MEMORY OF PROF. ALLAN PRED few weeks ago

Dear Aviva,

Thank you for writing. Yes, we did receive your donation in Allan’s honor–thank you!–and we put a letter of thanks and acknowledgement in the mail last week. Please look out for it.

You are not alone in missing Allan–many many people do. Sadly, his widow, Hjordis, also passed away not long ago.

Michael Watts is not yet technically retired, but he thought he would two years ago, and since we made a big public announcement then we’ve kept the technical truth quiet. He will in fact retire this summer. As you assumed, Walker, Reed, and Nat have all retired, as have Beatriz Manz, Gillian Hart, Paul Groth, Michael Johns, and Roger Byrne. We are anxiously awaiting authorization to recruit new human geography faculty.

It’s kind of hard to think of any of us as adequate to fill Allan’s shoes, but we all try to preserve his flexibility of mind and lucidity of thought. Our graduate students perhaps carry on his intellectual legacy best. If you haven’t heard of Trevor Paglen, he was one of Allan’s last PhDs:

http://www.paglen.com/

Thank you also for the links to your eulogies for Allan and David, and to your reflections. I am touched by your words and your enduring support for the department.

Best,

Nathan

On Monday, July 24, 2017 at 9:27 PM

From: marzan Khan <marzan.khan@mail.mcgill.ca>

Date: Monday, July 24, 2017 at 9:27 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Re: SERIES E VOLUME 2 –>>> FORMAT CONVERSION — I MUST find out what has been done to FINISH up this format conversion – Series E Volume 2

Hello Aviva,

Thank you very much for your kindness and support. It was great working for you. I apologize for not being able to finish my task to completion. You have been an excellent mentor and I will be grateful to you always.

Best of luck on the e-book and all your endeavors.

Sincerely,

Marzan Khan

On June 18, 2017, 9;39AM

Dear Aviva Lev-Ari,

Thank you very much for your email.

First of all I would like to congratulate you to your outstanding work, if I may. You are one of the very few people with really meaningful and scientific articles/updates on LinkedIn.

I recently liked one of your articles/updates “Molecular Pathogenesis of Progressive Lung Diseases” on LinkedIn, because it was an interesting article. We have a project here in China “Natural Breathing”, where we look at solutions for COPD. With all the air pollution in China, this is already a majour burden, and it is one that will become a larger burden in the coming years. As for your email, I am not quite sure what to make out of it honestly. Is it an offer to write or publish an article? In regards to China: Please do not hesitate to contact me, if you have questions or if I may help with contacts in the healthcare industry. We have a quite good network here.

Sincerely from Beijing

Dennis Wilkens, Managing Director, Medical Devices, Health 4.0, Toronto, Hamburg, Beijing, Distribution Network, Investments & Ventures, Jadevita International Inc., University of Hamburg

On 6/15/17, 5:43 AM, “Anamika Sarkar” <sarkaranamika@yahoo.com> wrote:

Hi Aviva,

Thanks! I am also excited to join Regeneron.

Congratulations to your success of publishing in Amazon. Your focus and perseverance to science is admirable.

Best

Anamika Sarkar, PhD

@@@@@@

From: “Mark Cobbold, MD, PhD, MGH” <mcobbold@mgh.harvard.edu>

Date: Wednesday, April 27, 2016 at 11:32 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: RE: LIVE ­ 8:00 am ­ 12:00 pm 4/25/2016 ­ First Look: The Next Wave of Cancer Breakthroughs @2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Westin Hotel, Boston | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Thanks Aviva.

You obviously work hard on this!

Keep up the hard work.

Mark

MARK COBBOLD, MD, PHD

Headshot

Associate Professor of Medicine, MGH Cancer Center

http://worldmedicalinnovation.org/speakers/mark-cobbold-md-phd/

 

From: Aviva Lev-Ari [mailto:AvivaLev-Ari@alum.berkeley.edu]
Sent: Tuesday, April 26, 2016 7:53 PM
To: Cobbold, Mark
Subject: LIVE ­ 8:00 am ­ 12:00 pm 4/25/2016 ­ First Look: The Next Wave of Cancer Breakthroughs @2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Westin Hotel, Boston | Leaders in Pharmaceutical Business Intelligence (LPBI) Group
 

https://pharmaceuticalintelligence.com/2016/04/25/live-800-am-1200-pm-4252016-first-look-the-next-wave-of-cancer-breakthroughs-2016-world-medical-innovation-forum-cancer-april-25-27-2016-westin-hotel-boston/

Aviva Lev-Ari, PhD, RN

Director & Founder

Leaders in Pharmaceutical Business Intelligence Group, Boston

Editor-in-Chief

http://pharmaceuticalintelligence.com

e-Mail: avivalev-ari@alum.berkeley.edu

SkypeID: HarpPlayer83 

LinkedIn Profile        Twitter Profile

@@@@@

From: Arquisch Tony <Tony.Arquisch@cpagroup.ch>

Date: Friday, March 18, 2016 at 11:46 AM

To: Aviva Lev-Ari <aviva.lev-ari@comcast.net>

Cc: Arie Berger <arisimonberger@gmail.com>, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>, ‘Maggie You’ <maggie.you@oriental-ventures.com>

Subject: RE: REVOTEK follow up for 3D printing – AVIVA

Hello Aviva: 

To answer your questions:

The ownership at regenHU is as is.

The CEO of regenHU is Mr. Marc Thurner

The other CPA Group companies are unchanged i.e. no updates

With that said, of course until there are any official announcements, we continue to sell products and services accordingly. If there is interest in a particular product and/or service I will be more than happy to assist. If there is an investment interest then please send me an official inquiry (in writing) with as many details as possible upon which I will present it to management. Once there is an interest we will send Non-disclosure agreements and start the negation phase accordingly.

I truly hope we can work together since I’m impressed with your activities. Have a great weekend.

Regards,

Tony

Tony Arquisch

Business Development Manager
Direct +41 26 653 71 84
Mobile +41 79 349 20 44
tony.arquisch@cpagroup.ch

CPA Group SA
Z.I. du Vivier 22
CH-1690 Villaz-St-Pierre

Switzerland
Tel. +41 26 653 71 71
www.cpagroup.ch

LinkedIn Profile  /  XING Profile  / Twitter Profile

@@@@@@@

From: Christopher Wells <cwells@personalizedmedicinecoalition.org>

Date: February 19, 2016 at 3:40:19 PM EST

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Cc: David Davenport <ddavenport@personalizedmedicinecoalition.org>

Subject: Re: I wish to nominate Larry H. Bernstein, MD, FCAP for 12th Annual Award for Leadership in Personalized Medicine

Dr. Lev-Ari:

Thank you so much for what is clearly a strong nomination. David Davenport, copied here, will make sure that our Board of Directors gives careful consideration to Dr. Bernstein’s qualifications for this award, and I will follow up with you personally once we have made a final decision. 

By the way, I am a fan of your work on Leaders in Pharmaceutical Business Intelligence. I am sure it is helpful for many personalized medicine stakeholders. 

Have a good weekend. 

Very sincerely,

Chris

Christopher J. Wells, M.P.A.

Communications Director

Cwells@personalizedmedicinecoalition.org

Direct: 202-589-1755 I Mobile: 202-580-9780

Personalized Medicine Coalition

Blog: Education & Advocacy

Twitter: @PerMedCoalition

1710 Rhode Island Ave. NW I Suite 700 I Washington, DC 20036

www.PersonalizedMedicineCoalition.org  

@@@@@@@

2/12/2016

2016 Communication Awards for Excellence in Reporting and Communicating Science, Medicine and Engineering Nomination

Book Title: * Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation
Publisher(s): * Amazon Kindle Direct
Publication Date: (Please select one): * November 2015
Book Entry Summary (Please limit to 100 words): * The explosion of scientific information has created difficulties tying together disparate discoveries, ideas, and potential applications. Pharmaceutical Business Intelligence is developing an innovative methodology for Global access to Biomedical knowledge rather than traditional search. To attain this complex goal they disseminate ORIGINAL Research via Content Curation by experts using critical thinking process & interpretation over open access networks, offering better organization and visibility of critical information useful for innovations in academic, clinical, and industrial research. Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation at http://www.amazon.com/dp/B018Q5MCN8 is nominated as an example of this methodology.
   

@@@@@@@

2/2/2016

Nominations for 2016 National Academies Communication Awards For Excellence in Reporting and Communicating Sciences, Engineering, and Medicine, Keck Futures Initiative

Editor-in-Chief: Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2016/02/02/nominations-for-2016-national-academies-communication-awards-for-excellence-in-reporting-and-communicating-sciences-engineering-and-medicine/

@@@@@@@@@

From: “Tilda Barliya, PhD” <tildabarliya@gmail.com>

Date: Tuesday, January 19, 2016 at 1:09 PM

To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>

Press Releases from Leaders in Pharmaceutical Business Intelligence (LPBI): FIVE new e-Book in our BioMed e-Series are NOW available for Kindle on Amazon.com | Leaders in Pharmaceutical Business Intelligence

Wow!!!!! That’s very impressive. So proud of being part of this group and project.  Good job everyone.

Thank you Aviva for being the leader of this group and pushing us forward. Thank you for being you.

Good job everyone!!!

Best

Tilda

@@@@@@@@@

From: Gregory Piatetsky-Shapiro <gregory@kdnuggets.com>

Date: Sunday, January 10, 2016 at 6:13 AM

To: Aviva Lev-Ari <aviva.lev-ari@comcast.net>

Subject: Re: big data start up for you to talk to…

Dear Aviva,

Happy New Year and congratulations on your amazing success in your latest venture – Pharmaceutical Intelligence!

Gregory

On 1/9/2016,  I wrote to Gregory:

My eight years in HealthCare, 2005-2012, could have been an entry into HealthCareIT, as we discussed in 2012. However, I decided to tackle Pharmaceutical Intelligence , instead. The learning curve was very steep and it was conquered in record time, as evidenced by building an amazing impactful infrastructure in Scientific Media in Pharmaceutical Intelligence:

Journal, ~4000 articles archived, 900,000 e-Readers

e-Books, 15 Title BioMed e-Series, eight are on Amazon.com in 2015, seven forthcoming, in 2016

Conference Press Coverage in Real Time, sixteen of the Leading in BioTech. In 4/2016, Partners HealthCare, Global Cancer Conference in Boston.

In 3D BioPrinting, we lunched a Subsidiary, TEAM is involved in Product Concepts Development using

  • BioMEMS for Gene Editing
  • BioMEMS for Tissue Engineering
  • BioMEMS and Stem Cells for Gene Therapy and Regenerative Medicine.

We are also involved involved in (a) Drug Discovery by structuring Joint Ventures and in (b) Funding Early Stage Biologics Drug Development and Medical Device Development.

@@@@@@@@

Please see #3

Mayo Clinic Center for Innovation is citing LPBI’s Article by Dr. Larry H Bernstein, MD, FCAP

16 NOV 5 FOR TODAY

Posted at 06:30h in Morning Update by Center for Innovation 0 Comments Share

  1. Responsible innovation in health care and dual use research. [ Health Kid ]
  2. A patient’s point of view. [ HRBR ]
  3. Drivers of Patient Experience. [ LPBI ]
  4. 5 ways providers can improve the patient experience. [ FierceHealthIT ]
  5. Telehealth is essential to lowering readmission rates. [ mHealthNews ]

@@@@@@@@

From: “Dr. MD. K. Singler” <Dr.MD.K.Singler@sciarticles.net>

Reply-To: “Dr. MD. K. Singler” <Dr.MD.K.Singler@sciarticles.net>

Date: Friday, November 13, 2015 at 10:14 AM

To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>

Subject: Invitation

Science and Education

November, 2015

Submit a manuscript

Journals

Articles

Subscribe

Search

Unsubscribe

Dear Colleague,

I am writing to let you know about recent highly accessed articles published in our open access journals and invite you to submit your next manuscript to the journal.

Read our top articles

Dr. MD. K. Singler

Editorial Assistant, Science and Education Publishing

@@@@@@@@@

From: Anne Sim <georgeclinicalau@gmail.com>

Date: Monday, August 3, 2015 at 3:39 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: contributing

Hello,

I am contacting you on behalf of George Clinical, a leading non-profit CRO in the Asia Pacific region. Our parent organization, The George Institute is a renowned medical research institute which has impacted medical practice and policy globally.

We are currently working to build upon our brand awareness by sharing our extensive knowledge and experience within the scientific and medical community. We would love to learn more about any opportunities (publishing, marketing, sponsorship, co-authorship) that you might have available.

We appreciate your time, and If you would be kind enough to provide us information on possible opportunities that you offer, we can review them and see which are a good fit between our organization and yours.

Thanks,

Anne Sim

@@@@@@@@@@@@@@@@@

From: Christopher Wells <cwells@personalizedmedicinecoalition.org>

Date: Wednesday, September 2, 2015 at 11:36 AM

To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>

Subject: Thank you for re-blogging our post

Hi Dr. Lev-Ari:

I noticed that you re-blogged our recent post on Education & Advocacy, titled “Turning a Corner: How This Month’s Decisions at FDA Inform the Debate on Drug Costs.” I just wanted to thank you for that. We are working to build a following for the blog, and a re-posting from an established and reputable source like your blog is helpful. 

I will keep an eye on content from your blog moving forward. Feel free to let me know if you ever post anything on personalized medicine. 

Thank you again.

Sincerely,

Chris

Christopher J. Wells, M.P.A.

Communications Director

Cwells@personalizedmedicinecoalition.org

Direct: 202-589-1755 I Mobile: 202-580-9780

Personalized Medicine Coalition

Blog:Education & Advocacy

Twitter: @PerMedCoalition

1710 Rhode Island Ave. NW I Suite 700 I Washington, DC 20036

www.PersonalizedMedicineCoalition.org  

Unknown@@@@@@@@@@@@@@@@@

 
10/19/2015

Dear Aviva:

I want to applaud you for building your own publishing and scientific communications empire. You have really grown since 5/2013 when you and Larry and I first met. Anyway, down to business. I need help in “telling my story” of why the current 5 Nucleotide Watson Crick Genetic Code (ATGCU) need to expand with two additional and natural purine nucleotides to cover the epigenetic level of gene regulation so that Novagon’s 7 nucleotide ATUICGX genetic + epigenetic = genomic code is more valid than the current 5 code which has never built a man made prescription drug or any therapy which does not have multiple side effects including thousands of deaths. This project has got to big for me and I would like to join with your group to be discuss, strategically, how we can logically and empirically prove natures natural 7 code is the right number of codes and not 5. I don’t know how to proceed, but if you are interested we could meet i.e. whoever you want to bring into the project is fine by me; there are people in your group who can edit and write or rewrite what I have done much better than me. Remember, I grew up in Helena, Arkansas, in the Delta region, on the Mississippi river. Lots of cotton, but not many brains, especially in the teaching ranks. Any way I have come along way from there but I still am deficit or maybe lazy in writing and editing. Although my ADHD might be a strong contributing factor. Any, way I have tried and finally willing to concede, One person cannot do it alone. I have reached out to you because you were the first to ask me to join your team as Expert, author writer. Kind of ironic now that I am coming to you with great content but unorganized with no media plan or strategy. If Larry is interested I should would like him part of the project, if you decide to accept my scientific content and as publisher you we jointly publish what value proposition we determine as a team. Thanks for your notice. I took it as a cosmic sign, and it would be your 7th venture, quite ironic under the circumstances. Thank you for your time and I hope you decide to let me into your publishing umbrella and get some help in creating content for your growing empire. Thanks, John Berger Novagon DNA

John Berger

Founder at Novagon DNA

   
 
@@@@@@@@@@@@@@@@@@

 

   

 

Dear Dr. Aviva Lev-Ari,

Greetings from SciRes Literature!

It is a great pleasure to invite you for the Editorial Board membership in SciRes Literature member Journals. SciRes Literature is an Open Access Publisher of twenty-eight internationally refereed, online, peer-reviewed scholarly Journals designed for scientists, physicians, doctors and researchers across the globe. Our mission is to support the rising horizons of the scientific innovations and promote the advancement in research community by increasing the online accessibility of quality research articles.

The Editorial Office is actively seeking qualified researchers and experts to be a part of our journal Editorial Board. In recognition to your distinguished accomplishments in the area of Immunology (related areas), we are pleased to invite you to be a part of our SRL Immunology & Immunotherapy journal.

You can find more information by visiting us at:
http://scireslit.com/Immunology

You can support, strengthen and contribute to our vision through your expertise in area by joining our Editorial Board.

If you are interested in serving as an editor, kindly send us your short biography, Research interests, CV and Photo to immunology@scireslit.com for review.

Please feel free to contact for any further queries

Anticipating a positive response.

Sincerely,

SASHA Sims
Editorial Office, SciRes Literature
SRL Immunology & Immunotherapy
1692 Coastal Highway
Delaware 19958, USA
Email: immunology@scireslit.com

 

 

Testimonials about LPBI

2021

UPDATED on 9/29/2021

Tweet

 
MIT Technology Review
 
@techreview
Replying to

and

Thanks for joining us again
@AVIVA1950. We loved your tweets yesterday!
 
@techreview is the handle of MIT Technology Review Twitter account followed by 1.1 Million followers

MIT Technology Review

 

Retweeted your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT Charles Hoskinson CEO and Founder, Input Output Global; Founder, Cardano, 2015 Nation scale [Ethiopia] and Global scale – records ledger and smart contracts, credentials identity, reversible auditable that operates at scale; Cofounder, Ethereum

This image has an empty alt attribute; its file name is MIT-Technology-Review.png
 
 

MIT Technology Review

Retweeted your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT Charles Hoskinson CEO and Founder, Input Output Global; Founder, Cardano, 2015 Nation scale [Ethiopia] and Global scale – records ledger and smart contracts, credentials identity, reversible auditable that operates at scale; Cofounder, Ethereum

MIT Technology Review

liked your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT  Nick Selby Chief Security Officer, Paxos Trust Company at Timehop GDPR a bridge of security disclosure to US Citizens 5% of EU opt out 7/418 ADM password changed User database was compromised protect customers data Recovery architecture monitor

MIT Technology Review

Retweeted your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT @EmTechMIT Wendy Nather Head of Advisory CISOs @Cisco mid 90s Two-way authentications Who are the attackers, changes, abuse of the platform by users Technology to buy Proactive Refresh Tech done by vendor is best security practice

MIT Technology Review

Retweeted your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT Kevin Scott CTO @Microsoft Compute is the only constraint Open source version of OpenAI API no need to build OS. Responsible AI within Microsoft – Standard for the whole company to be rolled up soon. Regulation to consider where we are going to be

 
 
 

 

UPDATED on 9/22/2021

From INTERNS in 2021 LPBI’s Summer Internship

From: “Ethan Coomber [Intern 2021]” <ethancoomber6@gmail.com>
Date: Monday, September 20, 2021 at 11:54 PM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>

Hi Aviva,

This past summer, I was able to intern for LPBI. I really enjoyed being able to expand upon what I had been learning in the classroom at school, and push myself to take on new, exciting challenges. Over the summer, I was given 2 projects that were extremely interesting, but were vital in helping LPBI grow as well. With the guidance of LPBI, as well as my own outreach, I was able to expose myself to the world of text to audio conversion, as well as further my understanding of data analytics. The combination of resources at my disposal as well as Aviva’s guidance allowed me to make the most of the opportunity in front of me.

The mentorship I received from LPBI was extremely valuable. Being able to work so closely with LPBI’s founder, Aviva Lev-Ari PhD, Rn, I was able to get a detailed understanding of LPBI’s mission and how it relates to the projects I was working on. Aviva was a great resource as she allowed me to explore and be creative in discovering solutions, but was also available if I ever required guidance or leadership. I am proud of the work I was able to accomplish under Aviva’s guidance.

Looking forward to staying in touch,

Ethan

UPDATED on 6/1/2021 for May 24, 2021

From: Mass General Brigham <innovations@partners.org>

Reply-To: <innovations@partners.org>

Date: Monday, May 24, 2021 at 9:31 AM

To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>

Subject: RECAP | World Forum | Day 3 | GCT | CEOs | Harvard | Investors

Notable Tweets

 
 
 

@mandywoodland

Fascinating #WMIF2021 panel on mRNA yesterday -“mRNA is the message, and we just have to decide what message we want to deliver to the cell,” said moderator Lindsey Baden, MD. “The promise of this technology could not be more front and center for all of us.”

@LeapsByBayer

Congratulations to the 2021 Innovation Discovery Grants winners: @lynchielydia, Peter Sage, @GrishchukL, Benjamin Kleinstiver, Petr Baranov, announced at the #WMIF2021. It’s exciting to see the range of breakthrough research in #geneticdisease at @MassGenBrigham

 
 

@DrLilitGaribyan

Gene and cell therapy have scalability problems that we need to solve. This is what is echoed this week at @MGBInnovation World Medical Innovation Forum. #gct #celltherapy #healthcare #innovation

@MPDexpert

“imagine how the future could look if gene therapy cost 1/100th what it does today” @VCAmir @PolarisVC #wmif2021

@AVIVA1950 is Aviva Lev-Ari, PhD, RN

#WMIF2021 @MGBInnovation Roger Kitterman VP, Venture, Mass General Brigham Saturation reached or more investment is coming in CGT Multi OMICS and academia originated innovations are the most attractive areas @pharma_BI @AVIVA1950

@AVIVA1950_PIcs

IMG_7167

UPDATED on 2/15/2021

From: Nigel Russell <nrussell@jofpm.com>

Date: Monday, February 15, 2021 at 10:31 AM

To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>

Subject: RE: About our Venture

Dear Dr. Lev-Ari: 

Thank you for the information and outreach. You have a very interesting platform.

I am interested in chatting.

 

Kind regards,

Nigel

 

Nigel Russell

President

The Journal of Precision Medicine & the Precision Medicine Leaders Summit

Updated on 1/6/2021

From: “Jennings, Charlotte (Reuters)” <Charlotte.Jennings@thomsonreuters.com>

Date: Tuesday, January 5, 2021 at 10:47 AM

To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>

Subject: RE: REUTERS NEXT ­ Press Registration Deadline this Friday (Jan 8)

Hi Aviva,

Thanks for getting back to me. Your press pass for REUTERS NEXT is now confirmed.

It would be great if you could also please share your attendance with your network and across social media. You can find all sharing materials in the media pack here –

Attendees Pack · Reuters Next · Virtual Forum: January 11-14, 2021 (reutersevents.com)

Here’s a tracked sign-up link you can use when sharing – https://bit.ly/35ddYqO

Any other questions please don’t hesitate to reach out!

All the best,
Charlotte

2020

Updated on 8/25/2020

From: Robin Neff Clebnik <robin@internboston.com>

Date: Tuesday, August 25, 2020 at 5:23 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Thank You!

Hi Aviva,

Thank you for your contribution to a very successful summer for our InternBoston students! Your gifts of time, expertise were invaluable to our interns—and to our program as a whole. Your organization’s willingness to participate in InternBoston’s Virtual Summer60™ program allows high school and college students the opportunity to explore learning beyond the traditional limits of their classrooms. The first-hand experiences students receive in the internship will help prepare them for college and beyond.

By participating as a mentor, you have provided Noam with an exceptional opportunity to learn more about a potential career field in a structured and educational environment. Your dedication and commitment to establishing a work plan, overseeing the intern’s progress, and encouraging independence through learning have undoubtedly made a positive and lasting impact.

We look forward to continuing our partnership and will check in with you shortly to discuss more interns for Fall 2020.

 

Best,

Robin

robin neff clebnik

Chief Internship Officer

t: 617.527.0055 

m: 617.875.4614

          

Updated on 8/23/2020

 

The VOICE of Dr. Larry H. Bernstein, MD, FCAP on 8/23/2020:

I discovered a new site in 2012, and thereafter met Aviva Lev-Ari, PhD, RN, https://lnkd.in/eEyn69r

the Director & Founder of the Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston.

That led me to participate in writing for her Open Access Online Scientific Journal for five intense years, 1,400 articles in total. It is now late August 2020, and I have no longer engaged in the writing because of aging limitations.

I can indeed say, the Founder of the LPBI Group in Boston, Aviva, has really been a very fortunate leader, innovator, and collaborator in the LPBI Group’s medical and life sciences publishing endeavors. 

Aviva curated about my contributions to http://pharmaceuticalintelligence.com in the following two monumental sources: 

https://pharmaceuticalintelligence.com/2013/12/10/the-young-surgeon-and-the-retired-pathologist-on-science-medicine-and-healthcare-policy-best-writers-among-the-writers/

  • Editorial & Publication of Articles in e-Books by Leaders in Pharmaceutical Business Intelligence: Contributions of Larry H Bernstein, MD, FCAP
    Curator: Aviva Lev-Ari, PhD, RN

With heartfelt gratitude to our Dear Dr. Larry

https://pharmaceuticalintelligence.com/2014/10/16/editorial-publication-of-articles-in-e-books-by-leaders-in-pharmaceutical-business-intelligence-contributions-of-larry-h-bernstein-md-fcap/

Aviva published my authored contents in 18 volumes https://lnkd.in/ekWGNqA and in the following two memorable articles:

  • Commentaries on each Volume’s Contribution to Medical Education by L.H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN – BioMedical e-Books e-Series: Multiple Volumes in Five e-Series

Authors: L.H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/biomed-e-books/commentaries-on-each-volumes-contribution-to-medical-education-by-l-h-bernstein-md-fcap-and-aviva-lev-ari-phd-rn-biomedical-e-books-e-series-multiple-volumes-in-five-e-series/

  • My Memories Tell a Story to Share

Author: Larry Howard Bernstein, MD, FCAP

https://pharmaceuticalintelligence.com/2020/04/19/my-memories-tell-a-story-to-share-by-larry-howard-bernstein-md-fcap/

Aviva initiated, organized, edited and proposed a narrator for my interview for the following PODCAST:

  • Podcast with Dr. Larry H. Bernstein, MD, FCAP, Interview by Gail S. Thornton, PhDc, Narrator’s Voice: Stephen J. Williams, PhD

https://pharmaceuticalintelligence.com/audio-podcasts/podcast-with-dr-larry-h-bernstein-md-fcap-interview-by-gail-s-thornton-phdc-narrators-voice-stephen-j-williams-phd/

 

Updated on 8/11/2020

The VOICES of Interns of LPBI’s 2020 Summer Internship Program on Data Curation and Data Annotation

The Voice of Internship Team’s Captain, Daniel, Menzin:

LPBI has provided me with an invaluable experience this summer, which has allowed me to grow in a variety of ways. Through close mentorship, we were exposed to principles of data science (i.e. AI, ML, NLP), data curation and annotation, biochemistry, and website development. In addition to daily mentorship by Aviva, we were provided with weekly sessions where we were taught by world-renowned scientists. These sessions provided us with crucial background knowledge, as well as instructions which allowed us to execute and create deliverables while developing our professional skills. Aviva tasked me with several IT projects this summer that were challenging. It was a great opportunity for me to take advantage of the resources around me and learn on my own. Aviva mentored me throughout every step of the process, always providing feedback and showing me how I could improve my deliverables. My summer at LPBI provided me with an incredible opportunity to not only learn more, but also apply what I had learned through the creation of important deliverables. With the breadth of information I’ve been exposed to at LPBI, my professional horizons will surely now be broadened after having been taught things essential to numerous different fields.

The Voice of Noam Steiner Tomer:

Interning at LPBI has been instrumental in both my professional and personal development. Reading and curating many of the cutting edge and insightful articles that LPBI offers contributed significantly to my intellectual growth and broadened greatly my professional horizons. Through this internship I got to not only learn from many renowned researchers but gave me the unique opportunity to work with them directly. I also acquired many technical skills from the on-the-job training such as curation and improved my self-learning skills. It has absolutely been the most valuable experience of my high school career. I have learned so much from your presentations and doing the assignments, and have discovered interests I never knew I had like Hematology!

The Voice of Zach Day:

This summer I interned at Leaders in Pharmaceutical Intelligence (LPBI) in social media and market research.    In this capacity, I participated in weekly classes taught by medical experts about the latest developments in Cancer and Genetics Research. I met regularly with the company’s Director and Founder, Dr Aviva Lev-Ari and attended team meetings.  I wrote two articles about the company and its founder and uploaded them to Wikipedia. I also generated content for the company’s website including eleven WordClouds using WordItOut.com. Overall this was a great experience because I learned a lot, I contributed a lot and greatly appreciate the mentoring and support that I received working with Dr. Lev-Ari. 

 

Updated on 6/3/2020

Professor Marcus Feldman Receives Stanford Biosciences Mentoring and Service Award

Reporter: Gail S. Thornton, M.A.

Marcus Feldman, Ph.D., the Burnet C. and Mildred Finley Wohlford Professor in the School of Humanities and Sciences and Professor of Biology at Stanford University, has been selected to receive the 2019-20 Stanford
Biosciences “Excellence in Mentoring and Service Award”. This honor is given to faculty who make distinguished contributions towards enhancing the quality of training and the mentoring experiences for Stanford Biosciences graduate students.

In recognizing Professor Feldman for this honor, William S. Talbot, Ph.D., Senior Associate Dean of Graduate Education and Postdoctoral Affairs,
Professor of Developmental Biology,  at Stanford University, thanked him for his “extraordinary contributions this year.” Professor Feldman will be formally acknowledged for receiving this award and an honorarium at the School of Medicine Graduation Celebration on Saturday, June 13, 2020.

###

Updated on 5/7/2020

From: Alan Kaul <alan@mom-inc.us>

Date: Thursday, May 7, 2020 at 9:03 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Cc: Vinit Nair <vinit@pracnet.org>

Subject: Pharmaceutical Intelligence

HI Aviva,

You asked for my help in promoting your portal and I’ve done something that I haven’t done for any other organization, I put a direct link to your portal on Medical Outcomes Management’s home page.

[ see www.mom-inc.us ]

This is the only link to another business on our company’s website. We may move it’s location, but it will remain highly visible and directly linked.

I hope that this link will prove helpul to both of us

Stay safe,

Alan

Updated on 4/19/2020

ADDED to this entry by Dr. Larry H. Bernstein, MD, FCAP on 8/17/2020

“I am thankful to Aviva for the opportunity to follow my interests in retirement. I have been away from the laboratory longer than I would like, but could follow the literature.”

Sincerely,

Larry Bernstein, MD

“Prior to moving I was contacted by Aviva Lev-Ari, PhD, RN who was building an online medical forum known as Leaders in Pharmaceutical Business Intelligence (LPBI) Group, and I became the Chief Scientific Officer (CSO). Over the decade I wrote many articles (1,390) in the Open Access online Scientific Journal http://pharmaceuticalintelligence.com that were included in 18 organized e-Books in Medicine. Dr. Lev-Ari’s accomplishment is quite impressive. The e-Books are all available on Amazon.com”

https://lnkd.in/ekWGNqA

In:

My Memories Tell a Story to Share, 4/19/2020

Author: Larry Howard Bernstein, MD, FCAP

Contact: 413-727-8523

https://pharmaceuticalintelligence.com/2020/04/19/my-memories-tell-a-story-to-share-by-larry-howard-bernstein-md-fcap/

Updated on 2/9/2020

Obtained by Gail S. Thornton on 2/7/2020

Leaders in Pharmaceutical Business Intelligence (LPBI) is among the best resources of original scientific and medical content for the scientific and business community that is carefully chosen and thoughtfully organized and presented. The site offers a valuable contribution to biomedical science by advancing knowledge and research efforts through its commitment to synthesize, analyze and interpret complex, medical and scientific disease information on any subject, as well as biomedical research innovation widely available to the scientific and non-research community. There is a vast amount of quality, curated information on the site organized in three inter-related domains of an e-Journal, series of 16 e-Books and e-scientific and medical conference proceedings that is produced by an esteemed group of collaborators. 

In today’s biomedical science environment, there is a wide range of available information in journals of all subject areas and web sites, including clinical data, public health data and even genomics information, that needs to be accessed. The value and uniqueness that LPBI brings to the scientific community is its consistent and enormous success in producing non-technical reviews of technical literature in the medical field, so that the scientific findings are much more accessible in real-time. In that way, the scientific community can further delve into specific areas of interest more readily. The site is a quality, professional resource for the biomedical field, which is unique to any field. 

I’ve had the pleasure to serve as content consultant to LPBI over the years and, specifically, as an author of a newly launched e-book entitled, Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology. 

 

 —Marcus W. Feldman, Ph.D., Burnett C. and Mildred Finley Wohlford Professor of Computational Biology in the School of Humanities and Sciences, and co-director of the Center for Computational, Evolutionary and Human Genetics, Stanford University. He is the author of more than 600 scientific papers and 10 books on evolution, ecology, mathematical biology and demography. He is a member of the U.S. National Academy of Sciences, the American Academy of Arts and Sciences and the American Philosophical Society. He was the 2011 Dan David laureate in Evolution and was awarded the 2016 Kimura Prize in Evolution by the Japanese Suzuki Foundation.

Updated on 1/31/2020

Notifications from ResearchGate

Vesa Cosmin Mihai recommended your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Apr 6, 2019

Md Azree Othuman Mydin and 2 others recommended your publications: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Mar 25, 2019

Bahra Karima followed your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Mar 25, 2019

Javad Parmah followed your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Nov 27, 2018

Sebastian Nemeth recommended your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Jul 29, 2018

Daniela Gitea and Gabriela Cioca recommended your publications: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Jul 27, 2018

Vyacheslav Lyashenko followed your publication: Regenerative and Translational Medicine: The Therapeutic Promise for Cardiovascular Diseases

Oct 10, 2016

Santiago Prieto Menchero followed your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Jan 9, 2016

Musaab Salih followed your publication: Metabolic Genomics & Pharmaceutics: Volume I

Dec 12, 2015

UPDATED on 1/10/2020

The following three testimonials resulted from three interviews conducted by Prof. Sheila M. Puffer (UC, Berkeley, PhD’84) in December 2019 for Prof. Puffer’s nomination of Dr. Lev-Ari for 2020 Campanile Excellence in Achievement Award. This award recognizes an alumnus/a whose remarkable professional achievements reflect the excellence of a UC Berkeley education.

Past Recipients

https://awards.berkeley.edu/achievement-awards

The recipients will be formally presented with their awards at Berkeley Charter Gala on May 14, 2020.

Dr. Marcus Feldman

Professor of Biology, Stanford University

Dr. Feldman, who has been deeply involved in Dr. Lev-Ari’s e-publishing venture, expressed his admiration for her career and contributions in multiple and diverse scientific and medical fields. ‘She single-handedly formed the venture to curate the biological medical literature and has produced 16 online books with her collaborators. She has had enormous success in producing nontechnical reviews of technical literature in the medical field, so that the scientific findings are much more accessible to the professional side as opposed to the research side. She has worked extremely hard on developing that professional resource for the biomedical field, which is unique to any field. Her accomplishments represent the best of what Berkeley can produce.”

 

Dr. Justin Pearlman

Professor of Medicine, Practicing Cardiology, UCLA, and Practicing Cardiologist

Dr. Pearlman was one of the early members of the electronic publishing team and served as the editor of three of the volumes. He noted that it was Dr. Lev-Ari’s idea to develop an online pharmacology journal of a completely new design called curation. She also came up with the idea of multimodality, to include videos and other media. He explained that expert reviewers provide reviews and critique the strength and weaknesses of the research and provide and additional information that open eyes to new opportunities. He himself was one of those experts who willingly became deeply involved in the project, and the caliber of his credentials attests to Dr. Lev-Ari’s persuasiveness in getting such experts to devote their time and talents to the project. Dr. Pearlman already had an established reputation as the Vice Chair of Medicine at UCLA and Chief of Cardiology, was an editor and writer, and had over 4,000 citations of his publications.  He explained: “By the sheer force of her personality, Aviva put together a team of experts, and she encourages a new generation to utilize this material. This is important because the new generation is not aware that articles can have their own agenda, such as needing to please granting organizations that fund the research. Aviva has a strong entrepreneurial spirit and investigates many different avenues to make things better – business, medical, biological, and scientific.”

 

Dr. Stephen Williams

Assistant Professor of Pharmacology at the Sbarro Health Research Organization at Temple University

Dr. Williams  has known Dr. Lev-Ari since 2012 when he noticed her call for collaboration on her electronic publishing project on several LinkedIn groups. He was intrigued and contacted her, and became one of the senior editors of the publishing project. “I have never met anyone so driven as Dr. Lev-Ari. She had a great vision and knows how to put that vision into practice. She has an impressive amount and quality of people she has direct contact with.

It was a no brainer. I said, ‘I have to work with her.’ I am very, very happy with that decision. The project developed into a site that deals with all areas of medicine and related scientific disciplines. It is an open access, open science forum with the goal of breaking down silos. In addition, she developed a methodology for real-time medical conference coverage.The whole world is dying for knowledge. People are hungry for this collaboration, including in both developed and developing countries.”

He explained how she created the project: “It is amazing how she set up the venture and has grown it over such a short time and involved the top people in many fields. To me it is absolutely amazing for such a niche website. She set a goal of bringing scientists together in an online community to provide comments and insights. To the degree that happened is fantastic. She personally knows and has gained the involvement of some of the most sought-after researchers in cancer and other fields as keynote conference speakers and the like. I believe some will be future Nobel laureates. She establishes great relationships and has a great rapport with everyone.”

Regarding Dr. Lev-Ari’s accomplishments and personal character, he noted: “She has more energy than some 20 and 30-somethings. She does not stop until she sees her vision realized. She has received many accolades for her accomplishments, including her work at Mitre Corporation. Since 8/2018, Dr. Lev-Ari was contacted by the President elect of the Massachusetts Academy of Sciences (MAS), Prof. Katya Ravid of Boston University, School of Medicine, to join MAS in the role of Liaison to the Biotechnology and eScientific Publishing industries for the term of August 2018-July 2021. In the MAS, Dr. Lev-Ari serve as Board member, Fellow, and Advisor to the Governing Board. http://www.maacadsci.org

She has in-depth knowledge of many medical fields. She wrote an article that is available on the publication website about reinventing yourself. And that is something that she has done over and over again. Her career includes complex IT, nursing, and scientific publishing in biomedicine and biomedical research. In scientific careers, you’re in a constant state of reinventing yourself. For others, that may seem scary, but for her it is exciting. I tell my colleagues and students to take it the way Dr. Lev-Ari takes it – as an absolutely exciting journey. In every part of her life she looks at it as an exciting journey, even the obstacles she had to overcome.”

11/27/2019

Dear Aviva,

Thank You note from sandraleebatista@yahoo.com

Happy Thanksgiving to you and your family! I am so very grateful for your friendship and mentorship over so many years.

We will be here in Los Angeles and it will be a quiet holiday full of reflections on gratitude.

Best wishes,

Sandra

5/29/2019

From: “Klein, Susan Beth” <sbklein@indiana.edu>

Date: Wednesday, May 29, 2019 at 3:13 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Re: Permission to reprint image

Thank you very much for permission to reprint and also your useful suggestions. I shall certainly consider all of this content!

Susan

Susan B. Klein, PhD

Department of Physics

Swain West 331

Indiana University, Bloomington

812.855.9687

From: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Sent: Wednesday, May 29, 2019 12:46 PM

To: Klein, Susan Beth

Cc: Stephen Williams, PhD; Marcus W Feldman; Dr. Larry Bernstein; Aviva Lev-Ari

Subject: Re: Permission to reprint image

 

Dear Prof. Klein,

Your e-mail, below called for my re-read of Dr. Larry H. Bernstein’s article where the figure you wish to re-publish was found.

It was indeed, a special pleasure to read again his article and to realize one more time, how important the curation work is for dissemination of scientific findings. Dr. Larry is a Biochemist, retired Pathologist and one of the best writers in Medical Sciences among the livings.

See

The Young Surgeon and The Retired Pathologist: On Science, Medicine and HealthCare Policy – The Best Writers Among the WRITERS

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2013/12/10/the-young-surgeon-and-the-retired-pathologist-on-science-medicine-and-healthcare-policy-best-writers-among-the-writers/

I recommend that in your forthcoming book on Radiation Biology you will consider the following suggestions: 

A. Include Agents that Damage DNA [as in Dr. Larry’s article, not limited to it]

B. Refer the reader to Dr. Larry’s article which is a unique resource on the topic of DNA and DNA Replication 

C. Please review the Table of Contents of our Genomics, Volume One, it may assist you with A, above

https://pharmaceuticalintelligence.com/biomed-e-books/genomics-orientations-for-personalized-medicine/volume-one-genomics-orientations-for-personalized-medicine/

Regarding re-publishing the figure:

I am suggesting to add the following comment: 

Image Source

Image is the copyright of Buzzle.com, cited in A Primer on DNA and DNA Replication by Reporter and Curator: Larry H. Bernstein, MD, FCAP 

https://pharmaceuticalintelligence.com/2014/07/29/a_primer_on_dna_and_dna_replication/

I wish you best of luck with researching the scientific literature for this very important and timely forthcoming text book on Radiation Biology.

Very proud to share with you that we have on Leaders in Pharmaceutical Intelligence portal:  http://pharmaceuticalintelligence.com    

 1,627,949 e-Readers, 678 Categories of Research and +10K Tags and 5,594 scientific article CURATIONS & Scientific reporting.

 

Please keep in touch and I encourage you to continue to search our Journal archive. 

Best regards,

PS

This e-mail is your e-written permission to re-publish figure as commented, above.

Leaders in Pharmaceutical Intelligence portal:  http://pharmaceuticalintelligence.com    

LPBI Group was created in 2012 by me, Aviva Lev-Ari, Ph.D., R.N. The Group has three interrelated healthcare content products: an open-access online scientific journal (Journal archive is an article corpus); a series of 16 BioMed e-books (BioMed e-Series is an e-Book corpus); and real-time coverage of BioMed scientific and medical conferences (An archive of conference e-Proceedings corpus). Through these transformative products, the Group effectively meets and exceeds the information needs of researchers, scientists and industry pharmaceutical and biotechnology executives by offering real-time and currently available medical and scientific information on any biomedical subject (700 categories). LPBI also makes information on cutting-edge biomedical research innovation widely available to the scientific and non-research community using a process of connections to multiple social media platforms, chiefly LinkedIn, Twitter and Facebook. The method of curation includes synthesis, analysis and interpretation of complex medical and scientific areas.

Aviva Lev-Ari, PhD, RN

Director & Founder

https://lnkd.in/eEyn69r

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

Editor-in-Chief

http://pharmaceuticalintelligence.com 

e-Mail: avivalev-ari@alum.berkeley.edu

(M) 617-775-0451

https://cal.berkeley.edu/AvivaLev-Ari,PhD,RN

SkypeID: HarpPlayer83          LinkedIn Profile        Twitter Profile

From: “Klein, Susan Beth” <sbklein@indiana.edu>

Date: Wednesday, May 29, 2019 at 9:12 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Re: Permission to reprint image

Thank you so much Aviva.

The url is https://pharmaceuticalintelligence.com/2014/07/29/a_primer_on_dna_and_dna_replication/.

The name of the article is “A Primer on DNA and DNA Replication”; Reporter and Curator: Larry H. Bernstein, MD, FCAP.

Appreciatively,

Susan

Susan B. Klein, PhD

Department of Physics

Swain West 331

Indiana University, Bloomington

812.855.9687

From: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Sent: Tuesday, May 28, 2019 12:17 PM

To: Klein, Susan Beth

Cc: Stephen Williams, PhD; Marcus W Feldman

Subject: Re: Permission to reprint image

 

Dear Prof. Klein,

It is always most endearing to correspond with another fellow Alumna of Berkeley.

Congratulations on your forthcoming book, Fundamentals of Radiation Biology. The publisher of the text is World Scientific, anticipated publication in 2023.

Thank you for reaching out to me for permission to reprint a figure.

Please e-mail me the name of the article you found this figure in on our Journal http://pharmaceuticalintelligence.com 

Or in one our our 16 e-Books in Life Sciences and Medicine on Amazon.com

https://lnkd.in/ekWGNqA

I will then research and grant you re-printing permission in e-writing.

Since your forthcoming text book is on Radiation Biology, in this context, I wish to bring to your attention two points:

1.You may find of interest the following e-Books of ours

Series B: Frontiers in Genomics Research

 

  • VOLUME 1: Genomics Orientations for Personalized Medicine. On Amazon.com since 11/23/2015

http://www.amazon.com/dp/B018DHBUO6

  • VOLUME 2: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology

https://pharmaceuticalintelligence.com/biomed-e-books/genomics-orientations-for-personalized-medicine/volume-two-genomics-methodologies-ngs-bioinformatics-simulations-and-the-genome-ontology/

Work-in-Progress

 

Series C: e-Books on Cancer & Oncology

 

  • Volume 1: Cancer Biology & Genomics for Disease Diagnosis. On Amazon.com since 8/11/2015

http://www.amazon.com/dp/B013RVYR2K

  • Volume 2: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery (Series C Book 2). On Amazon.com since 5/18/2017

http://www.amazon.com/dp/B071VQ6YYK

2. My articles on medical OUTCOMES of Radiation Biology  on Cardiotoxicity

Cardio-oncology and Onco-Cardiology Programs: Treatments for Cancer Patients with a History of Cardiovascular Disease

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2014/01/08/cardio-oncology-and-onco-cardiology-programs-treatments-for-cancer-patients-with-a-history-of-cardiovascular-disease/

3rd Annual Canadian Cardiac Oncology Network Conference, June 20 – 21, 2013, Ottawa Convention Centre

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2014/01/08/3rd-annual-canadian-cardiac-oncology-network-conference-june-20-21-2013-ottawa-convention-centre/

2019

http://cardiaconcology.ca/ccon-conference-2019-modern-changing-practices-in-cardio-oncology/agenda/

My Journal on Cardiotoxicity on Scoop.it

https://www.scoop.it/topic/cardiotoxicity

Looking forward to getting name of article when the figure had appeared in our publications.

Good luck,

Aviva Lev-Ari, PhD, RN

Director & Founder

https://lnkd.in/eEyn69r

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

Editor-in-Chief

http://pharmaceuticalintelligence.com 

e-Mail: avivalev-ari@alum.berkeley.edu

(M) 617-775-0451

https://cal.berkeley.edu/AvivaLev-Ari,PhD,RN

SkypeID: HarpPlayer83          LinkedIn Profile        Twitter Profile

From: “Klein, Susan Beth” <sbklein@indiana.edu>

Date: Tuesday, May 28, 2019 at 11:11 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Permission to reprint image

Hello Aviva Lev-Ari,

I am currently writing a book: Fundamentals of Radiation Biology. I would like to know if I might have your permission to reprint this figure in a section on DNA replication. The publisher of the text is World Scientific and we anticipate publication in 2023. I would very much appreciate your permission; this is a lovely illustration!

Regards,

Susan

Susan B. Klein, PhD

Department of Physics

Swain West 331

Indiana University, Bloomington

812.855.9687

(another Berkeley alum)

April 2019

2019 Ranking of Conference Influencers: On 4/9/2019, The Partners’ 2019 World Medical Innovation Forum #WMIF19

via @symplur‘s #Healthcare Hashtags http://bit.ly/WMIF19 

  • By “Mentions” – Ranked #4: @pharma_BI and
  • By “Tweets” – Ranked #2: @AVIVA1950

via NodeXL  http://bit.ly/2KB6cPN 

  • By “Betweenness Centrality” – Ranked #3: @AVIVA1950 and @pharma_BI

https://pharmaceuticalintelligence.com/2019/04/13/the-wmif19-influencers-via-symplurs-healthcare-hashtags-http-bit-ly-wmif19-by-mentions-and-by-tweets-ranked-4-pharma_bi-and-2-aviva1950-respectively-ranked-3-via-node/

4/21/2019

From: Amnon Danzig <amnon.danzig@gmail.com>

Date: Sunday, April 21, 2019 at 4:17 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: A Letter from Amnon Danzig

Dear Aviva

Now, I read the two docs in depth.

Sure, I have a few questions for my understanding. We can devote Skype for that to make sure I understand…

It is my honor to work with you and the team.

I found Gail and Rick extremely good players, partners and colleagues at the same time. And I would like to thank you for the opportunity to work with them.

I would like to thank you for your very fine and warm words about my contribution. GREAT!

I must confess that in the last three months I couldn’t do any real intellectual work. I need to finalize my speech at the conference and couldn’t touch it.

Why?

My thinking was always going to the ways to present LPBI Group the best it can.

I found myself very busy intellectually and emotionally how we can improve the way the IB will see us.

Example: the last two weeks I invested happily dozens and dozens for this assignment. On Thursday afternoon my son arrives and we spent a few hours together. Then, on 9 PM I set down to make the corrections you asked me. Took me another 3 hours, sent it and waited another two hours to see whether I need some more. Because I knew that on Friday you MUST send. It was kind of relief after two hours. When you sent us the update I saw it and felt “everything is okay” and I can put my mobile away for 24 hours: all the family, friends were around I thought it better to be disconnected.

I am very glad you found my contribution significant. Also, the way you express it is outstanding. Thank you!

Now, I will spend a few days about the conference and also looking for ways to find significant people to meet and discuss my new book. The idea to find more audience and hopefully potential clients.

If you happen to have ideas for me, great.

This is the reason I extend my time in NYC. 

BR 

Amnon

@@@@@

4/19/2019

LPBI Group: The Business Opportunity

Voice of Prof. Marcus W. Feldman

The intellectual property of LPBI is of three types: a corpus of curated articles in an open access online scientific Journal, a corpus of e-books in Medicine and Life Sciences, and a corpus of Biotech e-proceedings. This IP is highly relevant to five industrial and services sectors across twelve economic segments. LPBI has pioneered production of scientific content with unique curation methodology by a highly knowledgeable group of experts. The content and the potential consumers & acquirers and valuers of this content are represented graphically below. The three types of corpus, together with the very large audience that follows the content on various media, represent intangible assets of LPBI Group and can be represented as such to potential investors. Together with the tangible assets described in Document #2, the combination represents a unique opportunity for acquisition.

@@@@@

4/19/2019

LPBI Group: The Business Plan

Voice of Aviva Lev-Ari, Founder

The Business Plan representing work-in-progress generated by our business professionals, Amnon Danzig (AD), Gail Thornton (GST) and Rick Mandahl (RM).

  • The content is extracted from Document #2, the concept of the “Client End-User Perspective” and the “Acquirer Perspective” are contributions by Amnon Danzig (AD). 
  • The positioning of 12 economic segments in a 3D structure for each of these two perspectives represent contributions of AD, GST and RM, under the leadership of AD. They took the microeconomics Theory of the Firm to most interesting interpretation given for several Demand aspects related to the performance of Knowledge Workers in the digital workplace as potential users of LPBI Group’s products.
  • They followed the 3D illustration developed by Aviva Lev-Ari, PhD, RN (ALA) using three different axes for representation of same 12 economic segments. The view taken by ALA is of Industrial Organization Economics theoretical framework of comparisons among industrial and services sectors and within each sector competition among player drawing strategies for augmenting the competitive advantage by horizontal and vertical mergers. Opportunities for economies or scale, externalities, diversification and product differentiation. In ALA’s perspective, LPBI Group’s IP represents Supply side, a series of technologies poised to augment the core competencies of players in 12 economic segments as in Appendix C, below [which is identical to Table developed by ALA for Sections #4 & #5 in Document #2.
  • Further development of this Business Plan document will follow in the near future.

This Business Plan is based on and is complementary to Document #2 that provides a distinctive view on Intangible Assets, Sections #1 to #12 vs Tangible Assets and royalty payments which are present in Section #13 & #14 of Document #2.

This Business Plan consists of a conceptual framework developed by the business side of our Final Improvement Team (FIT members N=12). This conceptual framework is indeed unique in depth and breadth placing the unmet needs of potential acquirers by name, each in an economic segment, each economic segment within an Industrial and Services Sector. It demonstrates deep understanding of Demand side economics of the End-User in each of the 12 economic segments. This strategic thought process represents well AD’s business acumen for placing in the center the ultimate demand of end-users and the unmet needs of potential Acquirers that will be fulfilled on their behalf by LPBI Group’s IP – the features and functionality of the technologies we have developed since 2012.

 

@@@@@

4/14/2019

The #WMIF19 Influencers via ‘s  Hashtags http://bit.ly/WMIF19 – By Mentions and By Tweets Ranked #4: @pharma_BI and #2: @AVIVA1950, respectively. Ranked #3 via NodeXL Betweenness Centrality http://bit.ly/2KB6cPN

https://pharmaceuticalintelligence.com/2019/04/13/the-wmif19-influencers-via-symplurs-healthcare-hashtags-http-bit-ly-wmif19-by-mentions-and-by-tweets-ranked-4-pharma_bi-and-2-aviva1950-respectively-ranked-3-via-node/

4/13/2019

Twitter Data for LPBI Group’s Founder’s Twitter handle @AVIVA1950 was updated 

On 2/24/2019 — Tweets 8,060 Following 1,412 Followers 359 Likes 2,752

On 4/13/2019 — Tweets 9,018 Following 1,461 Followers 390 Likes 3,654

 

4/11/2019

Top 3 Ranked by Betweenness Centrality in Top 10 Influencers #WMIF19 @phsinnovation @evankirstel @aviva1950 –Tweeter Analytics by NodeXL http://bit.ly/2KB6cPNfor #WMIF19 by @PHSInnovation  at World Medical Innovation Forum ARTIFICIAL INTELLIGENCE, Boston, MA USA, Monday, April 8-10, 2019

https://pharmaceuticalintelligence.com/2019/04/11/top-3-ranked-by-betweenness-centrality-in-top-10-influencers-wmif19-phsinnovation-evankirstel-aviva1950-tweeter-analytics-by-nodexl-http-bit-ly-2kb6cpn-for-wmif19-by-phs/

@@@@

‘s  Hashtags  – Twitter Analytics published for http://bit.ly/WMIF19 

  • [Top 10 by Mentions – @pharma_BI = 4 with 181 mentions]  
  • [Top 10 by Tweets @AVIVA1950 = 2 with 229 Tweets (N = 152 Direct messages)]
 Pinned Tweet

⚡️As World   Forum comes to a close, here are TOP   via ‘s  Hashtags 🙏 to organizers for a stellar event & to all on  for a robust conversation!   👏 

@@@@

Top influencer 3rd place @AVIVA1950

This is a great analysis and I love that you found these two programs, NodeXL and Betweeness Centrality. These offer the best Twitter analytics and node analysis I have ever seen. Thanks for sharing and a great conference and great conference coverage in real time. Show the power of REALTIME CONFERENCE COVERAGE methodology @pharma_BI and @AVIVA1950 as well as power of LBPI Group.

https://nodexlgraphgallery.org/Pages/InteractiveGraph.aspx?graphID=193125

 

@@@@

From: “Gregory Piatetsky, KDnuggets” <editor1@kdnuggets.com>

Date: Wednesday, April 10, 2019 at 10:16 PM

To: Aviva Lev-Ari <aviva.lev-ari@comcast.net>, Gil Press <gpress900@gmail.com>

Subject: Re: Fwd: NodeXL Graph Gallery: Interactive Graph

Well done!  3rd place for #WMIF19 is good

See

Comparative Analysis of the Level of Engagement for Four Twitter Accounts: @KDNuggets (Big Data) @GilPress @Forbes @pharma_BI @AVIVA1950

 

@@@@

From: Leny <gochevav@mit.edu>

Date: Wednesday, November 28, 2018 at 11:30 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Re: MIT Center for Precision Cancer Medicine Inaugural Symposium – Question from Aviva Lev-Ari, PhD, RN

Dear Dr. Lev-Ari,

I actually have been meaning to reach out to you with an invitation to our symposium. We were both at the Personalized Medicine Coalition’s conference two week ago at Harvard Medical School, but I didn’t get a chance to speak to you in person.

To get a complimentary press pass, please visit cpcm.eventbrite.com -> select Tickets ->  select “Enter Promotional Code”-> enter CPCM2018 and that will allow you to select “Press” tickets.

Please do not hesitate to reach out if you have any additional questions.

Best,

Leny

Vasilena Gocheva, PhD | Assistant Director  | MIT Center for Precision Cancer Medicine  | 77 Massachusetts Avenue, 76-353  | Cambridge, MA 02139  | cpcm.mit.edu

From: Shankar Khatkale <shankar.k@gminsights.com>

Date: Tuesday, November 27, 2018 at 6:48 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Article Submission Request

Dear Editor,

An industry news titled ‘Precision Medicine Market Size worth $96.6bn by 2024’ by Global Market Insights is relevant to your esteemed website https://pharmaceuticalintelligence.com. This email is a suggestion to publish this news (content attached in word format or can be picked from link mentioned below) on your website with an objective to share the information with your audiences.

News Link: https://www.gminsights.com/pressrelease/precision-medicine-market

 Looking forward to hear from you.

 On behalf of and as instructed by Global Market Insights, Inc.

 Best Regards,

Shankar Khatkale |SEO Executive

 

From: Daphne Kwee <daphnekwee@farrerpark.com> on behalf of Daphne Kwee <daphnekwee@farrerpark.com>

Date: Monday, October 29, 2018 at 9:33 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Post retirement doctors establishing new career heights – Story Consideration

Dear Aviva,

Would you be interested in interviewing personalities in the medical Fraternity?

Particularly, Dr Leslie Lam. One of the renowned personality who was sued by the SMC and won after a 7 year battle. He is a medical veteran in his 70s but shows no signs of slowing down. He has re-established himself in Farrer Park Hospital and is blazing a trail with his new clinic. Having recently been conferred the Distinguished Graduate Award by the University College Dublin School of Medicine for his contribution toward medical education, research and support toward the community. Previous recipients of this award includes Professor Connor Ward who pioneered work on Cardiac abnormalities such as the co-described Ward-Romanov Syndrome.   

Dr Lam’s story strikes a chord with the government’s stand of lifelong learning and contribution. In addition to his clinical work, Dr Lam is an advisor to the Seychelles ministry of health, contributes regularly to teaching doctors and donating medical equipment to Myanmar. He also established a leading wine collection in order to fund his philanthropic works with charities in Singapore and Ireland, where he received his medical education. 

I have attached the award letter to this email for your information. 

Should you be interested in such a story angle, I do have other personalities here at Farrer Park Hospital for your consideration. Professor Tan Yew Oo, Singapore first medical oncologist, as well as Professor Soo Khee Chee, the founding director of Singapore’s National Cancer Centre. All these renowned medical personalities, who in their post retirement years, are still actively contributing toward Singapore’s future.

Do let me know if you would like to find out more to explore story possibilities. I would be happy to catch up over lunch or tea for a discussion.

 

Best regards,

Daphne

Executive

Corporate Communications

DID (65) 6705 2769  

www.farrerpark.com/hospital

From: “Prof. Nathan F. SAYRE (Chairman, Geography)” <nsayre@berkeley.edu>

Date: Friday, June 1, 2018 at 3:26 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Cc: Christian Gordon <cmgordon@berkeley.edu>, Robert Rhew <rrhew@berkeley.edu>

Subject: Re: I will be on BERKELEY Campus for the Homecoming Week, few days before and After, October 11, 2018 to October 16, 2018 — Hope to meet again

Dear Dr. Lev-Ari,

Thank you for your kind note, and wonderful to hear that you will be visiting campus in October. I’m happy to hear that you will see Professor Birgeneau and other Cal alumni in New England. I know the university will be ramping up its efforts in Boston and surrounding areas, to create more opportunities for alumni to connect with each other, and with Berkeley.

I would like to introduce you to Christian Gordon, our partner in development and alumni relations for geography and the division of social sciences. Christian can assist with setting up your visit and relevant meetings while you are on campus. He’s also happy to follow up with additional information, as well as additional opportunities in Boston to connect with Berkeley between now and October.

Very much looking forward to seeing you at Homecoming. Thanks again for sending your recollections of Allan and Berkeley!

Best,

Nathan

PS I’m cc’ing Professor Rob Rhew, who will succeed me as department chair on July 1st.

From: “Prof. Michael Watts” <mwatts@berkeley.edu>

Date: Sunday, May 13, 2018 at 1:29 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Re: Sharing with you — This May 2018, Official Newsletter has a Global distribution of half a million Inboxes: See article on Aviva Lev-Ari in ALUMNI SPOTLIGHT of American Friends of Hebrew University

Dear Aviva: a very long time!  Nice to hear from you and your later extraordinary career!  And it seems like you are now on Phase IV.  Very exciting.

I am retiring in June but will of course keep writing and conducting research.

You may have heard that Allan’s wife Hjordis passed away relatively recently.   It was nice to see their children again at the memorial.

Warmly, Michael

On Fri, May 11, 2018 at 12:01 PM, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu> wrote:

Sharing with you — This May 2018, Official Newsletter has a Global distribution of half a million Inboxes:  

See article on Aviva Lev-Ari in ALUMNI SPOTLIGHT of American Friends of Hebrew University – Please scroll down

If interested to read more, click on:

Aviva’s books on AMAZON.COM

https://www.amazon.com/s/ref=nb_sb_noss?url=search-alias%3Ddigital-text&field-keywords=Aviva+Lev-Ari&rh=n%3A133140011%2Ck%3AAviva+Lev-Ari

On Fri, May 25, 2018 at 12:44 PM, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu> wrote:

Dear Professors, Watts, Walker, Sayre, Laguerr and Segev, 

I hope you are well and will enjoy the months of Summer coming up.

We will have dinner with Berkeley’s ex-Chancellor, Prof. Robert Birgeneau in Boston on 6/16/2018, meeting with Alumni in New England. I am much looking forward to his talk and meeting alumni.

I will be on BERKELEY Campus on October 11, 2018 to October 16, 2018, planning to attend the Homecoming Week, October 12-14, 2018.

It will be my great pleasure to meet again, I hope you will be on Campus at least one day of the week in October 2018 when I will be on Campus and could meet you. Allan Pred will be missing on this visit, so sad.

I recently wrote my Recollections of my five years at Berkeley in two Parts, which you may find of interest to read, in particular, Part 2, which I authored as a curation, after my e-mail exchange with Prof. Michael Watts in May, 2018.

  • Recollections: Part 1 – My days at Berkeley, 9/1978 – 12/1983 – About my doctoral advisor, Allan Pred, other Professors and other Peers

https://pharmaceuticalintelligence.com/2018/03/15/recollections-my-days-at-berkeley-9-1978-12-1983-about-my-doctoral-advisor-allan-pred-other-professors-and-other-peer/

  • Recollections: Part 2 – “While Rolling” is preceded by “While Enrolling” Autobiographical Alumna Recollections of Berkeley – Aviva Lev-Ari, PhD’83

https://pharmaceuticalintelligence.com/2018/05/24/recollections-part-2-while-rolling-is-preceded-by-while-enrolling-autobiographical-alumna-recollections-of-berkeley-aviva-lev-ari-phd83/

Please Read these two:

I attended the 1998 – 100 years Geography Department celebration.

Please review the following, it can be included in the future Itinerant Geographer.

Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018

https://pharmaceuticalintelligence.com/2018/03/06/reflections-on-a-four-phase-career-aviva-lev-ari-phd-rn-march-2018/

Thank you – Good Luck to you

From: “Prof. Nathan F. SAYRE (Chairman, Geography)” <nsayre@berkeley.edu>

Date: Thursday, March 8, 2018 at 6:07 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Re: I MADE A CONTRIBUTION IN MEMORY OF PROF. ALLAN PRED few weeks ago

Dear Aviva,

Thank you for writing. Yes, we did receive your donation in Allan’s honor–thank you!–and we put a letter of thanks and acknowledgement in the mail last week. Please look out for it.

You are not alone in missing Allan–many many people do. Sadly, his widow, Hjordis, also passed away not long ago.

Michael Watts is not yet technically retired, but he thought he would two years ago, and since we made a big public announcement then we’ve kept the technical truth quiet. He will in fact retire this summer. As you assumed, Walker, Reed, and Nat have all retired, as have Beatriz Manz, Gillian Hart, Paul Groth, Michael Johns, and Roger Byrne. We are anxiously awaiting authorization to recruit new human geography faculty.

It’s kind of hard to think of any of us as adequate to fill Allan’s shoes, but we all try to preserve his flexibility of mind and lucidity of thought. Our graduate students perhaps carry on his intellectual legacy best. If you haven’t heard of Trevor Paglen, he was one of Allan’s last PhDs:

http://www.paglen.com/

Thank you also for the links to your eulogies for Allan and David, and to your reflections. I am touched by your words and your enduring support for the department.

Best,

Nathan

On Monday, July 24, 2017 at 9:27 PM

From: marzan Khan <marzan.khan@mail.mcgill.ca>

Date: Monday, July 24, 2017 at 9:27 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Re: SERIES E VOLUME 2 –>>> FORMAT CONVERSION — I MUST find out what has been done to FINISH up this format conversion – Series E Volume 2

Hello Aviva,

Thank you very much for your kindness and support. It was great working for you. I apologize for not being able to finish my task to completion. You have been an excellent mentor and I will be grateful to you always.

Best of luck on the e-book and all your endeavors.

Sincerely,

Marzan Khan

On June 18, 2017, 9;39AM

Dear Aviva Lev-Ari,

Thank you very much for your email.

First of all I would like to congratulate you to your outstanding work, if I may. You are one of the very few people with really meaningful and scientific articles/updates on LinkedIn.

I recently liked one of your articles/updates “Molecular Pathogenesis of Progressive Lung Diseases” on LinkedIn, because it was an interesting article. We have a project here in China “Natural Breathing”, where we look at solutions for COPD. With all the air pollution in China, this is already a majour burden, and it is one that will become a larger burden in the coming years. As for your email, I am not quite sure what to make out of it honestly. Is it an offer to write or publish an article? In regards to China: Please do not hesitate to contact me, if you have questions or if I may help with contacts in the healthcare industry. We have a quite good network here.

Sincerely from Beijing

Dennis Wilkens, Managing Director, Medical Devices, Health 4.0, Toronto, Hamburg, Beijing, Distribution Network, Investments & Ventures, Jadevita International Inc., University of Hamburg

On 6/15/17, 5:43 AM, “Anamika Sarkar” <sarkaranamika@yahoo.com> wrote:

Hi Aviva,

Thanks! I am also excited to join Regeneron.

Congratulations to your success of publishing in Amazon. Your focus and perseverance to science is admirable.

Best

Anamika Sarkar, PhD

@@@@@@

From: “Mark Cobbold, MD, PhD, MGH” <mcobbold@mgh.harvard.edu>

Date: Wednesday, April 27, 2016 at 11:32 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: RE: LIVE ­ 8:00 am ­ 12:00 pm 4/25/2016 ­ First Look: The Next Wave of Cancer Breakthroughs @2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Westin Hotel, Boston | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Thanks Aviva.

You obviously work hard on this!

Keep up the hard work.

Mark

MARK COBBOLD, MD, PHD

Headshot

Associate Professor of Medicine, MGH Cancer Center

http://worldmedicalinnovation.org/speakers/mark-cobbold-md-phd/

 

From: Aviva Lev-Ari [mailto:AvivaLev-Ari@alum.berkeley.edu]
Sent: Tuesday, April 26, 2016 7:53 PM
To: Cobbold, Mark
Subject: LIVE ­ 8:00 am ­ 12:00 pm 4/25/2016 ­ First Look: The Next Wave of Cancer Breakthroughs @2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Westin Hotel, Boston | Leaders in Pharmaceutical Business Intelligence (LPBI) Group
 

https://pharmaceuticalintelligence.com/2016/04/25/live-800-am-1200-pm-4252016-first-look-the-next-wave-of-cancer-breakthroughs-2016-world-medical-innovation-forum-cancer-april-25-27-2016-westin-hotel-boston/

Aviva Lev-Ari, PhD, RN

Director & Founder

Leaders in Pharmaceutical Business Intelligence Group, Boston

Editor-in-Chief

http://pharmaceuticalintelligence.com

e-Mail: avivalev-ari@alum.berkeley.edu

SkypeID: HarpPlayer83 

LinkedIn Profile        Twitter Profile

@@@@@

From: Arquisch Tony <Tony.Arquisch@cpagroup.ch>

Date: Friday, March 18, 2016 at 11:46 AM

To: Aviva Lev-Ari <aviva.lev-ari@comcast.net>

Cc: Arie Berger <arisimonberger@gmail.com>, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>, ‘Maggie You’ <maggie.you@oriental-ventures.com>

Subject: RE: REVOTEK follow up for 3D printing – AVIVA

Hello Aviva: 

To answer your questions:

The ownership at regenHU is as is.

The CEO of regenHU is Mr. Marc Thurner

The other CPA Group companies are unchanged i.e. no updates

With that said, of course until there are any official announcements, we continue to sell products and services accordingly. If there is interest in a particular product and/or service I will be more than happy to assist. If there is an investment interest then please send me an official inquiry (in writing) with as many details as possible upon which I will present it to management. Once there is an interest we will send Non-disclosure agreements and start the negation phase accordingly.

I truly hope we can work together since I’m impressed with your activities. Have a great weekend.

Regards,

Tony

Tony Arquisch

Business Development Manager
Direct +41 26 653 71 84
Mobile +41 79 349 20 44
tony.arquisch@cpagroup.ch

CPA Group SA
Z.I. du Vivier 22
CH-1690 Villaz-St-Pierre

Switzerland
Tel. +41 26 653 71 71
www.cpagroup.ch

LinkedIn Profile  /  XING Profile  / Twitter Profile

@@@@@@@

From: Christopher Wells <cwells@personalizedmedicinecoalition.org>

Date: February 19, 2016 at 3:40:19 PM EST

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Cc: David Davenport <ddavenport@personalizedmedicinecoalition.org>

Subject: Re: I wish to nominate Larry H. Bernstein, MD, FCAP for 12th Annual Award for Leadership in Personalized Medicine

Dr. Lev-Ari:

Thank you so much for what is clearly a strong nomination. David Davenport, copied here, will make sure that our Board of Directors gives careful consideration to Dr. Bernstein’s qualifications for this award, and I will follow up with you personally once we have made a final decision. 

By the way, I am a fan of your work on Leaders in Pharmaceutical Business Intelligence. I am sure it is helpful for many personalized medicine stakeholders. 

Have a good weekend. 

Very sincerely,

Chris

Christopher J. Wells, M.P.A.

Communications Director

Cwells@personalizedmedicinecoalition.org

Direct: 202-589-1755 I Mobile: 202-580-9780

Personalized Medicine Coalition

Blog: Education & Advocacy

Twitter: @PerMedCoalition

1710 Rhode Island Ave. NW I Suite 700 I Washington, DC 20036

www.PersonalizedMedicineCoalition.org  

@@@@@@@

2/12/2016

2016 Communication Awards for Excellence in Reporting and Communicating Science, Medicine and Engineering Nomination

Book Title: * Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation
Publisher(s): * Amazon Kindle Direct
Publication Date: (Please select one): * November 2015
Book Entry Summary (Please limit to 100 words): * The explosion of scientific information has created difficulties tying together disparate discoveries, ideas, and potential applications. Pharmaceutical Business Intelligence is developing an innovative methodology for Global access to Biomedical knowledge rather than traditional search. To attain this complex goal they disseminate ORIGINAL Research via Content Curation by experts using critical thinking process & interpretation over open access networks, offering better organization and visibility of critical information useful for innovations in academic, clinical, and industrial research. Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation at http://www.amazon.com/dp/B018Q5MCN8 is nominated as an example of this methodology.
   

@@@@@@@

2/2/2016

Nominations for 2016 National Academies Communication Awards For Excellence in Reporting and Communicating Sciences, Engineering, and Medicine, Keck Futures Initiative

Editor-in-Chief: Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2016/02/02/nominations-for-2016-national-academies-communication-awards-for-excellence-in-reporting-and-communicating-sciences-engineering-and-medicine/

@@@@@@@@@

From: “Tilda Barliya, PhD” <tildabarliya@gmail.com>

Date: Tuesday, January 19, 2016 at 1:09 PM

To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>

Press Releases from Leaders in Pharmaceutical Business Intelligence (LPBI): FIVE new e-Book in our BioMed e-Series are NOW available for Kindle on Amazon.com | Leaders in Pharmaceutical Business Intelligence

Wow!!!!! That’s very impressive. So proud of being part of this group and project.  Good job everyone.

Thank you Aviva for being the leader of this group and pushing us forward. Thank you for being you.

Good job everyone!!!

Best

Tilda

@@@@@@@@@

From: Gregory Piatetsky-Shapiro <gregory@kdnuggets.com>

Date: Sunday, January 10, 2016 at 6:13 AM

To: Aviva Lev-Ari <aviva.lev-ari@comcast.net>

Subject: Re: big data start up for you to talk to…

Dear Aviva,

Happy New Year and congratulations on your amazing success in your latest venture – Pharmaceutical Intelligence!

Gregory

On 1/9/2016,  I wrote to Gregory:

My eight years in HealthCare, 2005-2012, could have been an entry into HealthCareIT, as we discussed in 2012. However, I decided to tackle Pharmaceutical Intelligence , instead. The learning curve was very steep and it was conquered in record time, as evidenced by building an amazing impactful infrastructure in Scientific Media in Pharmaceutical Intelligence:

Journal, ~4000 articles archived, 900,000 e-Readers

e-Books, 15 Title BioMed e-Series, eight are on Amazon.com in 2015, seven forthcoming, in 2016

Conference Press Coverage in Real Time, sixteen of the Leading in BioTech. In 4/2016, Partners HealthCare, Global Cancer Conference in Boston.

In 3D BioPrinting, we lunched a Subsidiary, TEAM is involved in Product Concepts Development using

  • BioMEMS for Gene Editing
  • BioMEMS for Tissue Engineering
  • BioMEMS and Stem Cells for Gene Therapy and Regenerative Medicine.

We are also involved involved in (a) Drug Discovery by structuring Joint Ventures and in (b) Funding Early Stage Biologics Drug Development and Medical Device Development.

@@@@@@@@

Please see #3

Mayo Clinic Center for Innovation is citing LPBI’s Article by Dr. Larry H Bernstein, MD, FCAP

16 NOV 5 FOR TODAY

Posted at 06:30h in Morning Update by Center for Innovation 0 Comments Share

  1. Responsible innovation in health care and dual use research. [ Health Kid ]
  2. A patient’s point of view. [ HRBR ]
  3. Drivers of Patient Experience. [ LPBI ]
  4. 5 ways providers can improve the patient experience. [ FierceHealthIT ]
  5. Telehealth is essential to lowering readmission rates. [ mHealthNews ]

@@@@@@@@

From: “Dr. MD. K. Singler” <Dr.MD.K.Singler@sciarticles.net>

Reply-To: “Dr. MD. K. Singler” <Dr.MD.K.Singler@sciarticles.net>

Date: Friday, November 13, 2015 at 10:14 AM

To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>

Subject: Invitation

Science and Education

November, 2015

Submit a manuscript

Journals

Articles

Subscribe

Search

Unsubscribe

Dear Colleague,

I am writing to let you know about recent highly accessed articles published in our open access journals and invite you to submit your next manuscript to the journal.

Read our top articles

Dr. MD. K. Singler

Editorial Assistant, Science and Education Publishing

@@@@@@@@@

From: Anne Sim <georgeclinicalau@gmail.com>

Date: Monday, August 3, 2015 at 3:39 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: contributing

Hello,

I am contacting you on behalf of George Clinical, a leading non-profit CRO in the Asia Pacific region. Our parent organization, The George Institute is a renowned medical research institute which has impacted medical practice and policy globally.

We are currently working to build upon our brand awareness by sharing our extensive knowledge and experience within the scientific and medical community. We would love to learn more about any opportunities (publishing, marketing, sponsorship, co-authorship) that you might have available.

We appreciate your time, and If you would be kind enough to provide us information on possible opportunities that you offer, we can review them and see which are a good fit between our organization and yours.

Thanks,

Anne Sim

@@@@@@@@@@@@@@@@@

From: Christopher Wells <cwells@personalizedmedicinecoalition.org>

Date: Wednesday, September 2, 2015 at 11:36 AM

To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>

Subject: Thank you for re-blogging our post

Hi Dr. Lev-Ari:

I noticed that you re-blogged our recent post on Education & Advocacy, titled “Turning a Corner: How This Month’s Decisions at FDA Inform the Debate on Drug Costs.” I just wanted to thank you for that. We are working to build a following for the blog, and a re-posting from an established and reputable source like your blog is helpful. 

I will keep an eye on content from your blog moving forward. Feel free to let me know if you ever post anything on personalized medicine. 

Thank you again.

Sincerely,

Chris

Christopher J. Wells, M.P.A.

Communications Director

Cwells@personalizedmedicinecoalition.org

Direct: 202-589-1755 I Mobile: 202-580-9780

Personalized Medicine Coalition

Blog:Education & Advocacy

Twitter: @PerMedCoalition

1710 Rhode Island Ave. NW I Suite 700 I Washington, DC 20036

www.PersonalizedMedicineCoalition.org  

Unknown@@@@@@@@@@@@@@@@@

 
10/19/2015

Dear Aviva:

I want to applaud you for building your own publishing and scientific communications empire. You have really grown since 5/2013 when you and Larry and I first met. Anyway, down to business. I need help in “telling my story” of why the current 5 Nucleotide Watson Crick Genetic Code (ATGCU) need to expand with two additional and natural purine nucleotides to cover the epigenetic level of gene regulation so that Novagon’s 7 nucleotide ATUICGX genetic + epigenetic = genomic code is more valid than the current 5 code which has never built a man made prescription drug or any therapy which does not have multiple side effects including thousands of deaths. This project has got to big for me and I would like to join with your group to be discuss, strategically, how we can logically and empirically prove natures natural 7 code is the right number of codes and not 5. I don’t know how to proceed, but if you are interested we could meet i.e. whoever you want to bring into the project is fine by me; there are people in your group who can edit and write or rewrite what I have done much better than me. Remember, I grew up in Helena, Arkansas, in the Delta region, on the Mississippi river. Lots of cotton, but not many brains, especially in the teaching ranks. Any way I have come along way from there but I still am deficit or maybe lazy in writing and editing. Although my ADHD might be a strong contributing factor. Any, way I have tried and finally willing to concede, One person cannot do it alone. I have reached out to you because you were the first to ask me to join your team as Expert, author writer. Kind of ironic now that I am coming to you with great content but unorganized with no media plan or strategy. If Larry is interested I should would like him part of the project, if you decide to accept my scientific content and as publisher you we jointly publish what value proposition we determine as a team. Thanks for your notice. I took it as a cosmic sign, and it would be your 7th venture, quite ironic under the circumstances. Thank you for your time and I hope you decide to let me into your publishing umbrella and get some help in creating content for your growing empire. Thanks, John Berger Novagon DNA

John Berger

Founder at Novagon DNA

   
 
@@@@@@@@@@@@@@@@@@

 

   

 

Dear Dr. Aviva Lev-Ari,

Greetings from SciRes Literature!

It is a great pleasure to invite you for the Editorial Board membership in SciRes Literature member Journals. SciRes Literature is an Open Access Publisher of twenty-eight internationally refereed, online, peer-reviewed scholarly Journals designed for scientists, physicians, doctors and researchers across the globe. Our mission is to support the rising horizons of the scientific innovations and promote the advancement in research community by increasing the online accessibility of quality research articles.

The Editorial Office is actively seeking qualified researchers and experts to be a part of our journal Editorial Board. In recognition to your distinguished accomplishments in the area of Immunology (related areas), we are pleased to invite you to be a part of our SRL Immunology & Immunotherapy journal.

You can find more information by visiting us at:
http://scireslit.com/Immunology

You can support, strengthen and contribute to our vision through your expertise in area by joining our Editorial Board.

If you are interested in serving as an editor, kindly send us your short biography, Research interests, CV and Photo to immunology@scireslit.com for review.

Please feel free to contact for any further queries

Anticipating a positive response.

Sincerely,

SASHA Sims
Editorial Office, SciRes Literature
SRL Immunology & Immunotherapy
1692 Coastal Highway
Delaware 19958, USA
Email: immunology@scireslit.com

 

 

Testimonials about LPBI

2021

UPDATED on 9/29/2021

Tweet

 
MIT Technology Review
 
@techreview
Replying to

and

Thanks for joining us again
@AVIVA1950. We loved your tweets yesterday!
 
@techreview is the handle of MIT Technology Review Twitter account followed by 1.1 Million followers

MIT Technology Review

 

Retweeted your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT Charles Hoskinson CEO and Founder, Input Output Global; Founder, Cardano, 2015 Nation scale [Ethiopia] and Global scale – records ledger and smart contracts, credentials identity, reversible auditable that operates at scale; Cofounder, Ethereum

This image has an empty alt attribute; its file name is MIT-Technology-Review.png
 
 

MIT Technology Review

Retweeted your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT Charles Hoskinson CEO and Founder, Input Output Global; Founder, Cardano, 2015 Nation scale [Ethiopia] and Global scale – records ledger and smart contracts, credentials identity, reversible auditable that operates at scale; Cofounder, Ethereum

MIT Technology Review

liked your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT  Nick Selby Chief Security Officer, Paxos Trust Company at Timehop GDPR a bridge of security disclosure to US Citizens 5% of EU opt out 7/418 ADM password changed User database was compromised protect customers data Recovery architecture monitor

MIT Technology Review

Retweeted your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT @EmTechMIT Wendy Nather Head of Advisory CISOs @Cisco mid 90s Two-way authentications Who are the attackers, changes, abuse of the platform by users Technology to buy Proactive Refresh Tech done by vendor is best security practice

MIT Technology Review

Retweeted your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT Kevin Scott CTO @Microsoft Compute is the only constraint Open source version of OpenAI API no need to build OS. Responsible AI within Microsoft – Standard for the whole company to be rolled up soon. Regulation to consider where we are going to be

 
 
 

 

UPDATED on 9/22/2021

From INTERNS in 2021 LPBI’s Summer Internship

From: “Ethan Coomber [Intern 2021]” <ethancoomber6@gmail.com>
Date: Monday, September 20, 2021 at 11:54 PM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>

Hi Aviva,

This past summer, I was able to intern for LPBI. I really enjoyed being able to expand upon what I had been learning in the classroom at school, and push myself to take on new, exciting challenges. Over the summer, I was given 2 projects that were extremely interesting, but were vital in helping LPBI grow as well. With the guidance of LPBI, as well as my own outreach, I was able to expose myself to the world of text to audio conversion, as well as further my understanding of data analytics. The combination of resources at my disposal as well as Aviva’s guidance allowed me to make the most of the opportunity in front of me.

The mentorship I received from LPBI was extremely valuable. Being able to work so closely with LPBI’s founder, Aviva Lev-Ari PhD, Rn, I was able to get a detailed understanding of LPBI’s mission and how it relates to the projects I was working on. Aviva was a great resource as she allowed me to explore and be creative in discovering solutions, but was also available if I ever required guidance or leadership. I am proud of the work I was able to accomplish under Aviva’s guidance.

Looking forward to staying in touch,

Ethan

UPDATED on 6/1/2021 for May 24, 2021

From: Mass General Brigham <innovations@partners.org>

Reply-To: <innovations@partners.org>

Date: Monday, May 24, 2021 at 9:31 AM

To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>

Subject: RECAP | World Forum | Day 3 | GCT | CEOs | Harvard | Investors

Notable Tweets

 
 
 

@mandywoodland

Fascinating #WMIF2021 panel on mRNA yesterday -“mRNA is the message, and we just have to decide what message we want to deliver to the cell,” said moderator Lindsey Baden, MD. “The promise of this technology could not be more front and center for all of us.”

@LeapsByBayer

Congratulations to the 2021 Innovation Discovery Grants winners: @lynchielydia, Peter Sage, @GrishchukL, Benjamin Kleinstiver, Petr Baranov, announced at the #WMIF2021. It’s exciting to see the range of breakthrough research in #geneticdisease at @MassGenBrigham

 
 

@DrLilitGaribyan

Gene and cell therapy have scalability problems that we need to solve. This is what is echoed this week at @MGBInnovation World Medical Innovation Forum. #gct #celltherapy #healthcare #innovation

@MPDexpert

“imagine how the future could look if gene therapy cost 1/100th what it does today” @VCAmir @PolarisVC #wmif2021

@AVIVA1950 is Aviva Lev-Ari, PhD, RN

#WMIF2021 @MGBInnovation Roger Kitterman VP, Venture, Mass General Brigham Saturation reached or more investment is coming in CGT Multi OMICS and academia originated innovations are the most attractive areas @pharma_BI @AVIVA1950

@AVIVA1950_PIcs

IMG_7167

UPDATED on 2/15/2021

From: Nigel Russell <nrussell@jofpm.com>

Date: Monday, February 15, 2021 at 10:31 AM

To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>

Subject: RE: About our Venture

Dear Dr. Lev-Ari: 

Thank you for the information and outreach. You have a very interesting platform.

I am interested in chatting.

 

Kind regards,

Nigel

 

Nigel Russell

President

The Journal of Precision Medicine & the Precision Medicine Leaders Summit

Updated on 1/6/2021

From: “Jennings, Charlotte (Reuters)” <Charlotte.Jennings@thomsonreuters.com>

Date: Tuesday, January 5, 2021 at 10:47 AM

To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>

Subject: RE: REUTERS NEXT ­ Press Registration Deadline this Friday (Jan 8)

Hi Aviva,

Thanks for getting back to me. Your press pass for REUTERS NEXT is now confirmed.

It would be great if you could also please share your attendance with your network and across social media. You can find all sharing materials in the media pack here –

Attendees Pack · Reuters Next · Virtual Forum: January 11-14, 2021 (reutersevents.com)

Here’s a tracked sign-up link you can use when sharing – https://bit.ly/35ddYqO

Any other questions please don’t hesitate to reach out!

All the best,
Charlotte

2020

Updated on 8/25/2020

From: Robin Neff Clebnik <robin@internboston.com>

Date: Tuesday, August 25, 2020 at 5:23 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Thank You!

Hi Aviva,

Thank you for your contribution to a very successful summer for our InternBoston students! Your gifts of time, expertise were invaluable to our interns—and to our program as a whole. Your organization’s willingness to participate in InternBoston’s Virtual Summer60™ program allows high school and college students the opportunity to explore learning beyond the traditional limits of their classrooms. The first-hand experiences students receive in the internship will help prepare them for college and beyond.

By participating as a mentor, you have provided Noam with an exceptional opportunity to learn more about a potential career field in a structured and educational environment. Your dedication and commitment to establishing a work plan, overseeing the intern’s progress, and encouraging independence through learning have undoubtedly made a positive and lasting impact.

We look forward to continuing our partnership and will check in with you shortly to discuss more interns for Fall 2020.

 

Best,

Robin

robin neff clebnik

Chief Internship Officer

t: 617.527.0055 

m: 617.875.4614

          

Updated on 8/23/2020

 

The VOICE of Dr. Larry H. Bernstein, MD, FCAP on 8/23/2020:

I discovered a new site in 2012, and thereafter met Aviva Lev-Ari, PhD, RN, https://lnkd.in/eEyn69r

the Director & Founder of the Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston.

That led me to participate in writing for her Open Access Online Scientific Journal for five intense years, 1,400 articles in total. It is now late August 2020, and I have no longer engaged in the writing because of aging limitations.

I can indeed say, the Founder of the LPBI Group in Boston, Aviva, has really been a very fortunate leader, innovator, and collaborator in the LPBI Group’s medical and life sciences publishing endeavors. 

Aviva curated about my contributions to http://pharmaceuticalintelligence.com in the following two monumental sources: 

https://pharmaceuticalintelligence.com/2013/12/10/the-young-surgeon-and-the-retired-pathologist-on-science-medicine-and-healthcare-policy-best-writers-among-the-writers/

  • Editorial & Publication of Articles in e-Books by Leaders in Pharmaceutical Business Intelligence: Contributions of Larry H Bernstein, MD, FCAP
    Curator: Aviva Lev-Ari, PhD, RN

With heartfelt gratitude to our Dear Dr. Larry

https://pharmaceuticalintelligence.com/2014/10/16/editorial-publication-of-articles-in-e-books-by-leaders-in-pharmaceutical-business-intelligence-contributions-of-larry-h-bernstein-md-fcap/

Aviva published my authored contents in 18 volumes https://lnkd.in/ekWGNqA and in the following two memorable articles:

  • Commentaries on each Volume’s Contribution to Medical Education by L.H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN – BioMedical e-Books e-Series: Multiple Volumes in Five e-Series

Authors: L.H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/biomed-e-books/commentaries-on-each-volumes-contribution-to-medical-education-by-l-h-bernstein-md-fcap-and-aviva-lev-ari-phd-rn-biomedical-e-books-e-series-multiple-volumes-in-five-e-series/

  • My Memories Tell a Story to Share

Author: Larry Howard Bernstein, MD, FCAP

https://pharmaceuticalintelligence.com/2020/04/19/my-memories-tell-a-story-to-share-by-larry-howard-bernstein-md-fcap/

Aviva initiated, organized, edited and proposed a narrator for my interview for the following PODCAST:

  • Podcast with Dr. Larry H. Bernstein, MD, FCAP, Interview by Gail S. Thornton, PhDc, Narrator’s Voice: Stephen J. Williams, PhD

https://pharmaceuticalintelligence.com/audio-podcasts/podcast-with-dr-larry-h-bernstein-md-fcap-interview-by-gail-s-thornton-phdc-narrators-voice-stephen-j-williams-phd/

 

Updated on 8/11/2020

The VOICES of Interns of LPBI’s 2020 Summer Internship Program on Data Curation and Data Annotation

The Voice of Internship Team’s Captain, Daniel, Menzin:

LPBI has provided me with an invaluable experience this summer, which has allowed me to grow in a variety of ways. Through close mentorship, we were exposed to principles of data science (i.e. AI, ML, NLP), data curation and annotation, biochemistry, and website development. In addition to daily mentorship by Aviva, we were provided with weekly sessions where we were taught by world-renowned scientists. These sessions provided us with crucial background knowledge, as well as instructions which allowed us to execute and create deliverables while developing our professional skills. Aviva tasked me with several IT projects this summer that were challenging. It was a great opportunity for me to take advantage of the resources around me and learn on my own. Aviva mentored me throughout every step of the process, always providing feedback and showing me how I could improve my deliverables. My summer at LPBI provided me with an incredible opportunity to not only learn more, but also apply what I had learned through the creation of important deliverables. With the breadth of information I’ve been exposed to at LPBI, my professional horizons will surely now be broadened after having been taught things essential to numerous different fields.

The Voice of Noam Steiner Tomer:

Interning at LPBI has been instrumental in both my professional and personal development. Reading and curating many of the cutting edge and insightful articles that LPBI offers contributed significantly to my intellectual growth and broadened greatly my professional horizons. Through this internship I got to not only learn from many renowned researchers but gave me the unique opportunity to work with them directly. I also acquired many technical skills from the on-the-job training such as curation and improved my self-learning skills. It has absolutely been the most valuable experience of my high school career. I have learned so much from your presentations and doing the assignments, and have discovered interests I never knew I had like Hematology!

The Voice of Zach Day:

This summer I interned at Leaders in Pharmaceutical Intelligence (LPBI) in social media and market research.    In this capacity, I participated in weekly classes taught by medical experts about the latest developments in Cancer and Genetics Research. I met regularly with the company’s Director and Founder, Dr Aviva Lev-Ari and attended team meetings.  I wrote two articles about the company and its founder and uploaded them to Wikipedia. I also generated content for the company’s website including eleven WordClouds using WordItOut.com. Overall this was a great experience because I learned a lot, I contributed a lot and greatly appreciate the mentoring and support that I received working with Dr. Lev-Ari. 

 

Updated on 6/3/2020

Professor Marcus Feldman Receives Stanford Biosciences Mentoring and Service Award

Reporter: Gail S. Thornton, M.A.

Marcus Feldman, Ph.D., the Burnet C. and Mildred Finley Wohlford Professor in the School of Humanities and Sciences and Professor of Biology at Stanford University, has been selected to receive the 2019-20 Stanford
Biosciences “Excellence in Mentoring and Service Award”. This honor is given to faculty who make distinguished contributions towards enhancing the quality of training and the mentoring experiences for Stanford Biosciences graduate students.

In recognizing Professor Feldman for this honor, William S. Talbot, Ph.D., Senior Associate Dean of Graduate Education and Postdoctoral Affairs,
Professor of Developmental Biology,  at Stanford University, thanked him for his “extraordinary contributions this year.” Professor Feldman will be formally acknowledged for receiving this award and an honorarium at the School of Medicine Graduation Celebration on Saturday, June 13, 2020.

###

Updated on 5/7/2020

From: Alan Kaul <alan@mom-inc.us>

Date: Thursday, May 7, 2020 at 9:03 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Cc: Vinit Nair <vinit@pracnet.org>

Subject: Pharmaceutical Intelligence

HI Aviva,

You asked for my help in promoting your portal and I’ve done something that I haven’t done for any other organization, I put a direct link to your portal on Medical Outcomes Management’s home page.

[ see www.mom-inc.us ]

This is the only link to another business on our company’s website. We may move it’s location, but it will remain highly visible and directly linked.

I hope that this link will prove helpul to both of us

Stay safe,

Alan

Updated on 4/19/2020

ADDED to this entry by Dr. Larry H. Bernstein, MD, FCAP on 8/17/2020

“I am thankful to Aviva for the opportunity to follow my interests in retirement. I have been away from the laboratory longer than I would like, but could follow the literature.”

Sincerely,

Larry Bernstein, MD

“Prior to moving I was contacted by Aviva Lev-Ari, PhD, RN who was building an online medical forum known as Leaders in Pharmaceutical Business Intelligence (LPBI) Group, and I became the Chief Scientific Officer (CSO). Over the decade I wrote many articles (1,390) in the Open Access online Scientific Journal http://pharmaceuticalintelligence.com that were included in 18 organized e-Books in Medicine. Dr. Lev-Ari’s accomplishment is quite impressive. The e-Books are all available on Amazon.com”

https://lnkd.in/ekWGNqA

In:

My Memories Tell a Story to Share, 4/19/2020

Author: Larry Howard Bernstein, MD, FCAP

Contact: 413-727-8523

https://pharmaceuticalintelligence.com/2020/04/19/my-memories-tell-a-story-to-share-by-larry-howard-bernstein-md-fcap/

Updated on 2/9/2020

Obtained by Gail S. Thornton on 2/7/2020

Leaders in Pharmaceutical Business Intelligence (LPBI) is among the best resources of original scientific and medical content for the scientific and business community that is carefully chosen and thoughtfully organized and presented. The site offers a valuable contribution to biomedical science by advancing knowledge and research efforts through its commitment to synthesize, analyze and interpret complex, medical and scientific disease information on any subject, as well as biomedical research innovation widely available to the scientific and non-research community. There is a vast amount of quality, curated information on the site organized in three inter-related domains of an e-Journal, series of 16 e-Books and e-scientific and medical conference proceedings that is produced by an esteemed group of collaborators. 

In today’s biomedical science environment, there is a wide range of available information in journals of all subject areas and web sites, including clinical data, public health data and even genomics information, that needs to be accessed. The value and uniqueness that LPBI brings to the scientific community is its consistent and enormous success in producing non-technical reviews of technical literature in the medical field, so that the scientific findings are much more accessible in real-time. In that way, the scientific community can further delve into specific areas of interest more readily. The site is a quality, professional resource for the biomedical field, which is unique to any field. 

I’ve had the pleasure to serve as content consultant to LPBI over the years and, specifically, as an author of a newly launched e-book entitled, Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology. 

 

 —Marcus W. Feldman, Ph.D., Burnett C. and Mildred Finley Wohlford Professor of Computational Biology in the School of Humanities and Sciences, and co-director of the Center for Computational, Evolutionary and Human Genetics, Stanford University. He is the author of more than 600 scientific papers and 10 books on evolution, ecology, mathematical biology and demography. He is a member of the U.S. National Academy of Sciences, the American Academy of Arts and Sciences and the American Philosophical Society. He was the 2011 Dan David laureate in Evolution and was awarded the 2016 Kimura Prize in Evolution by the Japanese Suzuki Foundation.

Updated on 1/31/2020

Notifications from ResearchGate

Vesa Cosmin Mihai recommended your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Apr 6, 2019

Md Azree Othuman Mydin and 2 others recommended your publications: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Mar 25, 2019

Bahra Karima followed your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Mar 25, 2019

Javad Parmah followed your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Nov 27, 2018

Sebastian Nemeth recommended your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Jul 29, 2018

Daniela Gitea and Gabriela Cioca recommended your publications: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Jul 27, 2018

Vyacheslav Lyashenko followed your publication: Regenerative and Translational Medicine: The Therapeutic Promise for Cardiovascular Diseases

Oct 10, 2016

Santiago Prieto Menchero followed your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Jan 9, 2016

Musaab Salih followed your publication: Metabolic Genomics & Pharmaceutics: Volume I

Dec 12, 2015

UPDATED on 1/10/2020

The following three testimonials resulted from three interviews conducted by Prof. Sheila M. Puffer (UC, Berkeley, PhD’84) in December 2019 for Prof. Puffer’s nomination of Dr. Lev-Ari for 2020 Campanile Excellence in Achievement Award. This award recognizes an alumnus/a whose remarkable professional achievements reflect the excellence of a UC Berkeley education.

Past Recipients

https://awards.berkeley.edu/achievement-awards

The recipients will be formally presented with their awards at Berkeley Charter Gala on May 14, 2020.

Dr. Marcus Feldman

Professor of Biology, Stanford University

Dr. Feldman, who has been deeply involved in Dr. Lev-Ari’s e-publishing venture, expressed his admiration for her career and contributions in multiple and diverse scientific and medical fields. ‘She single-handedly formed the venture to curate the biological medical literature and has produced 16 online books with her collaborators. She has had enormous success in producing nontechnical reviews of technical literature in the medical field, so that the scientific findings are much more accessible to the professional side as opposed to the research side. She has worked extremely hard on developing that professional resource for the biomedical field, which is unique to any field. Her accomplishments represent the best of what Berkeley can produce.”

 

Dr. Justin Pearlman

Professor of Medicine, Practicing Cardiology, UCLA, and Practicing Cardiologist

Dr. Pearlman was one of the early members of the electronic publishing team and served as the editor of three of the volumes. He noted that it was Dr. Lev-Ari’s idea to develop an online pharmacology journal of a completely new design called curation. She also came up with the idea of multimodality, to include videos and other media. He explained that expert reviewers provide reviews and critique the strength and weaknesses of the research and provide and additional information that open eyes to new opportunities. He himself was one of those experts who willingly became deeply involved in the project, and the caliber of his credentials attests to Dr. Lev-Ari’s persuasiveness in getting such experts to devote their time and talents to the project. Dr. Pearlman already had an established reputation as the Vice Chair of Medicine at UCLA and Chief of Cardiology, was an editor and writer, and had over 4,000 citations of his publications.  He explained: “By the sheer force of her personality, Aviva put together a team of experts, and she encourages a new generation to utilize this material. This is important because the new generation is not aware that articles can have their own agenda, such as needing to please granting organizations that fund the research. Aviva has a strong entrepreneurial spirit and investigates many different avenues to make things better – business, medical, biological, and scientific.”

 

Dr. Stephen Williams

Assistant Professor of Pharmacology at the Sbarro Health Research Organization at Temple University

Dr. Williams  has known Dr. Lev-Ari since 2012 when he noticed her call for collaboration on her electronic publishing project on several LinkedIn groups. He was intrigued and contacted her, and became one of the senior editors of the publishing project. “I have never met anyone so driven as Dr. Lev-Ari. She had a great vision and knows how to put that vision into practice. She has an impressive amount and quality of people she has direct contact with.

It was a no brainer. I said, ‘I have to work with her.’ I am very, very happy with that decision. The project developed into a site that deals with all areas of medicine and related scientific disciplines. It is an open access, open science forum with the goal of breaking down silos. In addition, she developed a methodology for real-time medical conference coverage.The whole world is dying for knowledge. People are hungry for this collaboration, including in both developed and developing countries.”

He explained how she created the project: “It is amazing how she set up the venture and has grown it over such a short time and involved the top people in many fields. To me it is absolutely amazing for such a niche website. She set a goal of bringing scientists together in an online community to provide comments and insights. To the degree that happened is fantastic. She personally knows and has gained the involvement of some of the most sought-after researchers in cancer and other fields as keynote conference speakers and the like. I believe some will be future Nobel laureates. She establishes great relationships and has a great rapport with everyone.”

Regarding Dr. Lev-Ari’s accomplishments and personal character, he noted: “She has more energy than some 20 and 30-somethings. She does not stop until she sees her vision realized. She has received many accolades for her accomplishments, including her work at Mitre Corporation. Since 8/2018, Dr. Lev-Ari was contacted by the President elect of the Massachusetts Academy of Sciences (MAS), Prof. Katya Ravid of Boston University, School of Medicine, to join MAS in the role of Liaison to the Biotechnology and eScientific Publishing industries for the term of August 2018-July 2021. In the MAS, Dr. Lev-Ari serve as Board member, Fellow, and Advisor to the Governing Board. http://www.maacadsci.org

She has in-depth knowledge of many medical fields. She wrote an article that is available on the publication website about reinventing yourself. And that is something that she has done over and over again. Her career includes complex IT, nursing, and scientific publishing in biomedicine and biomedical research. In scientific careers, you’re in a constant state of reinventing yourself. For others, that may seem scary, but for her it is exciting. I tell my colleagues and students to take it the way Dr. Lev-Ari takes it – as an absolutely exciting journey. In every part of her life she looks at it as an exciting journey, even the obstacles she had to overcome.”

11/27/2019

Dear Aviva,

Thank You note from sandraleebatista@yahoo.com

Happy Thanksgiving to you and your family! I am so very grateful for your friendship and mentorship over so many years.

We will be here in Los Angeles and it will be a quiet holiday full of reflections on gratitude.

Best wishes,

Sandra

5/29/2019

From: “Klein, Susan Beth” <sbklein@indiana.edu>

Date: Wednesday, May 29, 2019 at 3:13 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Re: Permission to reprint image

Thank you very much for permission to reprint and also your useful suggestions. I shall certainly consider all of this content!

Susan

Susan B. Klein, PhD

Department of Physics

Swain West 331

Indiana University, Bloomington

812.855.9687

From: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Sent: Wednesday, May 29, 2019 12:46 PM

To: Klein, Susan Beth

Cc: Stephen Williams, PhD; Marcus W Feldman; Dr. Larry Bernstein; Aviva Lev-Ari

Subject: Re: Permission to reprint image

 

Dear Prof. Klein,

Your e-mail, below called for my re-read of Dr. Larry H. Bernstein’s article where the figure you wish to re-publish was found.

It was indeed, a special pleasure to read again his article and to realize one more time, how important the curation work is for dissemination of scientific findings. Dr. Larry is a Biochemist, retired Pathologist and one of the best writers in Medical Sciences among the livings.

See

The Young Surgeon and The Retired Pathologist: On Science, Medicine and HealthCare Policy – The Best Writers Among the WRITERS

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2013/12/10/the-young-surgeon-and-the-retired-pathologist-on-science-medicine-and-healthcare-policy-best-writers-among-the-writers/

I recommend that in your forthcoming book on Radiation Biology you will consider the following suggestions: 

A. Include Agents that Damage DNA [as in Dr. Larry’s article, not limited to it]

B. Refer the reader to Dr. Larry’s article which is a unique resource on the topic of DNA and DNA Replication 

C. Please review the Table of Contents of our Genomics, Volume One, it may assist you with A, above

https://pharmaceuticalintelligence.com/biomed-e-books/genomics-orientations-for-personalized-medicine/volume-one-genomics-orientations-for-personalized-medicine/

Regarding re-publishing the figure:

I am suggesting to add the following comment: 

Image Source

Image is the copyright of Buzzle.com, cited in A Primer on DNA and DNA Replication by Reporter and Curator: Larry H. Bernstein, MD, FCAP 

https://pharmaceuticalintelligence.com/2014/07/29/a_primer_on_dna_and_dna_replication/

I wish you best of luck with researching the scientific literature for this very important and timely forthcoming text book on Radiation Biology.

Very proud to share with you that we have on Leaders in Pharmaceutical Intelligence portal:  http://pharmaceuticalintelligence.com    

 1,627,949 e-Readers, 678 Categories of Research and +10K Tags and 5,594 scientific article CURATIONS & Scientific reporting.

 

Please keep in touch and I encourage you to continue to search our Journal archive. 

Best regards,

PS

This e-mail is your e-written permission to re-publish figure as commented, above.

Leaders in Pharmaceutical Intelligence portal:  http://pharmaceuticalintelligence.com    

LPBI Group was created in 2012 by me, Aviva Lev-Ari, Ph.D., R.N. The Group has three interrelated healthcare content products: an open-access online scientific journal (Journal archive is an article corpus); a series of 16 BioMed e-books (BioMed e-Series is an e-Book corpus); and real-time coverage of BioMed scientific and medical conferences (An archive of conference e-Proceedings corpus). Through these transformative products, the Group effectively meets and exceeds the information needs of researchers, scientists and industry pharmaceutical and biotechnology executives by offering real-time and currently available medical and scientific information on any biomedical subject (700 categories). LPBI also makes information on cutting-edge biomedical research innovation widely available to the scientific and non-research community using a process of connections to multiple social media platforms, chiefly LinkedIn, Twitter and Facebook. The method of curation includes synthesis, analysis and interpretation of complex medical and scientific areas.

Aviva Lev-Ari, PhD, RN

Director & Founder

https://lnkd.in/eEyn69r

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

Editor-in-Chief

http://pharmaceuticalintelligence.com 

e-Mail: avivalev-ari@alum.berkeley.edu

(M) 617-775-0451

https://cal.berkeley.edu/AvivaLev-Ari,PhD,RN

SkypeID: HarpPlayer83          LinkedIn Profile        Twitter Profile

From: “Klein, Susan Beth” <sbklein@indiana.edu>

Date: Wednesday, May 29, 2019 at 9:12 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Re: Permission to reprint image

Thank you so much Aviva.

The url is https://pharmaceuticalintelligence.com/2014/07/29/a_primer_on_dna_and_dna_replication/.

The name of the article is “A Primer on DNA and DNA Replication”; Reporter and Curator: Larry H. Bernstein, MD, FCAP.

Appreciatively,

Susan

Susan B. Klein, PhD

Department of Physics

Swain West 331

Indiana University, Bloomington

812.855.9687

From: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Sent: Tuesday, May 28, 2019 12:17 PM

To: Klein, Susan Beth

Cc: Stephen Williams, PhD; Marcus W Feldman

Subject: Re: Permission to reprint image

 

Dear Prof. Klein,

It is always most endearing to correspond with another fellow Alumna of Berkeley.

Congratulations on your forthcoming book, Fundamentals of Radiation Biology. The publisher of the text is World Scientific, anticipated publication in 2023.

Thank you for reaching out to me for permission to reprint a figure.

Please e-mail me the name of the article you found this figure in on our Journal http://pharmaceuticalintelligence.com 

Or in one our our 16 e-Books in Life Sciences and Medicine on Amazon.com

https://lnkd.in/ekWGNqA

I will then research and grant you re-printing permission in e-writing.

Since your forthcoming text book is on Radiation Biology, in this context, I wish to bring to your attention two points:

1.You may find of interest the following e-Books of ours

Series B: Frontiers in Genomics Research

 

  • VOLUME 1: Genomics Orientations for Personalized Medicine. On Amazon.com since 11/23/2015

http://www.amazon.com/dp/B018DHBUO6

  • VOLUME 2: Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology

https://pharmaceuticalintelligence.com/biomed-e-books/genomics-orientations-for-personalized-medicine/volume-two-genomics-methodologies-ngs-bioinformatics-simulations-and-the-genome-ontology/

Work-in-Progress

 

Series C: e-Books on Cancer & Oncology

 

  • Volume 1: Cancer Biology & Genomics for Disease Diagnosis. On Amazon.com since 8/11/2015

http://www.amazon.com/dp/B013RVYR2K

  • Volume 2: Cancer Therapies: Metabolic, Genomics, Interventional, Immunotherapy and Nanotechnology in Therapy Delivery (Series C Book 2). On Amazon.com since 5/18/2017

http://www.amazon.com/dp/B071VQ6YYK

2. My articles on medical OUTCOMES of Radiation Biology  on Cardiotoxicity

Cardio-oncology and Onco-Cardiology Programs: Treatments for Cancer Patients with a History of Cardiovascular Disease

Curator: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2014/01/08/cardio-oncology-and-onco-cardiology-programs-treatments-for-cancer-patients-with-a-history-of-cardiovascular-disease/

3rd Annual Canadian Cardiac Oncology Network Conference, June 20 – 21, 2013, Ottawa Convention Centre

Reporter: Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/2014/01/08/3rd-annual-canadian-cardiac-oncology-network-conference-june-20-21-2013-ottawa-convention-centre/

2019

http://cardiaconcology.ca/ccon-conference-2019-modern-changing-practices-in-cardio-oncology/agenda/

My Journal on Cardiotoxicity on Scoop.it

https://www.scoop.it/topic/cardiotoxicity

Looking forward to getting name of article when the figure had appeared in our publications.

Good luck,

Aviva Lev-Ari, PhD, RN

Director & Founder

https://lnkd.in/eEyn69r

Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston

Editor-in-Chief

http://pharmaceuticalintelligence.com 

e-Mail: avivalev-ari@alum.berkeley.edu

(M) 617-775-0451

https://cal.berkeley.edu/AvivaLev-Ari,PhD,RN

SkypeID: HarpPlayer83          LinkedIn Profile        Twitter Profile

From: “Klein, Susan Beth” <sbklein@indiana.edu>

Date: Tuesday, May 28, 2019 at 11:11 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Permission to reprint image

Hello Aviva Lev-Ari,

I am currently writing a book: Fundamentals of Radiation Biology. I would like to know if I might have your permission to reprint this figure in a section on DNA replication. The publisher of the text is World Scientific and we anticipate publication in 2023. I would very much appreciate your permission; this is a lovely illustration!

Regards,

Susan

Susan B. Klein, PhD

Department of Physics

Swain West 331

Indiana University, Bloomington

812.855.9687

(another Berkeley alum)

April 2019

2019 Ranking of Conference Influencers: On 4/9/2019, The Partners’ 2019 World Medical Innovation Forum #WMIF19

via @symplur‘s #Healthcare Hashtags http://bit.ly/WMIF19 

  • By “Mentions” – Ranked #4: @pharma_BI and
  • By “Tweets” – Ranked #2: @AVIVA1950

via NodeXL  http://bit.ly/2KB6cPN 

  • By “Betweenness Centrality” – Ranked #3: @AVIVA1950 and @pharma_BI

https://pharmaceuticalintelligence.com/2019/04/13/the-wmif19-influencers-via-symplurs-healthcare-hashtags-http-bit-ly-wmif19-by-mentions-and-by-tweets-ranked-4-pharma_bi-and-2-aviva1950-respectively-ranked-3-via-node/

4/21/2019

From: Amnon Danzig <amnon.danzig@gmail.com>

Date: Sunday, April 21, 2019 at 4:17 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: A Letter from Amnon Danzig

Dear Aviva

Now, I read the two docs in depth.

Sure, I have a few questions for my understanding. We can devote Skype for that to make sure I understand…

It is my honor to work with you and the team.

I found Gail and Rick extremely good players, partners and colleagues at the same time. And I would like to thank you for the opportunity to work with them.

I would like to thank you for your very fine and warm words about my contribution. GREAT!

I must confess that in the last three months I couldn’t do any real intellectual work. I need to finalize my speech at the conference and couldn’t touch it.

Why?

My thinking was always going to the ways to present LPBI Group the best it can.

I found myself very busy intellectually and emotionally how we can improve the way the IB will see us.

Example: the last two weeks I invested happily dozens and dozens for this assignment. On Thursday afternoon my son arrives and we spent a few hours together. Then, on 9 PM I set down to make the corrections you asked me. Took me another 3 hours, sent it and waited another two hours to see whether I need some more. Because I knew that on Friday you MUST send. It was kind of relief after two hours. When you sent us the update I saw it and felt “everything is okay” and I can put my mobile away for 24 hours: all the family, friends were around I thought it better to be disconnected.

I am very glad you found my contribution significant. Also, the way you express it is outstanding. Thank you!

Now, I will spend a few days about the conference and also looking for ways to find significant people to meet and discuss my new book. The idea to find more audience and hopefully potential clients.

If you happen to have ideas for me, great.

This is the reason I extend my time in NYC. 

BR 

Amnon

@@@@@

4/19/2019

LPBI Group: The Business Opportunity

Voice of Prof. Marcus W. Feldman

The intellectual property of LPBI is of three types: a corpus of curated articles in an open access online scientific Journal, a corpus of e-books in Medicine and Life Sciences, and a corpus of Biotech e-proceedings. This IP is highly relevant to five industrial and services sectors across twelve economic segments. LPBI has pioneered production of scientific content with unique curation methodology by a highly knowledgeable group of experts. The content and the potential consumers & acquirers and valuers of this content are represented graphically below. The three types of corpus, together with the very large audience that follows the content on various media, represent intangible assets of LPBI Group and can be represented as such to potential investors. Together with the tangible assets described in Document #2, the combination represents a unique opportunity for acquisition.

@@@@@

4/19/2019

LPBI Group: The Business Plan

Voice of Aviva Lev-Ari, Founder

The Business Plan representing work-in-progress generated by our business professionals, Amnon Danzig (AD), Gail Thornton (GST) and Rick Mandahl (RM).

  • The content is extracted from Document #2, the concept of the “Client End-User Perspective” and the “Acquirer Perspective” are contributions by Amnon Danzig (AD). 
  • The positioning of 12 economic segments in a 3D structure for each of these two perspectives represent contributions of AD, GST and RM, under the leadership of AD. They took the microeconomics Theory of the Firm to most interesting interpretation given for several Demand aspects related to the performance of Knowledge Workers in the digital workplace as potential users of LPBI Group’s products.
  • They followed the 3D illustration developed by Aviva Lev-Ari, PhD, RN (ALA) using three different axes for representation of same 12 economic segments. The view taken by ALA is of Industrial Organization Economics theoretical framework of comparisons among industrial and services sectors and within each sector competition among player drawing strategies for augmenting the competitive advantage by horizontal and vertical mergers. Opportunities for economies or scale, externalities, diversification and product differentiation. In ALA’s perspective, LPBI Group’s IP represents Supply side, a series of technologies poised to augment the core competencies of players in 12 economic segments as in Appendix C, below [which is identical to Table developed by ALA for Sections #4 & #5 in Document #2.
  • Further development of this Business Plan document will follow in the near future.

This Business Plan is based on and is complementary to Document #2 that provides a distinctive view on Intangible Assets, Sections #1 to #12 vs Tangible Assets and royalty payments which are present in Section #13 & #14 of Document #2.

This Business Plan consists of a conceptual framework developed by the business side of our Final Improvement Team (FIT members N=12). This conceptual framework is indeed unique in depth and breadth placing the unmet needs of potential acquirers by name, each in an economic segment, each economic segment within an Industrial and Services Sector. It demonstrates deep understanding of Demand side economics of the End-User in each of the 12 economic segments. This strategic thought process represents well AD’s business acumen for placing in the center the ultimate demand of end-users and the unmet needs of potential Acquirers that will be fulfilled on their behalf by LPBI Group’s IP – the features and functionality of the technologies we have developed since 2012.

 

@@@@@

4/14/2019

The #WMIF19 Influencers via ‘s  Hashtags http://bit.ly/WMIF19 – By Mentions and By Tweets Ranked #4: @pharma_BI and #2: @AVIVA1950, respectively. Ranked #3 via NodeXL Betweenness Centrality http://bit.ly/2KB6cPN

https://pharmaceuticalintelligence.com/2019/04/13/the-wmif19-influencers-via-symplurs-healthcare-hashtags-http-bit-ly-wmif19-by-mentions-and-by-tweets-ranked-4-pharma_bi-and-2-aviva1950-respectively-ranked-3-via-node/

4/13/2019

Twitter Data for LPBI Group’s Founder’s Twitter handle @AVIVA1950 was updated 

On 2/24/2019 — Tweets 8,060 Following 1,412 Followers 359 Likes 2,752

On 4/13/2019 — Tweets 9,018 Following 1,461 Followers 390 Likes 3,654

 

4/11/2019

Top 3 Ranked by Betweenness Centrality in Top 10 Influencers #WMIF19 @phsinnovation @evankirstel @aviva1950 –Tweeter Analytics by NodeXL http://bit.ly/2KB6cPNfor #WMIF19 by @PHSInnovation  at World Medical Innovation Forum ARTIFICIAL INTELLIGENCE, Boston, MA USA, Monday, April 8-10, 2019

https://pharmaceuticalintelligence.com/2019/04/11/top-3-ranked-by-betweenness-centrality-in-top-10-influencers-wmif19-phsinnovation-evankirstel-aviva1950-tweeter-analytics-by-nodexl-http-bit-ly-2kb6cpn-for-wmif19-by-phs/

@@@@

‘s  Hashtags  – Twitter Analytics published for http://bit.ly/WMIF19 

  • [Top 10 by Mentions – @pharma_BI = 4 with 181 mentions]  
  • [Top 10 by Tweets @AVIVA1950 = 2 with 229 Tweets (N = 152 Direct messages)]
 Pinned Tweet

⚡️As World   Forum comes to a close, here are TOP   via ‘s  Hashtags 🙏 to organizers for a stellar event & to all on  for a robust conversation!   👏 

@@@@

Top influencer 3rd place @AVIVA1950

This is a great analysis and I love that you found these two programs, NodeXL and Betweeness Centrality. These offer the best Twitter analytics and node analysis I have ever seen. Thanks for sharing and a great conference and great conference coverage in real time. Show the power of REALTIME CONFERENCE COVERAGE methodology @pharma_BI and @AVIVA1950 as well as power of LBPI Group.

https://nodexlgraphgallery.org/Pages/InteractiveGraph.aspx?graphID=193125

 

@@@@

From: “Gregory Piatetsky, KDnuggets” <editor1@kdnuggets.com>

Date: Wednesday, April 10, 2019 at 10:16 PM

To: Aviva Lev-Ari <aviva.lev-ari@comcast.net>, Gil Press <gpress900@gmail.com>

Subject: Re: Fwd: NodeXL Graph Gallery: Interactive Graph

Well done!  3rd place for #WMIF19 is good

See

Comparative Analysis of the Level of Engagement for Four Twitter Accounts: @KDNuggets (Big Data) @GilPress @Forbes @pharma_BI @AVIVA1950

 

@@@@

From: Leny <gochevav@mit.edu>

Date: Wednesday, November 28, 2018 at 11:30 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Re: MIT Center for Precision Cancer Medicine Inaugural Symposium – Question from Aviva Lev-Ari, PhD, RN

Dear Dr. Lev-Ari,

I actually have been meaning to reach out to you with an invitation to our symposium. We were both at the Personalized Medicine Coalition’s conference two week ago at Harvard Medical School, but I didn’t get a chance to speak to you in person.

To get a complimentary press pass, please visit cpcm.eventbrite.com -> select Tickets ->  select “Enter Promotional Code”-> enter CPCM2018 and that will allow you to select “Press” tickets.

Please do not hesitate to reach out if you have any additional questions.

Best,

Leny

Vasilena Gocheva, PhD | Assistant Director  | MIT Center for Precision Cancer Medicine  | 77 Massachusetts Avenue, 76-353  | Cambridge, MA 02139  | cpcm.mit.edu

From: Shankar Khatkale <shankar.k@gminsights.com>

Date: Tuesday, November 27, 2018 at 6:48 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Article Submission Request

Dear Editor,

An industry news titled ‘Precision Medicine Market Size worth $96.6bn by 2024’ by Global Market Insights is relevant to your esteemed website https://pharmaceuticalintelligence.com. This email is a suggestion to publish this news (content attached in word format or can be picked from link mentioned below) on your website with an objective to share the information with your audiences.

News Link: https://www.gminsights.com/pressrelease/precision-medicine-market

 Looking forward to hear from you.

 On behalf of and as instructed by Global Market Insights, Inc.

 Best Regards,

Shankar Khatkale |SEO Executive

 

From: Daphne Kwee <daphnekwee@farrerpark.com> on behalf of Daphne Kwee <daphnekwee@farrerpark.com>

Date: Monday, October 29, 2018 at 9:33 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Post retirement doctors establishing new career heights – Story Consideration

Dear Aviva,

Would you be interested in interviewing personalities in the medical Fraternity?

Particularly, Dr Leslie Lam. One of the renowned personality who was sued by the SMC and won after a 7 year battle. He is a medical veteran in his 70s but shows no signs of slowing down. He has re-established himself in Farrer Park Hospital and is blazing a trail with his new clinic. Having recently been conferred the Distinguished Graduate Award by the University College Dublin School of Medicine for his contribution toward medical education, research and support toward the community. Previous recipients of this award includes Professor Connor Ward who pioneered work on Cardiac abnormalities such as the co-described Ward-Romanov Syndrome.   

Dr Lam’s story strikes a chord with the government’s stand of lifelong learning and contribution. In addition to his clinical work, Dr Lam is an advisor to the Seychelles ministry of health, contributes regularly to teaching doctors and donating medical equipment to Myanmar. He also established a leading wine collection in order to fund his philanthropic works with charities in Singapore and Ireland, where he received his medical education. 

I have attached the award letter to this email for your information. 

Should you be interested in such a story angle, I do have other personalities here at Farrer Park Hospital for your consideration. Professor Tan Yew Oo, Singapore first medical oncologist, as well as Professor Soo Khee Chee, the founding director of Singapore’s National Cancer Centre. All these renowned medical personalities, who in their post retirement years, are still actively contributing toward Singapore’s future.

Do let me know if you would like to find out more to explore story possibilities. I would be happy to catch up over lunch or tea for a discussion.

 

Best regards,

Daphne

Executive

Corporate Communications

DID (65) 6705 2769  

www.farrerpark.com/hospital

From: “Prof. Nathan F. SAYRE (Chairman, Geography)” <nsayre@berkeley.edu>

Date: Friday, June 1, 2018 at 3:26 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Cc: Christian Gordon <cmgordon@berkeley.edu>, Robert Rhew <rrhew@berkeley.edu>

Subject: Re: I will be on BERKELEY Campus for the Homecoming Week, few days before and After, October 11, 2018 to October 16, 2018 — Hope to meet again

Dear Dr. Lev-Ari,

Thank you for your kind note, and wonderful to hear that you will be visiting campus in October. I’m happy to hear that you will see Professor Birgeneau and other Cal alumni in New England. I know the university will be ramping up its efforts in Boston and surrounding areas, to create more opportunities for alumni to connect with each other, and with Berkeley.

I would like to introduce you to Christian Gordon, our partner in development and alumni relations for geography and the division of social sciences. Christian can assist with setting up your visit and relevant meetings while you are on campus. He’s also happy to follow up with additional information, as well as additional opportunities in Boston to connect with Berkeley between now and October.

Very much looking forward to seeing you at Homecoming. Thanks again for sending your recollections of Allan and Berkeley!

Best,

Nathan

PS I’m cc’ing Professor Rob Rhew, who will succeed me as department chair on July 1st.

From: “Prof. Michael Watts” <mwatts@berkeley.edu>

Date: Sunday, May 13, 2018 at 1:29 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Re: Sharing with you — This May 2018, Official Newsletter has a Global distribution of half a million Inboxes: See article on Aviva Lev-Ari in ALUMNI SPOTLIGHT of American Friends of Hebrew University

Dear Aviva: a very long time!  Nice to hear from you and your later extraordinary career!  And it seems like you are now on Phase IV.  Very exciting.

I am retiring in June but will of course keep writing and conducting research.

You may have heard that Allan’s wife Hjordis passed away relatively recently.   It was nice to see their children again at the memorial.

Warmly, Michael

On Fri, May 11, 2018 at 12:01 PM, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu> wrote:

Sharing with you — This May 2018, Official Newsletter has a Global distribution of half a million Inboxes:  

See article on Aviva Lev-Ari in ALUMNI SPOTLIGHT of American Friends of Hebrew University – Please scroll down

If interested to read more, click on:

Aviva’s books on AMAZON.COM

https://www.amazon.com/s/ref=nb_sb_noss?url=search-alias%3Ddigital-text&field-keywords=Aviva+Lev-Ari&rh=n%3A133140011%2Ck%3AAviva+Lev-Ari

On Fri, May 25, 2018 at 12:44 PM, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu> wrote:

Dear Professors, Watts, Walker, Sayre, Laguerr and Segev, 

I hope you are well and will enjoy the months of Summer coming up.

We will have dinner with Berkeley’s ex-Chancellor, Prof. Robert Birgeneau in Boston on 6/16/2018, meeting with Alumni in New England. I am much looking forward to his talk and meeting alumni.

I will be on BERKELEY Campus on October 11, 2018 to October 16, 2018, planning to attend the Homecoming Week, October 12-14, 2018.

It will be my great pleasure to meet again, I hope you will be on Campus at least one day of the week in October 2018 when I will be on Campus and could meet you. Allan Pred will be missing on this visit, so sad.

I recently wrote my Recollections of my five years at Berkeley in two Parts, which you may find of interest to read, in particular, Part 2, which I authored as a curation, after my e-mail exchange with Prof. Michael Watts in May, 2018.

  • Recollections: Part 1 – My days at Berkeley, 9/1978 – 12/1983 – About my doctoral advisor, Allan Pred, other Professors and other Peers

https://pharmaceuticalintelligence.com/2018/03/15/recollections-my-days-at-berkeley-9-1978-12-1983-about-my-doctoral-advisor-allan-pred-other-professors-and-other-peer/

  • Recollections: Part 2 – “While Rolling” is preceded by “While Enrolling” Autobiographical Alumna Recollections of Berkeley – Aviva Lev-Ari, PhD’83

https://pharmaceuticalintelligence.com/2018/05/24/recollections-part-2-while-rolling-is-preceded-by-while-enrolling-autobiographical-alumna-recollections-of-berkeley-aviva-lev-ari-phd83/

Please Read these two:

I attended the 1998 – 100 years Geography Department celebration.

Please review the following, it can be included in the future Itinerant Geographer.

Reflections on a Four-phase Career: Aviva Lev-Ari, PhD, RN, March 2018

https://pharmaceuticalintelligence.com/2018/03/06/reflections-on-a-four-phase-career-aviva-lev-ari-phd-rn-march-2018/

Thank you – Good Luck to you

From: “Prof. Nathan F. SAYRE (Chairman, Geography)” <nsayre@berkeley.edu>

Date: Thursday, March 8, 2018 at 6:07 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Re: I MADE A CONTRIBUTION IN MEMORY OF PROF. ALLAN PRED few weeks ago

Dear Aviva,

Thank you for writing. Yes, we did receive your donation in Allan’s honor–thank you!–and we put a letter of thanks and acknowledgement in the mail last week. Please look out for it.

You are not alone in missing Allan–many many people do. Sadly, his widow, Hjordis, also passed away not long ago.

Michael Watts is not yet technically retired, but he thought he would two years ago, and since we made a big public announcement then we’ve kept the technical truth quiet. He will in fact retire this summer. As you assumed, Walker, Reed, and Nat have all retired, as have Beatriz Manz, Gillian Hart, Paul Groth, Michael Johns, and Roger Byrne. We are anxiously awaiting authorization to recruit new human geography faculty.

It’s kind of hard to think of any of us as adequate to fill Allan’s shoes, but we all try to preserve his flexibility of mind and lucidity of thought. Our graduate students perhaps carry on his intellectual legacy best. If you haven’t heard of Trevor Paglen, he was one of Allan’s last PhDs:

http://www.paglen.com/

Thank you also for the links to your eulogies for Allan and David, and to your reflections. I am touched by your words and your enduring support for the department.

Best,

Nathan

On Monday, July 24, 2017 at 9:27 PM

From: marzan Khan <marzan.khan@mail.mcgill.ca>

Date: Monday, July 24, 2017 at 9:27 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Re: SERIES E VOLUME 2 –>>> FORMAT CONVERSION — I MUST find out what has been done to FINISH up this format conversion – Series E Volume 2

Hello Aviva,

Thank you very much for your kindness and support. It was great working for you. I apologize for not being able to finish my task to completion. You have been an excellent mentor and I will be grateful to you always.

Best of luck on the e-book and all your endeavors.

Sincerely,

Marzan Khan

On June 18, 2017, 9;39AM

Dear Aviva Lev-Ari,

Thank you very much for your email.

First of all I would like to congratulate you to your outstanding work, if I may. You are one of the very few people with really meaningful and scientific articles/updates on LinkedIn.

I recently liked one of your articles/updates “Molecular Pathogenesis of Progressive Lung Diseases” on LinkedIn, because it was an interesting article. We have a project here in China “Natural Breathing”, where we look at solutions for COPD. With all the air pollution in China, this is already a majour burden, and it is one that will become a larger burden in the coming years. As for your email, I am not quite sure what to make out of it honestly. Is it an offer to write or publish an article? In regards to China: Please do not hesitate to contact me, if you have questions or if I may help with contacts in the healthcare industry. We have a quite good network here.

Sincerely from Beijing

Dennis Wilkens, Managing Director, Medical Devices, Health 4.0, Toronto, Hamburg, Beijing, Distribution Network, Investments & Ventures, Jadevita International Inc., University of Hamburg

On 6/15/17, 5:43 AM, “Anamika Sarkar” <sarkaranamika@yahoo.com> wrote:

Hi Aviva,

Thanks! I am also excited to join Regeneron.

Congratulations to your success of publishing in Amazon. Your focus and perseverance to science is admirable.

Best

Anamika Sarkar, PhD

@@@@@@

From: “Mark Cobbold, MD, PhD, MGH” <mcobbold@mgh.harvard.edu>

Date: Wednesday, April 27, 2016 at 11:32 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: RE: LIVE ­ 8:00 am ­ 12:00 pm 4/25/2016 ­ First Look: The Next Wave of Cancer Breakthroughs @2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Westin Hotel, Boston | Leaders in Pharmaceutical Business Intelligence (LPBI) Group

Thanks Aviva.

You obviously work hard on this!

Keep up the hard work.

Mark

MARK COBBOLD, MD, PHD

Headshot

Associate Professor of Medicine, MGH Cancer Center

http://worldmedicalinnovation.org/speakers/mark-cobbold-md-phd/

 

From: Aviva Lev-Ari [mailto:AvivaLev-Ari@alum.berkeley.edu]
Sent: Tuesday, April 26, 2016 7:53 PM
To: Cobbold, Mark
Subject: LIVE ­ 8:00 am ­ 12:00 pm 4/25/2016 ­ First Look: The Next Wave of Cancer Breakthroughs @2016 World Medical Innovation Forum: CANCER, April 25-27, 2016, Westin Hotel, Boston | Leaders in Pharmaceutical Business Intelligence (LPBI) Group
 

https://pharmaceuticalintelligence.com/2016/04/25/live-800-am-1200-pm-4252016-first-look-the-next-wave-of-cancer-breakthroughs-2016-world-medical-innovation-forum-cancer-april-25-27-2016-westin-hotel-boston/

Aviva Lev-Ari, PhD, RN

Director & Founder

Leaders in Pharmaceutical Business Intelligence Group, Boston

Editor-in-Chief

http://pharmaceuticalintelligence.com

e-Mail: avivalev-ari@alum.berkeley.edu

SkypeID: HarpPlayer83 

LinkedIn Profile        Twitter Profile

@@@@@

From: Arquisch Tony <Tony.Arquisch@cpagroup.ch>

Date: Friday, March 18, 2016 at 11:46 AM

To: Aviva Lev-Ari <aviva.lev-ari@comcast.net>

Cc: Arie Berger <arisimonberger@gmail.com>, Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>, ‘Maggie You’ <maggie.you@oriental-ventures.com>

Subject: RE: REVOTEK follow up for 3D printing – AVIVA

Hello Aviva: 

To answer your questions:

The ownership at regenHU is as is.

The CEO of regenHU is Mr. Marc Thurner

The other CPA Group companies are unchanged i.e. no updates

With that said, of course until there are any official announcements, we continue to sell products and services accordingly. If there is interest in a particular product and/or service I will be more than happy to assist. If there is an investment interest then please send me an official inquiry (in writing) with as many details as possible upon which I will present it to management. Once there is an interest we will send Non-disclosure agreements and start the negation phase accordingly.

I truly hope we can work together since I’m impressed with your activities. Have a great weekend.

Regards,

Tony

Tony Arquisch

Business Development Manager
Direct +41 26 653 71 84
Mobile +41 79 349 20 44
tony.arquisch@cpagroup.ch

CPA Group SA
Z.I. du Vivier 22
CH-1690 Villaz-St-Pierre

Switzerland
Tel. +41 26 653 71 71
www.cpagroup.ch

LinkedIn Profile  /  XING Profile  / Twitter Profile

@@@@@@@

From: Christopher Wells <cwells@personalizedmedicinecoalition.org>

Date: February 19, 2016 at 3:40:19 PM EST

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Cc: David Davenport <ddavenport@personalizedmedicinecoalition.org>

Subject: Re: I wish to nominate Larry H. Bernstein, MD, FCAP for 12th Annual Award for Leadership in Personalized Medicine

Dr. Lev-Ari:

Thank you so much for what is clearly a strong nomination. David Davenport, copied here, will make sure that our Board of Directors gives careful consideration to Dr. Bernstein’s qualifications for this award, and I will follow up with you personally once we have made a final decision. 

By the way, I am a fan of your work on Leaders in Pharmaceutical Business Intelligence. I am sure it is helpful for many personalized medicine stakeholders. 

Have a good weekend. 

Very sincerely,

Chris

Christopher J. Wells, M.P.A.

Communications Director

Cwells@personalizedmedicinecoalition.org

Direct: 202-589-1755 I Mobile: 202-580-9780

Personalized Medicine Coalition

Blog: Education & Advocacy

Twitter: @PerMedCoalition

1710 Rhode Island Ave. NW I Suite 700 I Washington, DC 20036

www.PersonalizedMedicineCoalition.org  

@@@@@@@

2/12/2016

2016 Communication Awards for Excellence in Reporting and Communicating Science, Medicine and Engineering Nomination

Book Title: * Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation
Publisher(s): * Amazon Kindle Direct
Publication Date: (Please select one): * November 2015
Book Entry Summary (Please limit to 100 words): * The explosion of scientific information has created difficulties tying together disparate discoveries, ideas, and potential applications. Pharmaceutical Business Intelligence is developing an innovative methodology for Global access to Biomedical knowledge rather than traditional search. To attain this complex goal they disseminate ORIGINAL Research via Content Curation by experts using critical thinking process & interpretation over open access networks, offering better organization and visibility of critical information useful for innovations in academic, clinical, and industrial research. Volume Two: Cardiovascular Original Research: Cases in Methodology Design for Content Co-Curation at http://www.amazon.com/dp/B018Q5MCN8 is nominated as an example of this methodology.
   

@@@@@@@

2/2/2016

Nominations for 2016 National Academies Communication Awards For Excellence in Reporting and Communicating Sciences, Engineering, and Medicine, Keck Futures Initiative

Editor-in-Chief: Aviva Lev-Ari, PhD, RN

http://pharmaceuticalintelligence.com/2016/02/02/nominations-for-2016-national-academies-communication-awards-for-excellence-in-reporting-and-communicating-sciences-engineering-and-medicine/

@@@@@@@@@

From: “Tilda Barliya, PhD” <tildabarliya@gmail.com>

Date: Tuesday, January 19, 2016 at 1:09 PM

To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>

Press Releases from Leaders in Pharmaceutical Business Intelligence (LPBI): FIVE new e-Book in our BioMed e-Series are NOW available for Kindle on Amazon.com | Leaders in Pharmaceutical Business Intelligence

Wow!!!!! That’s very impressive. So proud of being part of this group and project.  Good job everyone.

Thank you Aviva for being the leader of this group and pushing us forward. Thank you for being you.

Good job everyone!!!

Best

Tilda

@@@@@@@@@

From: Gregory Piatetsky-Shapiro <gregory@kdnuggets.com>

Date: Sunday, January 10, 2016 at 6:13 AM

To: Aviva Lev-Ari <aviva.lev-ari@comcast.net>

Subject: Re: big data start up for you to talk to…

Dear Aviva,

Happy New Year and congratulations on your amazing success in your latest venture – Pharmaceutical Intelligence!

Gregory

On 1/9/2016,  I wrote to Gregory:

My eight years in HealthCare, 2005-2012, could have been an entry into HealthCareIT, as we discussed in 2012. However, I decided to tackle Pharmaceutical Intelligence , instead. The learning curve was very steep and it was conquered in record time, as evidenced by building an amazing impactful infrastructure in Scientific Media in Pharmaceutical Intelligence:

Journal, ~4000 articles archived, 900,000 e-Readers

e-Books, 15 Title BioMed e-Series, eight are on Amazon.com in 2015, seven forthcoming, in 2016

Conference Press Coverage in Real Time, sixteen of the Leading in BioTech. In 4/2016, Partners HealthCare, Global Cancer Conference in Boston.

In 3D BioPrinting, we lunched a Subsidiary, TEAM is involved in Product Concepts Development using

  • BioMEMS for Gene Editing
  • BioMEMS for Tissue Engineering
  • BioMEMS and Stem Cells for Gene Therapy and Regenerative Medicine.

We are also involved involved in (a) Drug Discovery by structuring Joint Ventures and in (b) Funding Early Stage Biologics Drug Development and Medical Device Development.

@@@@@@@@

Please see #3

Mayo Clinic Center for Innovation is citing LPBI’s Article by Dr. Larry H Bernstein, MD, FCAP

16 NOV 5 FOR TODAY

Posted at 06:30h in Morning Update by Center for Innovation 0 Comments Share

  1. Responsible innovation in health care and dual use research. [ Health Kid ]
  2. A patient’s point of view. [ HRBR ]
  3. Drivers of Patient Experience. [ LPBI ]
  4. 5 ways providers can improve the patient experience. [ FierceHealthIT ]
  5. Telehealth is essential to lowering readmission rates. [ mHealthNews ]

@@@@@@@@

From: “Dr. MD. K. Singler” <Dr.MD.K.Singler@sciarticles.net>

Reply-To: “Dr. MD. K. Singler” <Dr.MD.K.Singler@sciarticles.net>

Date: Friday, November 13, 2015 at 10:14 AM

To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>

Subject: Invitation

Science and Education

November, 2015

Submit a manuscript

Journals

Articles

Subscribe

Search

Unsubscribe

Dear Colleague,

I am writing to let you know about recent highly accessed articles published in our open access journals and invite you to submit your next manuscript to the journal.

Read our top articles

Dr. MD. K. Singler

Editorial Assistant, Science and Education Publishing

@@@@@@@@@

From: Anne Sim <georgeclinicalau@gmail.com>

Date: Monday, August 3, 2015 at 3:39 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: contributing

Hello,

I am contacting you on behalf of George Clinical, a leading non-profit CRO in the Asia Pacific region. Our parent organization, The George Institute is a renowned medical research institute which has impacted medical practice and policy globally.

We are currently working to build upon our brand awareness by sharing our extensive knowledge and experience within the scientific and medical community. We would love to learn more about any opportunities (publishing, marketing, sponsorship, co-authorship) that you might have available.

We appreciate your time, and If you would be kind enough to provide us information on possible opportunities that you offer, we can review them and see which are a good fit between our organization and yours.

Thanks,

Anne Sim

@@@@@@@@@@@@@@@@@

From: Christopher Wells <cwells@personalizedmedicinecoalition.org>

Date: Wednesday, September 2, 2015 at 11:36 AM

To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>

Subject: Thank you for re-blogging our post

Hi Dr. Lev-Ari:

I noticed that you re-blogged our recent post on Education & Advocacy, titled “Turning a Corner: How This Month’s Decisions at FDA Inform the Debate on Drug Costs.” I just wanted to thank you for that. We are working to build a following for the blog, and a re-posting from an established and reputable source like your blog is helpful. 

I will keep an eye on content from your blog moving forward. Feel free to let me know if you ever post anything on personalized medicine. 

Thank you again.

Sincerely,

Chris

Christopher J. Wells, M.P.A.

Communications Director

Cwells@personalizedmedicinecoalition.org

Direct: 202-589-1755 I Mobile: 202-580-9780

Personalized Medicine Coalition

Blog:Education & Advocacy

Twitter: @PerMedCoalition

1710 Rhode Island Ave. NW I Suite 700 I Washington, DC 20036

www.PersonalizedMedicineCoalition.org  

Unknown@@@@@@@@@@@@@@@@@

 
10/19/2015

Dear Aviva:

I want to applaud you for building your own publishing and scientific communications empire. You have really grown since 5/2013 when you and Larry and I first met. Anyway, down to business. I need help in “telling my story” of why the current 5 Nucleotide Watson Crick Genetic Code (ATGCU) need to expand with two additional and natural purine nucleotides to cover the epigenetic level of gene regulation so that Novagon’s 7 nucleotide ATUICGX genetic + epigenetic = genomic code is more valid than the current 5 code which has never built a man made prescription drug or any therapy which does not have multiple side effects including thousands of deaths. This project has got to big for me and I would like to join with your group to be discuss, strategically, how we can logically and empirically prove natures natural 7 code is the right number of codes and not 5. I don’t know how to proceed, but if you are interested we could meet i.e. whoever you want to bring into the project is fine by me; there are people in your group who can edit and write or rewrite what I have done much better than me. Remember, I grew up in Helena, Arkansas, in the Delta region, on the Mississippi river. Lots of cotton, but not many brains, especially in the teaching ranks. Any way I have come along way from there but I still am deficit or maybe lazy in writing and editing. Although my ADHD might be a strong contributing factor. Any, way I have tried and finally willing to concede, One person cannot do it alone. I have reached out to you because you were the first to ask me to join your team as Expert, author writer. Kind of ironic now that I am coming to you with great content but unorganized with no media plan or strategy. If Larry is interested I should would like him part of the project, if you decide to accept my scientific content and as publisher you we jointly publish what value proposition we determine as a team. Thanks for your notice. I took it as a cosmic sign, and it would be your 7th venture, quite ironic under the circumstances. Thank you for your time and I hope you decide to let me into your publishing umbrella and get some help in creating content for your growing empire. Thanks, John Berger Novagon DNA

John Berger

Founder at Novagon DNA

   
 
@@@@@@@@@@@@@@@@@@

 

   

 

Dear Dr. Aviva Lev-Ari,

Greetings from SciRes Literature!

It is a great pleasure to invite you for the Editorial Board membership in SciRes Literature member Journals. SciRes Literature is an Open Access Publisher of twenty-eight internationally refereed, online, peer-reviewed scholarly Journals designed for scientists, physicians, doctors and researchers across the globe. Our mission is to support the rising horizons of the scientific innovations and promote the advancement in research community by increasing the online accessibility of quality research articles.

The Editorial Office is actively seeking qualified researchers and experts to be a part of our journal Editorial Board. In recognition to your distinguished accomplishments in the area of Immunology (related areas), we are pleased to invite you to be a part of our SRL Immunology & Immunotherapy journal.

You can find more information by visiting us at:
http://scireslit.com/Immunology

You can support, strengthen and contribute to our vision through your expertise in area by joining our Editorial Board.

If you are interested in serving as an editor, kindly send us your short biography, Research interests, CV and Photo to immunology@scireslit.com for review.

Please feel free to contact for any further queries

Anticipating a positive response.

Sincerely,

SASHA Sims
Editorial Office, SciRes Literature
SRL Immunology & Immunotherapy
1692 Coastal Highway
Delaware 19958, USA
Email: immunology@scireslit.com

 

 

Testimonials about LPBI

2021

UPDATED on 9/29/2021

Tweet

 
MIT Technology Review
 
@techreview
Replying to

and

Thanks for joining us again
@AVIVA1950. We loved your tweets yesterday!
 
@techreview is the handle of MIT Technology Review Twitter account followed by 1.1 Million followers

MIT Technology Review

 

Retweeted your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT Charles Hoskinson CEO and Founder, Input Output Global; Founder, Cardano, 2015 Nation scale [Ethiopia] and Global scale – records ledger and smart contracts, credentials identity, reversible auditable that operates at scale; Cofounder, Ethereum

This image has an empty alt attribute; its file name is MIT-Technology-Review.png
 
 

MIT Technology Review

Retweeted your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT Charles Hoskinson CEO and Founder, Input Output Global; Founder, Cardano, 2015 Nation scale [Ethiopia] and Global scale – records ledger and smart contracts, credentials identity, reversible auditable that operates at scale; Cofounder, Ethereum

MIT Technology Review

liked your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT  Nick Selby Chief Security Officer, Paxos Trust Company at Timehop GDPR a bridge of security disclosure to US Citizens 5% of EU opt out 7/418 ADM password changed User database was compromised protect customers data Recovery architecture monitor

MIT Technology Review

Retweeted your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT @EmTechMIT Wendy Nather Head of Advisory CISOs @Cisco mid 90s Two-way authentications Who are the attackers, changes, abuse of the platform by users Technology to buy Proactive Refresh Tech done by vendor is best security practice

MIT Technology Review

Retweeted your Tweet

@pharma_BI @AVIVA1950 #EmTechMIT Kevin Scott CTO @Microsoft Compute is the only constraint Open source version of OpenAI API no need to build OS. Responsible AI within Microsoft – Standard for the whole company to be rolled up soon. Regulation to consider where we are going to be

 
 
 

 

UPDATED on 9/22/2021

From INTERNS in 2021 LPBI’s Summer Internship

From: “Ethan Coomber [Intern 2021]” <ethancoomber6@gmail.com>
Date: Monday, September 20, 2021 at 11:54 PM
To: Aviva Lev-Ari <avivalev-ari@alum.berkeley.edu>

Hi Aviva,

This past summer, I was able to intern for LPBI. I really enjoyed being able to expand upon what I had been learning in the classroom at school, and push myself to take on new, exciting challenges. Over the summer, I was given 2 projects that were extremely interesting, but were vital in helping LPBI grow as well. With the guidance of LPBI, as well as my own outreach, I was able to expose myself to the world of text to audio conversion, as well as further my understanding of data analytics. The combination of resources at my disposal as well as Aviva’s guidance allowed me to make the most of the opportunity in front of me.

The mentorship I received from LPBI was extremely valuable. Being able to work so closely with LPBI’s founder, Aviva Lev-Ari PhD, Rn, I was able to get a detailed understanding of LPBI’s mission and how it relates to the projects I was working on. Aviva was a great resource as she allowed me to explore and be creative in discovering solutions, but was also available if I ever required guidance or leadership. I am proud of the work I was able to accomplish under Aviva’s guidance.

Looking forward to staying in touch,

Ethan

UPDATED on 6/1/2021 for May 24, 2021

From: Mass General Brigham <innovations@partners.org>

Reply-To: <innovations@partners.org>

Date: Monday, May 24, 2021 at 9:31 AM

To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>

Subject: RECAP | World Forum | Day 3 | GCT | CEOs | Harvard | Investors

Notable Tweets

 
 
 

@mandywoodland

Fascinating #WMIF2021 panel on mRNA yesterday -“mRNA is the message, and we just have to decide what message we want to deliver to the cell,” said moderator Lindsey Baden, MD. “The promise of this technology could not be more front and center for all of us.”

@LeapsByBayer

Congratulations to the 2021 Innovation Discovery Grants winners: @lynchielydia, Peter Sage, @GrishchukL, Benjamin Kleinstiver, Petr Baranov, announced at the #WMIF2021. It’s exciting to see the range of breakthrough research in #geneticdisease at @MassGenBrigham

 
 

@DrLilitGaribyan

Gene and cell therapy have scalability problems that we need to solve. This is what is echoed this week at @MGBInnovation World Medical Innovation Forum. #gct #celltherapy #healthcare #innovation

@MPDexpert

“imagine how the future could look if gene therapy cost 1/100th what it does today” @VCAmir @PolarisVC #wmif2021

@AVIVA1950 is Aviva Lev-Ari, PhD, RN

#WMIF2021 @MGBInnovation Roger Kitterman VP, Venture, Mass General Brigham Saturation reached or more investment is coming in CGT Multi OMICS and academia originated innovations are the most attractive areas @pharma_BI @AVIVA1950

@AVIVA1950_PIcs

IMG_7167

UPDATED on 2/15/2021

From: Nigel Russell <nrussell@jofpm.com>

Date: Monday, February 15, 2021 at 10:31 AM

To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>

Subject: RE: About our Venture

Dear Dr. Lev-Ari: 

Thank you for the information and outreach. You have a very interesting platform.

I am interested in chatting.

 

Kind regards,

Nigel

 

Nigel Russell

President

The Journal of Precision Medicine & the Precision Medicine Leaders Summit

Updated on 1/6/2021

From: “Jennings, Charlotte (Reuters)” <Charlotte.Jennings@thomsonreuters.com>

Date: Tuesday, January 5, 2021 at 10:47 AM

To: “Aviva Lev-Ari, PhD, RN” <AvivaLev-Ari@alum.berkeley.edu>

Subject: RE: REUTERS NEXT ­ Press Registration Deadline this Friday (Jan 8)

Hi Aviva,

Thanks for getting back to me. Your press pass for REUTERS NEXT is now confirmed.

It would be great if you could also please share your attendance with your network and across social media. You can find all sharing materials in the media pack here –

Attendees Pack · Reuters Next · Virtual Forum: January 11-14, 2021 (reutersevents.com)

Here’s a tracked sign-up link you can use when sharing – https://bit.ly/35ddYqO

Any other questions please don’t hesitate to reach out!

All the best,
Charlotte

2020

Updated on 8/25/2020

From: Robin Neff Clebnik <robin@internboston.com>

Date: Tuesday, August 25, 2020 at 5:23 PM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Subject: Thank You!

Hi Aviva,

Thank you for your contribution to a very successful summer for our InternBoston students! Your gifts of time, expertise were invaluable to our interns—and to our program as a whole. Your organization’s willingness to participate in InternBoston’s Virtual Summer60™ program allows high school and college students the opportunity to explore learning beyond the traditional limits of their classrooms. The first-hand experiences students receive in the internship will help prepare them for college and beyond.

By participating as a mentor, you have provided Noam with an exceptional opportunity to learn more about a potential career field in a structured and educational environment. Your dedication and commitment to establishing a work plan, overseeing the intern’s progress, and encouraging independence through learning have undoubtedly made a positive and lasting impact.

We look forward to continuing our partnership and will check in with you shortly to discuss more interns for Fall 2020.

 

Best,

Robin

robin neff clebnik

Chief Internship Officer

t: 617.527.0055 

m: 617.875.4614

          

Updated on 8/23/2020

 

The VOICE of Dr. Larry H. Bernstein, MD, FCAP on 8/23/2020:

I discovered a new site in 2012, and thereafter met Aviva Lev-Ari, PhD, RN, https://lnkd.in/eEyn69r

the Director & Founder of the Leaders in Pharmaceutical Business Intelligence (LPBI) Group, Boston.

That led me to participate in writing for her Open Access Online Scientific Journal for five intense years, 1,400 articles in total. It is now late August 2020, and I have no longer engaged in the writing because of aging limitations.

I can indeed say, the Founder of the LPBI Group in Boston, Aviva, has really been a very fortunate leader, innovator, and collaborator in the LPBI Group’s medical and life sciences publishing endeavors. 

Aviva curated about my contributions to http://pharmaceuticalintelligence.com in the following two monumental sources: 

https://pharmaceuticalintelligence.com/2013/12/10/the-young-surgeon-and-the-retired-pathologist-on-science-medicine-and-healthcare-policy-best-writers-among-the-writers/

  • Editorial & Publication of Articles in e-Books by Leaders in Pharmaceutical Business Intelligence: Contributions of Larry H Bernstein, MD, FCAP
    Curator: Aviva Lev-Ari, PhD, RN

With heartfelt gratitude to our Dear Dr. Larry

https://pharmaceuticalintelligence.com/2014/10/16/editorial-publication-of-articles-in-e-books-by-leaders-in-pharmaceutical-business-intelligence-contributions-of-larry-h-bernstein-md-fcap/

Aviva published my authored contents in 18 volumes https://lnkd.in/ekWGNqA and in the following two memorable articles:

  • Commentaries on each Volume’s Contribution to Medical Education by L.H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN – BioMedical e-Books e-Series: Multiple Volumes in Five e-Series

Authors: L.H. Bernstein, MD, FCAP and Aviva Lev-Ari, PhD, RN

https://pharmaceuticalintelligence.com/biomed-e-books/commentaries-on-each-volumes-contribution-to-medical-education-by-l-h-bernstein-md-fcap-and-aviva-lev-ari-phd-rn-biomedical-e-books-e-series-multiple-volumes-in-five-e-series/

  • My Memories Tell a Story to Share

Author: Larry Howard Bernstein, MD, FCAP

https://pharmaceuticalintelligence.com/2020/04/19/my-memories-tell-a-story-to-share-by-larry-howard-bernstein-md-fcap/

Aviva initiated, organized, edited and proposed a narrator for my interview for the following PODCAST:

  • Podcast with Dr. Larry H. Bernstein, MD, FCAP, Interview by Gail S. Thornton, PhDc, Narrator’s Voice: Stephen J. Williams, PhD

https://pharmaceuticalintelligence.com/audio-podcasts/podcast-with-dr-larry-h-bernstein-md-fcap-interview-by-gail-s-thornton-phdc-narrators-voice-stephen-j-williams-phd/

 

Updated on 8/11/2020

The VOICES of Interns of LPBI’s 2020 Summer Internship Program on Data Curation and Data Annotation

The Voice of Internship Team’s Captain, Daniel, Menzin:

LPBI has provided me with an invaluable experience this summer, which has allowed me to grow in a variety of ways. Through close mentorship, we were exposed to principles of data science (i.e. AI, ML, NLP), data curation and annotation, biochemistry, and website development. In addition to daily mentorship by Aviva, we were provided with weekly sessions where we were taught by world-renowned scientists. These sessions provided us with crucial background knowledge, as well as instructions which allowed us to execute and create deliverables while developing our professional skills. Aviva tasked me with several IT projects this summer that were challenging. It was a great opportunity for me to take advantage of the resources around me and learn on my own. Aviva mentored me throughout every step of the process, always providing feedback and showing me how I could improve my deliverables. My summer at LPBI provided me with an incredible opportunity to not only learn more, but also apply what I had learned through the creation of important deliverables. With the breadth of information I’ve been exposed to at LPBI, my professional horizons will surely now be broadened after having been taught things essential to numerous different fields.

The Voice of Noam Steiner Tomer:

Interning at LPBI has been instrumental in both my professional and personal development. Reading and curating many of the cutting edge and insightful articles that LPBI offers contributed significantly to my intellectual growth and broadened greatly my professional horizons. Through this internship I got to not only learn from many renowned researchers but gave me the unique opportunity to work with them directly. I also acquired many technical skills from the on-the-job training such as curation and improved my self-learning skills. It has absolutely been the most valuable experience of my high school career. I have learned so much from your presentations and doing the assignments, and have discovered interests I never knew I had like Hematology!

The Voice of Zach Day:

This summer I interned at Leaders in Pharmaceutical Intelligence (LPBI) in social media and market research.    In this capacity, I participated in weekly classes taught by medical experts about the latest developments in Cancer and Genetics Research. I met regularly with the company’s Director and Founder, Dr Aviva Lev-Ari and attended team meetings.  I wrote two articles about the company and its founder and uploaded them to Wikipedia. I also generated content for the company’s website including eleven WordClouds using WordItOut.com. Overall this was a great experience because I learned a lot, I contributed a lot and greatly appreciate the mentoring and support that I received working with Dr. Lev-Ari. 

 

Updated on 6/3/2020

Professor Marcus Feldman Receives Stanford Biosciences Mentoring and Service Award

Reporter: Gail S. Thornton, M.A.

Marcus Feldman, Ph.D., the Burnet C. and Mildred Finley Wohlford Professor in the School of Humanities and Sciences and Professor of Biology at Stanford University, has been selected to receive the 2019-20 Stanford
Biosciences “Excellence in Mentoring and Service Award”. This honor is given to faculty who make distinguished contributions towards enhancing the quality of training and the mentoring experiences for Stanford Biosciences graduate students.

In recognizing Professor Feldman for this honor, William S. Talbot, Ph.D., Senior Associate Dean of Graduate Education and Postdoctoral Affairs,
Professor of Developmental Biology,  at Stanford University, thanked him for his “extraordinary contributions this year.” Professor Feldman will be formally acknowledged for receiving this award and an honorarium at the School of Medicine Graduation Celebration on Saturday, June 13, 2020.

###

Updated on 5/7/2020

From: Alan Kaul <alan@mom-inc.us>

Date: Thursday, May 7, 2020 at 9:03 AM

To: Aviva Lev-Ari <AvivaLev-Ari@alum.berkeley.edu>

Cc: Vinit Nair <vinit@pracnet.org>

Subject: Pharmaceutical Intelligence

HI Aviva,

You asked for my help in promoting your portal and I’ve done something that I haven’t done for any other organization, I put a direct link to your portal on Medical Outcomes Management’s home page.

[ see www.mom-inc.us ]

This is the only link to another business on our company’s website. We may move it’s location, but it will remain highly visible and directly linked.

I hope that this link will prove helpul to both of us

Stay safe,

Alan

Updated on 4/19/2020

ADDED to this entry by Dr. Larry H. Bernstein, MD, FCAP on 8/17/2020

“I am thankful to Aviva for the opportunity to follow my interests in retirement. I have been away from the laboratory longer than I would like, but could follow the literature.”

Sincerely,

Larry Bernstein, MD

“Prior to moving I was contacted by Aviva Lev-Ari, PhD, RN who was building an online medical forum known as Leaders in Pharmaceutical Business Intelligence (LPBI) Group, and I became the Chief Scientific Officer (CSO). Over the decade I wrote many articles (1,390) in the Open Access online Scientific Journal http://pharmaceuticalintelligence.com that were included in 18 organized e-Books in Medicine. Dr. Lev-Ari’s accomplishment is quite impressive. The e-Books are all available on Amazon.com”

https://lnkd.in/ekWGNqA

In:

My Memories Tell a Story to Share, 4/19/2020

Author: Larry Howard Bernstein, MD, FCAP

Contact: 413-727-8523

https://pharmaceuticalintelligence.com/2020/04/19/my-memories-tell-a-story-to-share-by-larry-howard-bernstein-md-fcap/

Updated on 2/9/2020

Obtained by Gail S. Thornton on 2/7/2020

Leaders in Pharmaceutical Business Intelligence (LPBI) is among the best resources of original scientific and medical content for the scientific and business community that is carefully chosen and thoughtfully organized and presented. The site offers a valuable contribution to biomedical science by advancing knowledge and research efforts through its commitment to synthesize, analyze and interpret complex, medical and scientific disease information on any subject, as well as biomedical research innovation widely available to the scientific and non-research community. There is a vast amount of quality, curated information on the site organized in three inter-related domains of an e-Journal, series of 16 e-Books and e-scientific and medical conference proceedings that is produced by an esteemed group of collaborators. 

In today’s biomedical science environment, there is a wide range of available information in journals of all subject areas and web sites, including clinical data, public health data and even genomics information, that needs to be accessed. The value and uniqueness that LPBI brings to the scientific community is its consistent and enormous success in producing non-technical reviews of technical literature in the medical field, so that the scientific findings are much more accessible in real-time. In that way, the scientific community can further delve into specific areas of interest more readily. The site is a quality, professional resource for the biomedical field, which is unique to any field. 

I’ve had the pleasure to serve as content consultant to LPBI over the years and, specifically, as an author of a newly launched e-book entitled, Latest in Genomics Methodologies for Therapeutics: Gene Editing, NGS & BioInformatics, Simulations and the Genome Ontology. 

 

 —Marcus W. Feldman, Ph.D., Burnett C. and Mildred Finley Wohlford Professor of Computational Biology in the School of Humanities and Sciences, and co-director of the Center for Computational, Evolutionary and Human Genetics, Stanford University. He is the author of more than 600 scientific papers and 10 books on evolution, ecology, mathematical biology and demography. He is a member of the U.S. National Academy of Sciences, the American Academy of Arts and Sciences and the American Philosophical Society. He was the 2011 Dan David laureate in Evolution and was awarded the 2016 Kimura Prize in Evolution by the Japanese Suzuki Foundation.

Updated on 1/31/2020

Notifications from ResearchGate

Vesa Cosmin Mihai recommended your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Apr 6, 2019

Md Azree Othuman Mydin and 2 others recommended your publications: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Mar 25, 2019

Bahra Karima followed your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Mar 25, 2019

Javad Parmah followed your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Nov 27, 2018

Sebastian Nemeth recommended your publication: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Jul 29, 2018

Daniela Gitea and Gabriela Cioca recommended your publications: Etiologies of Cardiovascular Diseases: Epigenetics, Genetics and Genomics

Jul 27, 2018

Vyacheslav Lyashenko followed your publication: Regenerative and Translational Medicine: The Therapeutic Promise for Cardiovascul